US20070021390A1 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments - Google Patents
Derivatives of heterocycles with 5 members, their preparation and their use as medicaments Download PDFInfo
- Publication number
- US20070021390A1 US20070021390A1 US11/256,901 US25690105A US2007021390A1 US 20070021390 A1 US20070021390 A1 US 20070021390A1 US 25690105 A US25690105 A US 25690105A US 2007021390 A1 US2007021390 A1 US 2007021390A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- group
- radical
- independently
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 96
- 238000002360 preparation method Methods 0.000 title description 33
- 239000003814 drug Substances 0.000 title description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 232
- 238000000034 method Methods 0.000 claims abstract description 74
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract 4
- -1 methylenedioxy Chemical group 0.000 claims description 706
- 125000000217 alkyl group Chemical group 0.000 claims description 385
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 373
- 229910052757 nitrogen Inorganic materials 0.000 claims description 165
- 125000003545 alkoxy group Chemical group 0.000 claims description 154
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 154
- 125000003342 alkenyl group Chemical group 0.000 claims description 132
- 125000000304 alkynyl group Chemical group 0.000 claims description 125
- 125000003118 aryl group Chemical group 0.000 claims description 111
- 125000005842 heteroatom Chemical group 0.000 claims description 103
- 125000005282 allenyl group Chemical group 0.000 claims description 98
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 92
- 125000001424 substituent group Chemical group 0.000 claims description 81
- 229910052736 halogen Inorganic materials 0.000 claims description 77
- 150000002367 halogens Chemical class 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 71
- 239000001257 hydrogen Substances 0.000 claims description 70
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 70
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 229910052760 oxygen Inorganic materials 0.000 claims description 57
- 125000004432 carbon atom Chemical group C* 0.000 claims description 46
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 44
- PTUCPHGSAFOJAU-MGONOCMRSA-N (4s)-5-amino-4-[[(2s)-2-[[(2s)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-[3-[4-(3-chlorophenyl)phenyl]-1,2-oxazol-5-yl]propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N)CP(O)(=O)C=1C=CC(Br)=CC=1)C(ON=1)=CC=1C(C=C1)=CC=C1C1=CC=CC(Cl)=C1 PTUCPHGSAFOJAU-MGONOCMRSA-N 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000003282 alkyl amino group Chemical group 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 32
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 32
- 125000004076 pyridyl group Chemical group 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- JKKOLPWDKQDVJE-UHFFFAOYSA-N 3-[(3-fluoro-4-methoxyphenyl)methylamino]-6-(trifluoromethyl)quinoxaline-2-carboxylic acid Chemical compound C1=C(F)C(OC)=CC=C1CNC1=NC2=CC(C(F)(F)F)=CC=C2N=C1C(O)=O JKKOLPWDKQDVJE-UHFFFAOYSA-N 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 14
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000004467 aryl imino group Chemical group 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- RFEBDZANCVHDLP-UHFFFAOYSA-N 3-[(4-cyanophenyl)methylamino]-6-(trifluoromethyl)quinoxaline-2-carboxylic acid Chemical compound OC(=O)C1=NC2=CC=C(C(F)(F)F)C=C2N=C1NCC1=CC=C(C#N)C=C1 RFEBDZANCVHDLP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 9
- RESCXMFWHJDRNB-UHFFFAOYSA-N sr26 Chemical compound NC1=CN=C2N3C=CC(C)=CC3=NC2=C1C RESCXMFWHJDRNB-UHFFFAOYSA-N 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- VZBQJKIOAOUYJL-UHFFFAOYSA-N (1-methyl-1h-imidazol-2-yl)-(3-methyl-4-{3-[(pyridin-3-ylmethyl)-amino]-propoxy}-benzofuran-2-yl)-methanone Chemical compound C=12C(C)=C(C(=O)C=3N(C=CN=3)C)OC2=CC=CC=1OCCCNCC1=CC=CN=C1 VZBQJKIOAOUYJL-UHFFFAOYSA-N 0.000 claims description 7
- CXBAABOAUNPLDL-UHFFFAOYSA-N 3-(4-benzoylanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione Chemical compound COc1ccccc1C1=C(Nc2ccc(cc2)C(=O)c2ccccc2)C(=O)NC1=O CXBAABOAUNPLDL-UHFFFAOYSA-N 0.000 claims description 7
- GGCSQMNZKHRBJW-UHFFFAOYSA-N 3-[(4-ethoxyphenyl)methylamino]-6-(trifluoromethyl)quinoxaline-2-carboxylic acid Chemical compound C1=CC(OCC)=CC=C1CNC1=NC2=CC(C(F)(F)F)=CC=C2N=C1C(O)=O GGCSQMNZKHRBJW-UHFFFAOYSA-N 0.000 claims description 7
- ZOUTYVWHWSUKPL-RNCFNFMXSA-N C[C@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O Chemical compound C[C@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O ZOUTYVWHWSUKPL-RNCFNFMXSA-N 0.000 claims description 7
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- NDHYEIVULGZZBZ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-(methylaminomethyl)-1,3-thiazol-4-yl]phenol Chemical compound S1C(CNC)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 NDHYEIVULGZZBZ-UHFFFAOYSA-N 0.000 claims description 3
- YBIATPYFMDGVHN-UHFFFAOYSA-N 2,6-ditert-butyl-4-[4-(2-piperazin-1-ylethyl)-1,3-oxazol-2-yl]phenol hydrochloride Chemical compound Cl.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2OC=C(CCN3CCNCC3)N=2)=C1 YBIATPYFMDGVHN-UHFFFAOYSA-N 0.000 claims description 3
- CCVQEWGLSZNIQP-UHFFFAOYSA-N 3-[2-[2-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-oxazol-4-yl]ethyl-methylamino]propanenitrile Chemical compound N#CCCN(C)CCC1=COC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=N1 CCVQEWGLSZNIQP-UHFFFAOYSA-N 0.000 claims description 3
- CPMPDJUVSZYPTG-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[[2-hydroxyethyl(methyl)amino]methyl]-1,3-thiazol-4-yl]phenol Chemical compound S1C(CN(CCO)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 CPMPDJUVSZYPTG-UHFFFAOYSA-N 0.000 claims description 2
- VWUUDMXMGLVDHQ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[4-(2-hydroxyethyl)-1,3-oxazol-2-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2OC=C(CCO)N=2)=C1 VWUUDMXMGLVDHQ-UHFFFAOYSA-N 0.000 claims description 2
- BRKONPFUXJPGAY-UHFFFAOYSA-N 2,6-ditert-butyl-4-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2SC=C(CO)N=2)=C1 BRKONPFUXJPGAY-UHFFFAOYSA-N 0.000 claims description 2
- NNSXLJQREFPTRB-UHFFFAOYSA-N 2,6-ditert-butyl-4-[4-[2-[methyl(prop-2-ynyl)amino]ethyl]-1,3-oxazol-2-yl]phenol Chemical compound C#CCN(C)CCC1=COC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=N1 NNSXLJQREFPTRB-UHFFFAOYSA-N 0.000 claims description 2
- LOWKQMDXLJRXGE-UHFFFAOYSA-N 2-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl-methylamino]acetonitrile Chemical compound S1C(CN(CC#N)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 LOWKQMDXLJRXGE-UHFFFAOYSA-N 0.000 claims description 2
- ZJFRYRLFVAGHKP-UHFFFAOYSA-N 4-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl-methylamino]butanenitrile Chemical compound S1C(CN(CCCC#N)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 ZJFRYRLFVAGHKP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 39
- JYNZIOFUHBJABQ-UHFFFAOYSA-N allyl-{6-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-hexyl-}-methyl-amin Chemical compound C=1OC2=CC(OCCCCCCN(C)CC=C)=CC=C2C=1C1=CC=C(Br)C=C1 JYNZIOFUHBJABQ-UHFFFAOYSA-N 0.000 claims 2
- SJSSFUMSAFMFNM-NSHDSACASA-N (2s)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 SJSSFUMSAFMFNM-NSHDSACASA-N 0.000 claims 1
- TZNNHORRSWKEND-UHFFFAOYSA-N 2,6-ditert-butyl-4-[4-(2-piperazin-1-ylethyl)-1,3-oxazol-2-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2OC=C(CCN3CCNCC3)N=2)=C1 TZNNHORRSWKEND-UHFFFAOYSA-N 0.000 claims 1
- RCZPTAPVAGTTOR-UHFFFAOYSA-N 2,6-ditert-butyl-4-[4-(methylaminomethyl)-1,3-thiazol-2-yl]phenol hydrochloride Chemical compound Cl.CNCC1=CSC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=N1 RCZPTAPVAGTTOR-UHFFFAOYSA-N 0.000 claims 1
- ZHDHSBKTLRLUCQ-UHFFFAOYSA-N 6-[4-(6-bromo-1,2-benzothiazol-3-yl)phenoxy]-n-methyl-n-prop-2-enylhexan-1-amine Chemical compound C1=CC(OCCCCCCN(C)CC=C)=CC=C1C1=NSC2=CC(Br)=CC=C12 ZHDHSBKTLRLUCQ-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 305
- 230000008018 melting Effects 0.000 description 298
- 238000002844 melting Methods 0.000 description 298
- 239000012458 free base Substances 0.000 description 177
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 120
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 75
- 238000010586 diagram Methods 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- 125000005843 halogen group Chemical group 0.000 description 57
- 239000000203 mixture Substances 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 52
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 52
- 239000002904 solvent Substances 0.000 description 51
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 239000002253 acid Substances 0.000 description 47
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
- 125000004430 oxygen atom Chemical group O* 0.000 description 41
- 125000004434 sulfur atom Chemical group 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000000543 intermediate Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 150000001412 amines Chemical group 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- 239000007787 solid Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 150000007513 acids Chemical class 0.000 description 26
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 25
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 239000000843 powder Substances 0.000 description 23
- 108010052164 Sodium Channels Proteins 0.000 description 22
- 102000018674 Sodium Channels Human genes 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 22
- 125000006239 protecting group Chemical group 0.000 description 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 22
- 239000003480 eluent Substances 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 21
- 235000019341 magnesium sulphate Nutrition 0.000 description 20
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 17
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 17
- 239000012047 saturated solution Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 238000010511 deprotection reaction Methods 0.000 description 14
- 238000005502 peroxidation Methods 0.000 description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 13
- 229960000583 acetic acid Drugs 0.000 description 13
- 125000002883 imidazolyl group Chemical group 0.000 description 13
- 238000011017 operating method Methods 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 150000003557 thiazoles Chemical class 0.000 description 13
- 150000003857 carboxamides Chemical class 0.000 description 12
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 150000005840 aryl radicals Chemical class 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 10
- 125000002837 carbocyclic group Chemical group 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- 235000010290 biphenyl Nutrition 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 8
- 150000002460 imidazoles Chemical class 0.000 description 8
- 150000002916 oxazoles Chemical class 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 239000012429 reaction media Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- BAIRYLCZWZOXAL-UHFFFAOYSA-N 3-(butoxycarbonylamino)propanoic acid Chemical compound CCCCOC(=O)NCCC(O)=O BAIRYLCZWZOXAL-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 238000005893 bromination reaction Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- 238000010908 decantation Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- KDPFHBWKQMYZKF-UHFFFAOYSA-N 2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethanamine Chemical compound N1C(CCN)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 KDPFHBWKQMYZKF-UHFFFAOYSA-N 0.000 description 5
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000031709 bromination Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- AXMPFOXRWZXZFA-UHFFFAOYSA-N heptyl carbamate Chemical compound CCCCCCCOC(N)=O AXMPFOXRWZXZFA-UHFFFAOYSA-N 0.000 description 5
- 150000002547 isoxazolines Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 4
- MKHUGLZLKVCOGF-UHFFFAOYSA-N 1-[4-[(6-aminoquinolin-4-yl)amino]phenyl]-3-[5-tert-butyl-2-(3-methylphenyl)pyrazol-3-yl]urea Chemical compound CC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)NC=2C=CC(NC=3C4=CC(N)=CC=C4N=CC=3)=CC=2)=C1 MKHUGLZLKVCOGF-UHFFFAOYSA-N 0.000 description 4
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 4
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 4
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- DSODRWWHAUGSGD-UHFFFAOYSA-N [5-(carbamimidoylsulfanylmethyl)thiophen-2-yl]methyl carbamimidothioate;dihydrochloride Chemical compound Cl.Cl.NC(=N)SCC1=CC=C(CSC(N)=N)S1 DSODRWWHAUGSGD-UHFFFAOYSA-N 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 4
- HQFYIDOMCULPIW-UHFFFAOYSA-N n-methylprop-2-yn-1-amine Chemical compound CNCC#C HQFYIDOMCULPIW-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- CYJAWBVQRMVFEO-UHFFFAOYSA-N piperazine-2,6-dione Chemical compound O=C1CNCC(=O)N1 CYJAWBVQRMVFEO-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- PGJIJHNIIQRRGV-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]octanoic acid Chemical compound CCCCCCC(C(O)=O)NC(=O)OC(C)(C)C PGJIJHNIIQRRGV-UHFFFAOYSA-N 0.000 description 3
- CCMLIFHRMDXEBM-UHFFFAOYSA-N 2-phenyl-1,3-thiazol-4-ol Chemical class OC1=CSC(C=2C=CC=CC=2)=N1 CCMLIFHRMDXEBM-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 125000006501 nitrophenyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- DNPNINLQXASJSN-UHFFFAOYSA-N tert-butyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 DNPNINLQXASJSN-UHFFFAOYSA-N 0.000 description 3
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- GTEXTHNEQJVFPE-UHFFFAOYSA-N (1-benzyl-4-phenylimidazol-2-yl)methanamine Chemical compound NCC1=NC(C=2C=CC=CC=2)=CN1CC1=CC=CC=C1 GTEXTHNEQJVFPE-UHFFFAOYSA-N 0.000 description 2
- UICOPAANNFMFRH-MRXNPFEDSA-N (1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)N)=NC=1C1=CC=CC=C1 UICOPAANNFMFRH-MRXNPFEDSA-N 0.000 description 2
- QJTZUFDRYUDSHO-XMMPIXPASA-N (1r)-n-benzyl-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NCC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 QJTZUFDRYUDSHO-XMMPIXPASA-N 0.000 description 2
- OIZPBJQMIUSFGO-QFIPXVFZSA-N (1s)-1-[5-(3-bromophenyl)-1h-imidazol-2-yl]-1-cyclohexyl-n-(cyclohexylmethyl)methanamine Chemical compound BrC1=CC=CC(C=2N=C(NC=2)[C@@H](NCC2CCCCC2)C2CCCCC2)=C1 OIZPBJQMIUSFGO-QFIPXVFZSA-N 0.000 description 2
- FOJCXTAWQOQQBF-QFIPXVFZSA-N (1s)-1-cyclohexyl-n-(cyclohexylmethyl)-1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@@H](NCC2CCCCC2)C2CCCCC2)=N1 FOJCXTAWQOQQBF-QFIPXVFZSA-N 0.000 description 2
- SDKADFYQORIJQG-QFIPXVFZSA-N (1s)-1-cyclohexyl-n-(cyclohexylmethyl)-1-[5-[3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]methanamine Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(NC=2)[C@@H](NCC2CCCCC2)C2CCCCC2)=C1 SDKADFYQORIJQG-QFIPXVFZSA-N 0.000 description 2
- HRELUUJYACRYGH-UHFFFAOYSA-N (5-phenyl-1h-imidazol-2-yl)methanamine Chemical compound N1C(CN)=NC=C1C1=CC=CC=C1 HRELUUJYACRYGH-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- LICKDWCYNCCCOJ-HNNXBMFYSA-N (s)-cyclohexyl-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1([C@H](N)C=2NC=C(N=2)C=2C=CC(F)=CC=2)CCCCC1 LICKDWCYNCCCOJ-HNNXBMFYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- CKZMGVXFCYVEHY-UHFFFAOYSA-N 1-(5-cyclohexyl-1h-imidazol-2-yl)heptan-1-amine Chemical compound N1C(C(N)CCCCCC)=NC(C2CCCCC2)=C1 CKZMGVXFCYVEHY-UHFFFAOYSA-N 0.000 description 2
- DXZJXKPTEKBKTF-UHFFFAOYSA-N 1-[5-(3-bromophenyl)-1h-imidazol-2-yl]-5-methylhexan-1-amine Chemical compound N1C(C(N)CCCC(C)C)=NC(C=2C=C(Br)C=CC=2)=C1 DXZJXKPTEKBKTF-UHFFFAOYSA-N 0.000 description 2
- BKDINLKWZBENKQ-UHFFFAOYSA-N 1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]heptan-1-amine Chemical compound N1C(C(N)CCCCCC)=NC(C=2C=CC(F)=CC=2)=C1 BKDINLKWZBENKQ-UHFFFAOYSA-N 0.000 description 2
- HXBSQJZPAFCWLU-UHFFFAOYSA-N 1-phenyl-n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]methanamine Chemical compound N=1C(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CNC=1CNCC1=CC=CC=C1 HXBSQJZPAFCWLU-UHFFFAOYSA-N 0.000 description 2
- QSZCGGBDNYTQHH-UHFFFAOYSA-N 2,3-dimethoxyphenol Chemical compound COC1=CC=CC(O)=C1OC QSZCGGBDNYTQHH-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- HAQZOFISOAXSHD-UHFFFAOYSA-N 2-bromo-1-(10h-phenothiazin-2-yl)ethanone Chemical compound C1=CC=C2NC3=CC(C(=O)CBr)=CC=C3SC2=C1 HAQZOFISOAXSHD-UHFFFAOYSA-N 0.000 description 2
- UYPXQSLSPUBZQW-UHFFFAOYSA-N 2-bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone Chemical compound CC(C)(C)C1=CC(C(=O)CBr)=CC(C(C)(C)C)=C1O UYPXQSLSPUBZQW-UHFFFAOYSA-N 0.000 description 2
- ADLIDZNESKOPIP-UHFFFAOYSA-N 2-bromo-1-cyclohexylethanone Chemical compound BrCC(=O)C1CCCCC1 ADLIDZNESKOPIP-UHFFFAOYSA-N 0.000 description 2
- YERQIOHZAIKQJU-UHFFFAOYSA-N 2-chloro-1-(10h-phenothiazin-2-yl)ethanone Chemical compound C1=CC=C2NC3=CC(C(=O)CCl)=CC=C3SC2=C1 YERQIOHZAIKQJU-UHFFFAOYSA-N 0.000 description 2
- AFXKCBFBGDUFAM-UHFFFAOYSA-N 2-methylpropan-2-amine;hydrofluoride Chemical compound [F-].CC(C)(C)[NH3+] AFXKCBFBGDUFAM-UHFFFAOYSA-N 0.000 description 2
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 2
- AMAFOMIBEAFCPF-UHFFFAOYSA-N 6-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid Chemical compound CC(C)CCCC(C(O)=O)NC(=O)OC(C)(C)C AMAFOMIBEAFCPF-UHFFFAOYSA-N 0.000 description 2
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- FHSPYURXUUPIND-UHFFFAOYSA-N butyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 FHSPYURXUUPIND-UHFFFAOYSA-N 0.000 description 2
- OTYQCJPRAVNWGG-UHFFFAOYSA-N butyl n-[2-[5-(4-pyrrolidin-1-ylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)N2CCCC2)=C1 OTYQCJPRAVNWGG-UHFFFAOYSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000003971 isoxazolinyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002642 lithium compounds Chemical class 0.000 description 2
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- LPQBCFDLDCHGDR-IBGZPJMESA-N n-[(s)-cyclohexyl-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methyl]cyclobutanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@@H](NC2CCC2)C2CCCCC2)=N1 LPQBCFDLDCHGDR-IBGZPJMESA-N 0.000 description 2
- YCBTUKDCIDSPFO-NRFANRHFSA-N n-[(s)-cyclohexyl-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@@H](NC2CCCCC2)C2CCCCC2)=N1 YCBTUKDCIDSPFO-NRFANRHFSA-N 0.000 description 2
- DHSQCTGLPOAHLB-NRFANRHFSA-N n-[(s)-cyclohexyl-[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CNC([C@@H](NC2CCCCC2)C2CCCCC2)=N1 DHSQCTGLPOAHLB-NRFANRHFSA-N 0.000 description 2
- YTONWDZJHSGFCJ-UHFFFAOYSA-N n-[1-(5-cyclohexyl-1h-imidazol-2-yl)heptyl]cyclohexanamine Chemical compound N=1C(C2CCCCC2)=CNC=1C(CCCCCC)NC1CCCCC1 YTONWDZJHSGFCJ-UHFFFAOYSA-N 0.000 description 2
- SJRGBJWZPDBYFC-UHFFFAOYSA-N n-[1-[5-(3-bromophenyl)-1h-imidazol-2-yl]-5-methylhexyl]cyclohexanamine Chemical compound N=1C(C=2C=C(Br)C=CC=2)=CNC=1C(CCCC(C)C)NC1CCCCC1 SJRGBJWZPDBYFC-UHFFFAOYSA-N 0.000 description 2
- MUFCOGIHWXWPLM-UHFFFAOYSA-N n-[1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]heptyl]cyclohexanamine Chemical compound N=1C(C=2C=CC(F)=CC=2)=CNC=1C(CCCCCC)NC1CCCCC1 MUFCOGIHWXWPLM-UHFFFAOYSA-N 0.000 description 2
- GNRUVSQGCXVQBZ-UHFFFAOYSA-N n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]pentanamide Chemical compound N1C(CCNC(=O)CCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 GNRUVSQGCXVQBZ-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- KOFJTOPZJLSNIG-UHFFFAOYSA-N n-methyl-1-[4-(10h-phenothiazin-2-yl)-1,3-thiazol-2-yl]methanamine;hydrochloride Chemical compound Cl.S1C(CNC)=NC(C=2C=C3NC4=CC=CC=C4SC3=CC=2)=C1 KOFJTOPZJLSNIG-UHFFFAOYSA-N 0.000 description 2
- ZVVCAJHCTAIIEZ-UHFFFAOYSA-N n-methyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]methanamine Chemical compound N1C(CNC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 ZVVCAJHCTAIIEZ-UHFFFAOYSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- MYDQAEQZZKVJSL-UHFFFAOYSA-N pentyl carbamate Chemical compound CCCCCOC(N)=O MYDQAEQZZKVJSL-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical class BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229940072033 potash Drugs 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- OUONOQLMECWEAO-UHFFFAOYSA-N tert-butyl n-[1-(5-cyclohexyl-1h-imidazol-2-yl)heptyl]carbamate Chemical compound N1C(C(NC(=O)OC(C)(C)C)CCCCCC)=NC(C2CCCCC2)=C1 OUONOQLMECWEAO-UHFFFAOYSA-N 0.000 description 2
- MDLBNMPBLYYQOW-UHFFFAOYSA-N tert-butyl n-[1-[5-(3-bromophenyl)-1h-imidazol-2-yl]-5-methylhexyl]carbamate Chemical compound N1C(C(NC(=O)OC(C)(C)C)CCCC(C)C)=NC(C=2C=C(Br)C=CC=2)=C1 MDLBNMPBLYYQOW-UHFFFAOYSA-N 0.000 description 2
- TXNUGIAWBVKVNE-UHFFFAOYSA-N tert-butyl n-[1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]heptyl]carbamate Chemical compound N1C(C(NC(=O)OC(C)(C)C)CCCCCC)=NC(C=2C=CC(F)=CC=2)=C1 TXNUGIAWBVKVNE-UHFFFAOYSA-N 0.000 description 2
- VXMJEMJQRVMGNS-UHFFFAOYSA-N tert-butyl n-[2-(methylamino)acetyl]carbamate Chemical compound CNCC(=O)NC(=O)OC(C)(C)C VXMJEMJQRVMGNS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- BJACFPBFRZLQMC-HXUWFJFHSA-N (1r)-1-(1-benzyl-4-tert-butylimidazol-2-yl)-2-(1h-indol-3-yl)ethanamine Chemical compound C1([C@H](N)CC=2C3=CC=CC=C3NC=2)=NC(C(C)(C)C)=CN1CC1=CC=CC=C1 BJACFPBFRZLQMC-HXUWFJFHSA-N 0.000 description 1
- DBLBVZGJDHSHCG-LLVKDONJSA-N (1r)-1-(5-phenyl-1h-imidazol-2-yl)butan-1-amine Chemical compound N1C([C@H](N)CCC)=NC(C=2C=CC=CC=2)=C1 DBLBVZGJDHSHCG-LLVKDONJSA-N 0.000 description 1
- XQFMQMXJXWTGON-MRVPVSSYSA-N (1r)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound N1C([C@H](N)C)=NC(C=2C=CC=CC=2)=C1 XQFMQMXJXWTGON-MRVPVSSYSA-N 0.000 description 1
- CVSKZYBHWNXXFE-CYBMUJFWSA-N (1r)-1-(5-tert-butyl-1h-imidazol-2-yl)-2-(1h-indol-3-yl)ethanamine Chemical compound CC(C)(C)C1=CNC([C@H](N)CC=2C3=CC=CC=C3NC=2)=N1 CVSKZYBHWNXXFE-CYBMUJFWSA-N 0.000 description 1
- NHYSVYAMYLRPLT-QGZVFWFLSA-N (1r)-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]butan-1-amine Chemical compound N1C([C@H](N)CCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 NHYSVYAMYLRPLT-QGZVFWFLSA-N 0.000 description 1
- FOJCXTAWQOQQBF-JOCHJYFZSA-N (1r)-1-cyclohexyl-n-(cyclohexylmethyl)-1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@H](NCC2CCCCC2)C2CCCCC2)=N1 FOJCXTAWQOQQBF-JOCHJYFZSA-N 0.000 description 1
- XNGHLKZJCRGJNR-HSZRJFAPSA-N (1r)-2-(1-benzothiophen-3-yl)-n-benzyl-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3SC=2)NCC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 XNGHLKZJCRGJNR-HSZRJFAPSA-N 0.000 description 1
- SATXQCYBGKTZDS-QGZVFWFLSA-N (1r)-2-(1h-indol-3-yl)-1-(1-methyl-4-phenylimidazol-2-yl)ethanamine Chemical compound N1=C([C@H](N)CC=2C3=CC=CC=C3NC=2)N(C)C=C1C1=CC=CC=C1 SATXQCYBGKTZDS-QGZVFWFLSA-N 0.000 description 1
- TUDZRLBBTZPVLJ-MRXNPFEDSA-N (1r)-2-(1h-indol-3-yl)-1-[5-(4-nitrophenyl)-1h-imidazol-2-yl]ethanamine Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)N)=NC=1C1=CC=C([N+]([O-])=O)C=C1 TUDZRLBBTZPVLJ-MRXNPFEDSA-N 0.000 description 1
- GAOJHRHXCMILAV-RUZDIDTESA-N (1r)-2-(1h-indol-3-yl)-n-(2-phenoxyethyl)-1-(4-phenyl-1,3-thiazol-2-yl)ethanamine Chemical compound N([C@H](CC=1C2=CC=CC=C2NC=1)C=1SC=C(N=1)C=1C=CC=CC=1)CCOC1=CC=CC=C1 GAOJHRHXCMILAV-RUZDIDTESA-N 0.000 description 1
- OSAFDBKMPOXIRY-RUZDIDTESA-N (1r)-2-(1h-indol-3-yl)-n-(2-phenoxyethyl)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound N([C@H](CC=1C2=CC=CC=C2NC=1)C=1NC=C(N=1)C=1C=CC=CC=1)CCOC1=CC=CC=C1 OSAFDBKMPOXIRY-RUZDIDTESA-N 0.000 description 1
- WTQOJTRSZXRVNB-RUZDIDTESA-N (1r)-2-(1h-indol-3-yl)-n-(2-phenylethyl)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound N([C@H](CC=1C2=CC=CC=C2NC=1)C=1NC=C(N=1)C=1C=CC=CC=1)CCC1=CC=CC=C1 WTQOJTRSZXRVNB-RUZDIDTESA-N 0.000 description 1
- SUROWKKLQJARCI-OAHLLOKOSA-N (1r)-2-cyclohexyl-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C([C@@H](N)C=1NC=C(N=1)C=1C=CC=CC=1)C1CCCCC1 SUROWKKLQJARCI-OAHLLOKOSA-N 0.000 description 1
- MNHHEQMTZVXLJI-OAQYLSRUSA-N (1r)-2-cyclohexyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethanamine Chemical compound C([C@@H](N)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)C1CCCCC1 MNHHEQMTZVXLJI-OAQYLSRUSA-N 0.000 description 1
- XGKWALHJXZAHEN-MRXNPFEDSA-N (1r)-3-phenyl-1-(5-phenyl-1h-imidazol-2-yl)propan-1-amine Chemical compound C([C@@H](N)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 XGKWALHJXZAHEN-MRXNPFEDSA-N 0.000 description 1
- MJZRAWWEPVENFN-JOCHJYFZSA-N (1r)-3-phenyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-1-amine Chemical compound C([C@@H](N)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 MJZRAWWEPVENFN-JOCHJYFZSA-N 0.000 description 1
- LSCRUVHEGCSLQJ-MUUNZHRXSA-N (1r)-n-benzyl-1-(1-benzyl-4-tert-butylimidazol-2-yl)-2-(1h-indol-3-yl)ethanamine Chemical compound C1([C@@H](CC=2C3=CC=CC=C3NC=2)NCC=2C=CC=CC=2)=NC(C(C)(C)C)=CN1CC1=CC=CC=C1 LSCRUVHEGCSLQJ-MUUNZHRXSA-N 0.000 description 1
- FIOFUZZVMHSNSK-OAQYLSRUSA-N (1r)-n-benzyl-1-(4,5-dimethyl-1,3-oxazol-2-yl)-2-(1h-indol-3-yl)ethanamine Chemical compound O1C(C)=C(C)N=C1[C@H](NCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 FIOFUZZVMHSNSK-OAQYLSRUSA-N 0.000 description 1
- HWTQLTXHBSDMSH-GDLZYMKVSA-N (1r)-n-benzyl-1-(4,5-diphenyl-1h-imidazol-2-yl)-2-(1h-indol-3-yl)ethanamine Chemical compound N1C([C@@H](CC=2C3=CC=CC=C3NC=2)NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HWTQLTXHBSDMSH-GDLZYMKVSA-N 0.000 description 1
- BULDTQGYYWMWHI-GOSISDBHSA-N (1r)-n-benzyl-1-(5-phenyl-1h-imidazol-2-yl)butan-1-amine Chemical compound N([C@H](CCC)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 BULDTQGYYWMWHI-GOSISDBHSA-N 0.000 description 1
- NTSPIGWULRSHOZ-CQSZACIVSA-N (1r)-n-benzyl-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound N([C@H](C)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 NTSPIGWULRSHOZ-CQSZACIVSA-N 0.000 description 1
- LXIYFUGXYCMCHW-XMMPIXPASA-N (1r)-n-benzyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]butan-1-amine Chemical compound N([C@H](CCC)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 LXIYFUGXYCMCHW-XMMPIXPASA-N 0.000 description 1
- HCVWBZVOGNPCTG-XMMPIXPASA-N (1r)-n-benzyl-2-(1h-indol-3-yl)-1-(4-phenyl-1,3-thiazol-2-yl)ethanamine Chemical compound C=1SC([C@@H](CC=2C3=CC=CC=C3NC=2)NCC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 HCVWBZVOGNPCTG-XMMPIXPASA-N 0.000 description 1
- PHIGPUKLLCGMJQ-RUZDIDTESA-N (1r)-n-benzyl-2-(1h-indol-3-yl)-1-(5-methyl-4-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound CC=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NCC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 PHIGPUKLLCGMJQ-RUZDIDTESA-N 0.000 description 1
- KBAHBFBXRZYMDC-AREMUKBSSA-N (1r)-n-benzyl-2-(1h-indol-3-yl)-n-methyl-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound CN([C@H](CC=1C2=CC=CC=C2NC=1)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 KBAHBFBXRZYMDC-AREMUKBSSA-N 0.000 description 1
- OVUKCJFGBNDHAE-JOCHJYFZSA-N (1r)-n-benzyl-2-cyclohexyl-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C([C@@H](NCC=1C=CC=CC=1)C=1NC=C(N=1)C=1C=CC=CC=1)C1CCCCC1 OVUKCJFGBNDHAE-JOCHJYFZSA-N 0.000 description 1
- FLDJQLWIHZCIMF-MUUNZHRXSA-N (1r)-n-benzyl-2-cyclohexyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethanamine Chemical compound C([C@@H](NCC=1C=CC=CC=1)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)C1CCCCC1 FLDJQLWIHZCIMF-MUUNZHRXSA-N 0.000 description 1
- XEGOBWFEPPJFGR-JOCHJYFZSA-N (1r)-n-benzyl-2-phenyl-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C([C@@H](NCC=1C=CC=CC=1)C=1NC=C(N=1)C=1C=CC=CC=1)C1=CC=CC=C1 XEGOBWFEPPJFGR-JOCHJYFZSA-N 0.000 description 1
- IYRZPPBAZFVIHA-LJQANCHMSA-N (1r)-n-benzyl-3-methyl-1-(5-phenyl-1h-imidazol-2-yl)butan-1-amine Chemical compound N([C@H](CC(C)C)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 IYRZPPBAZFVIHA-LJQANCHMSA-N 0.000 description 1
- XSDCHFAEAGWCSQ-HSZRJFAPSA-N (1r)-n-benzyl-3-phenyl-1-(5-phenyl-1h-imidazol-2-yl)propan-1-amine Chemical compound C([C@@H](NCC=1C=CC=CC=1)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 XSDCHFAEAGWCSQ-HSZRJFAPSA-N 0.000 description 1
- VOOXGDLWUQZKCC-GDLZYMKVSA-N (1r)-n-benzyl-3-phenyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-1-amine Chemical compound C([C@@H](NCC=1C=CC=CC=1)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 VOOXGDLWUQZKCC-GDLZYMKVSA-N 0.000 description 1
- BADYIKAODHNODR-HNNXBMFYSA-N (1s)-1-(4,5-diphenyl-1h-imidazol-2-yl)propan-1-amine Chemical compound N1C([C@@H](N)CC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BADYIKAODHNODR-HNNXBMFYSA-N 0.000 description 1
- XGVLGEQKVPMVJT-INIZCTEOSA-N (1s)-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-1-amine Chemical compound N1C([C@@H](N)CC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 XGVLGEQKVPMVJT-INIZCTEOSA-N 0.000 description 1
- GBYIATLEUAZAAI-QFIPXVFZSA-N (1s)-1-cyclohexyl-n-(cyclohexylmethyl)-1-(5-phenyl-1h-imidazol-2-yl)methanamine Chemical compound C1([C@H](NCC2CCCCC2)C=2NC=C(N=2)C=2C=CC=CC=2)CCCCC1 GBYIATLEUAZAAI-QFIPXVFZSA-N 0.000 description 1
- LUPLREHWLJETNO-QFIPXVFZSA-N (1s)-1-cyclohexyl-n-(cyclohexylmethyl)-1-[5-(3-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound FC1=CC=CC(C=2N=C(NC=2)[C@@H](NCC2CCCCC2)C2CCCCC2)=C1 LUPLREHWLJETNO-QFIPXVFZSA-N 0.000 description 1
- LHPKRCQZDNOIAD-IBGZPJMESA-N (1s)-1-cyclohexyl-n-(cyclopropylmethyl)-1-(5-phenyl-1h-imidazol-2-yl)methanamine Chemical compound C1([C@H](NCC2CC2)C=2NC=C(N=2)C=2C=CC=CC=2)CCCCC1 LHPKRCQZDNOIAD-IBGZPJMESA-N 0.000 description 1
- JYBWBVUBFXDDGD-IBGZPJMESA-N (1s)-1-cyclohexyl-n-(cyclopropylmethyl)-1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@@H](NCC2CC2)C2CCCCC2)=N1 JYBWBVUBFXDDGD-IBGZPJMESA-N 0.000 description 1
- PNSVTPKUIWQSLL-LBPRGKRZSA-N (1s)-3-methyl-1-(5-phenyl-1h-imidazol-2-yl)butan-1-amine Chemical compound N1C([C@@H](N)CC(C)C)=NC(C=2C=CC=CC=2)=C1 PNSVTPKUIWQSLL-LBPRGKRZSA-N 0.000 description 1
- CKCCAWIRLZOQKP-QFIPXVFZSA-N (1s)-n-benzyl-1-(4,5-diphenyl-1h-imidazol-2-yl)propan-1-amine Chemical compound N([C@@H](CC)C=1NC(=C(N=1)C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 CKCCAWIRLZOQKP-QFIPXVFZSA-N 0.000 description 1
- MMSRFOBJMPUFGE-QHCPKHFHSA-N (1s)-n-benzyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-1-amine Chemical compound N([C@@H](CC)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 MMSRFOBJMPUFGE-QHCPKHFHSA-N 0.000 description 1
- QJTZUFDRYUDSHO-DEOSSOPVSA-N (1s)-n-benzyl-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound C=1NC([C@H](CC=2C3=CC=CC=C3NC=2)NCC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 QJTZUFDRYUDSHO-DEOSSOPVSA-N 0.000 description 1
- VVIXOTCTYAILNP-UHFFFAOYSA-N (2-amino-2-oxoethyl)-methylazanium;chloride Chemical compound Cl.CNCC(N)=O VVIXOTCTYAILNP-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- QSJFCCLYTHEPBO-UHFFFAOYSA-N (4,5-diphenyl-1h-imidazol-2-yl)methanamine Chemical compound N1C(CN)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QSJFCCLYTHEPBO-UHFFFAOYSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- JBKOPWRZXHJNJK-HNNXBMFYSA-N (s)-cyclohexyl-[5-(3,4-difluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1([C@H](N)C=2NC=C(N=2)C=2C=C(F)C(F)=CC=2)CCCCC1 JBKOPWRZXHJNJK-HNNXBMFYSA-N 0.000 description 1
- RMFFDXNTFRAESU-INIZCTEOSA-N (s)-cyclohexyl-[5-(3-fluoro-4-methoxyphenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1=C(F)C(OC)=CC=C1C1=CNC([C@@H](N)C2CCCCC2)=N1 RMFFDXNTFRAESU-INIZCTEOSA-N 0.000 description 1
- RJLDCSNSFOPHPN-HNNXBMFYSA-N (s)-cyclohexyl-[5-(3-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound C1([C@H](N)C=2NC=C(N=2)C=2C=C(F)C=CC=2)CCCCC1 RJLDCSNSFOPHPN-HNNXBMFYSA-N 0.000 description 1
- JWSBGZYNXISBLV-UHFFFAOYSA-N 1-(1-benzyl-4-phenylimidazol-2-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1=NC(C=2C=CC=CC=2)=CN1CC1=CC=CC=C1 JWSBGZYNXISBLV-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- RCXFSBRMWBFWMH-UHFFFAOYSA-N 1-(2-bromo-4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1Br RCXFSBRMWBFWMH-UHFFFAOYSA-N 0.000 description 1
- RMQSAWLXFOMSSU-UHFFFAOYSA-N 1-(4,5-diphenyl-1h-imidazol-2-yl)-n-methylmethanamine Chemical compound N1C(CNC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 RMQSAWLXFOMSSU-UHFFFAOYSA-N 0.000 description 1
- JNLSNOWPBCNSOZ-UHFFFAOYSA-N 1-(5-phenyl-1h-imidazol-2-yl)heptan-1-amine Chemical compound N1C(C(N)CCCCCC)=NC(C=2C=CC=CC=2)=C1 JNLSNOWPBCNSOZ-UHFFFAOYSA-N 0.000 description 1
- CWKOLMNWCHUKQL-HSZRJFAPSA-N 1-[(1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]-3-phenylurea Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)NC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 CWKOLMNWCHUKQL-HSZRJFAPSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- OGCGYLXULXCGON-UHFFFAOYSA-N 1-[2-(2-bromoacetyl)phenothiazin-10-yl]-2-chloroethanone Chemical compound C1=C(C(=O)CBr)C=C2N(C(=O)CCl)C3=CC=CC=C3SC2=C1 OGCGYLXULXCGON-UHFFFAOYSA-N 0.000 description 1
- XZKFBZOAIGFZSU-UHFFFAOYSA-N 1-bromo-4-methylpentane Chemical compound CC(C)CCCBr XZKFBZOAIGFZSU-UHFFFAOYSA-N 0.000 description 1
- LFDPCVMXSXYDQA-UHFFFAOYSA-N 1-ethenylpyridin-1-ium;hydrobromide Chemical compound Br.C=C[N+]1=CC=CC=C1 LFDPCVMXSXYDQA-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- OTDQSXKJUGQUBG-UHFFFAOYSA-N 1-phenyl-n-[(5-phenyl-1h-imidazol-2-yl)methyl]methanamine Chemical compound N=1C(C=2C=CC=CC=2)=CNC=1CNCC1=CC=CC=C1 OTDQSXKJUGQUBG-UHFFFAOYSA-N 0.000 description 1
- QHHOYYAVDZQLAP-UHFFFAOYSA-N 1-tert-butyl-3-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]thiourea Chemical group N1C(CCNC(=S)NC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 QHHOYYAVDZQLAP-UHFFFAOYSA-N 0.000 description 1
- NYSHHUCKHJLFCS-UHFFFAOYSA-N 1-tert-butyl-3-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]urea Chemical group N1C(CCNC(=O)NC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 NYSHHUCKHJLFCS-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- UWMGDYFKYFNMLP-UHFFFAOYSA-N 2,2-dimethylpropyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group N1C(CCNC(=O)OCC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 UWMGDYFKYFNMLP-UHFFFAOYSA-N 0.000 description 1
- BMZBFEOLHFSVTR-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-(methylaminomethyl)-1,3-thiazol-4-yl]phenol;hydrochloride Chemical compound Cl.S1C(CNC)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 BMZBFEOLHFSVTR-UHFFFAOYSA-N 0.000 description 1
- VISGYBMMMCCUFF-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-(methylaminomethyl)-1h-imidazol-5-yl]phenol Chemical compound N1C(CNC)=NC=C1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 VISGYBMMMCCUFF-UHFFFAOYSA-N 0.000 description 1
- BJFWVLXPDUBYDD-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[(n-methyl-4-nitroanilino)methyl]-1,3-thiazol-4-yl]phenol Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N(C)CC(SC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 BJFWVLXPDUBYDD-UHFFFAOYSA-N 0.000 description 1
- ODIVESGPMWBQOY-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[(n-methyl-4-nitroanilino)methyl]-1h-imidazol-5-yl]phenol Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N(C)CC(NC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 ODIVESGPMWBQOY-UHFFFAOYSA-N 0.000 description 1
- CABVIIJUHLYHKP-MHZLTWQESA-N 2,6-ditert-butyl-4-[2-[(s)-cyclohexyl-(cyclohexylmethylamino)methyl]-1h-imidazol-5-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(NC=2)[C@@H](NCC2CCCCC2)C2CCCCC2)=C1 CABVIIJUHLYHKP-MHZLTWQESA-N 0.000 description 1
- KYXTWYZRLSFAJM-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[[(3-nitrophenyl)methylamino]methyl]-1,3-thiazol-4-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CNCC=3C=C(C=CC=3)[N+]([O-])=O)SC=2)=C1 KYXTWYZRLSFAJM-UHFFFAOYSA-N 0.000 description 1
- NSSRINWVSYSLAG-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[[(4-nitrophenyl)methylamino]methyl]-1,3-thiazol-4-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CNCC=3C=CC(=CC=3)[N+]([O-])=O)SC=2)=C1 NSSRINWVSYSLAG-UHFFFAOYSA-N 0.000 description 1
- QEBNLFRFUYWWGR-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[[4-(dimethylamino)-n-methylanilino]methyl]-1,3-thiazol-4-yl]phenol Chemical compound C1=CC(N(C)C)=CC=C1N(C)CC1=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=CS1 QEBNLFRFUYWWGR-UHFFFAOYSA-N 0.000 description 1
- AMDZCRQLSLSBRE-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[[methyl(prop-2-ynyl)amino]methyl]-1,3-thiazol-4-yl]phenol Chemical compound S1C(CN(CC#C)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 AMDZCRQLSLSBRE-UHFFFAOYSA-N 0.000 description 1
- AOLBAIJBFRBIQE-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-[[methyl-[(4-nitrophenyl)methyl]amino]methyl]-1,3-thiazol-4-yl]phenol Chemical compound C=1C=C([N+]([O-])=O)C=CC=1CN(C)CC(SC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 AOLBAIJBFRBIQE-UHFFFAOYSA-N 0.000 description 1
- BCXUTETYMPZQEF-UHFFFAOYSA-N 2,6-ditert-butyl-4-[5-(2-hydroxyethyl)-4,5-dihydro-1,2-oxazol-3-yl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2CC(CCO)ON=2)=C1 BCXUTETYMPZQEF-UHFFFAOYSA-N 0.000 description 1
- PCWRXBYSADPRLU-UHFFFAOYSA-N 2-(5-phenyl-1h-imidazol-2-yl)propan-2-amine Chemical compound N1C(C(C)(N)C)=NC(C=2C=CC=CC=2)=C1 PCWRXBYSADPRLU-UHFFFAOYSA-N 0.000 description 1
- CBBFWSMELCDMPZ-UHFFFAOYSA-N 2-(methylamino)acetamide Chemical compound CNCC(N)=O CBBFWSMELCDMPZ-UHFFFAOYSA-N 0.000 description 1
- PVVRRUUMHFWFQV-UHFFFAOYSA-N 2-(methylamino)acetonitrile Chemical compound CNCC#N PVVRRUUMHFWFQV-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- PZMIXMGZCNXUGS-UHFFFAOYSA-N 2-[amino(cyclohexyl)amino]-3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoic acid Chemical compound CC(C)(C)OC(=O)C(C(O)=O)N(N)C1CCCCC1 PZMIXMGZCNXUGS-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- MZBXSQBQPJWECM-UHFFFAOYSA-N 2-bromo-1-(3-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=CC(Br)=C1 MZBXSQBQPJWECM-UHFFFAOYSA-N 0.000 description 1
- CIBGXJVJPZCMFX-UHFFFAOYSA-N 2-bromobutanenitrile Chemical compound CCC(Br)C#N CIBGXJVJPZCMFX-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- RIRQUEWOTWOTPW-UHFFFAOYSA-N 2-bromohexanenitrile Chemical compound CCCCC(Br)C#N RIRQUEWOTWOTPW-UHFFFAOYSA-N 0.000 description 1
- OETNUCMBHKNECJ-UHFFFAOYSA-N 2-bromopentanenitrile Chemical compound CCCC(Br)C#N OETNUCMBHKNECJ-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- ARHQTTKUMFDVJJ-UHFFFAOYSA-N 2-chloro-1-(2,3-dihydroindol-1-yl)ethanone Chemical compound C1=CC=C2N(C(=O)CCl)CCC2=C1 ARHQTTKUMFDVJJ-UHFFFAOYSA-N 0.000 description 1
- KJCWZTRFZJNXNK-UHFFFAOYSA-N 2-methylpropyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group N1C(CCNC(=O)OCC(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 KJCWZTRFZJNXNK-UHFFFAOYSA-N 0.000 description 1
- FZTBAQBBLSYHJZ-UHFFFAOYSA-N 2-phenyl-1,3-oxazol-4-ol Chemical class OC1=COC(C=2C=CC=CC=2)=N1 FZTBAQBBLSYHJZ-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- UNIJBMUBHBAUET-UHFFFAOYSA-N 3-(methylamino)propanenitrile Chemical compound CNCCC#N UNIJBMUBHBAUET-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- LVYNXWGJGFBTRU-UHFFFAOYSA-N 3-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-1-amine Chemical compound N1C(CCCN)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 LVYNXWGJGFBTRU-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- HAQOEWGSBVQDHB-UHFFFAOYSA-N 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CN)SC=2)=C1 HAQOEWGSBVQDHB-UHFFFAOYSA-N 0.000 description 1
- XWGZIZNOKZMWTP-UHFFFAOYSA-N 4-[2-[(4-amino-n-methylanilino)methyl]-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound C=1C=C(N)C=CC=1N(C)CC(SC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 XWGZIZNOKZMWTP-UHFFFAOYSA-N 0.000 description 1
- QCRCSUWHMZKOIS-UHFFFAOYSA-N 4-[2-[(4-amino-n-methylanilino)methyl]-1h-imidazol-5-yl]-2,6-ditert-butylphenol Chemical compound C=1C=C(N)C=CC=1N(C)CC(NC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 QCRCSUWHMZKOIS-UHFFFAOYSA-N 0.000 description 1
- PMISWUGLDBTBPR-FQEVSTJZSA-N 4-[2-[(s)-amino(cyclohexyl)methyl]-1h-imidazol-5-yl]-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(NC=2)[C@@H](N)C2CCCCC2)=C1 PMISWUGLDBTBPR-FQEVSTJZSA-N 0.000 description 1
- NJKXDECYEIWISC-IBGZPJMESA-N 4-[2-[(s)-amino(cyclohexyl)methyl]-1h-imidazol-5-yl]-n,n-diethylaniline Chemical compound C1=CC(N(CC)CC)=CC=C1C1=CNC([C@@H](N)C2CCCCC2)=N1 NJKXDECYEIWISC-IBGZPJMESA-N 0.000 description 1
- RLRFQPPTKIWYGL-VWLOTQADSA-N 4-[2-[(s)-cyclohexyl-(cyclohexylamino)methyl]-1h-imidazol-5-yl]-n,n-diethylaniline Chemical compound C1=CC(N(CC)CC)=CC=C1C1=CNC([C@@H](NC2CCCCC2)C2CCCCC2)=N1 RLRFQPPTKIWYGL-VWLOTQADSA-N 0.000 description 1
- OZLYLXLOMHMSSL-SANMLTNESA-N 4-[2-[(s)-cyclohexyl-(cyclohexylmethylamino)methyl]-1h-imidazol-5-yl]-n,n-diethylaniline Chemical compound C1=CC(N(CC)CC)=CC=C1C1=CNC([C@@H](NCC2CCCCC2)C2CCCCC2)=N1 OZLYLXLOMHMSSL-SANMLTNESA-N 0.000 description 1
- ZCQHYJOKZDAFNH-UHFFFAOYSA-N 4-[2-[[(4-aminophenyl)methyl-methylamino]methyl]-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound C=1C=C(N)C=CC=1CN(C)CC(SC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 ZCQHYJOKZDAFNH-UHFFFAOYSA-N 0.000 description 1
- QALQGXVXRLCIPU-UHFFFAOYSA-N 4-[2-[[(4-aminophenyl)methylamino]methyl]-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CNCC=3C=CC(N)=CC=3)SC=2)=C1 QALQGXVXRLCIPU-UHFFFAOYSA-N 0.000 description 1
- KKSQTZGJQNSEPA-UHFFFAOYSA-N 4-[2-[[benzyl(methyl)amino]methyl]-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound C=1C=CC=CC=1CN(C)CC(SC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 KKSQTZGJQNSEPA-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- WBWYCSJXVVHAFZ-UHFFFAOYSA-N 4-amino-n-[[5-(3,5-ditert-butyl-4-hydroxyphenyl)-1h-imidazol-2-yl]methyl]-n-methylbenzamide Chemical compound C=1C=C(N)C=CC=1C(=O)N(C)CC(NC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 WBWYCSJXVVHAFZ-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- YEULGLQYNMIRNC-UHFFFAOYSA-N 5-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl-methylamino]pentanenitrile Chemical compound S1C(CN(CCCCC#N)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 YEULGLQYNMIRNC-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- NLLPWEGAINWVOW-UHFFFAOYSA-N 6-(5-phenyl-1h-imidazol-2-yl)hexan-1-amine Chemical compound N1C(CCCCCCN)=NC(C=2C=CC=CC=2)=C1 NLLPWEGAINWVOW-UHFFFAOYSA-N 0.000 description 1
- IBTPSWBOLPLLFX-UHFFFAOYSA-N 6-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl-methylamino]hexanenitrile Chemical compound S1C(CN(CCCCCC#N)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 IBTPSWBOLPLLFX-UHFFFAOYSA-N 0.000 description 1
- SALGAMBRFYHHKF-UHFFFAOYSA-N 6-phenyl-5-(5-phenyl-1h-imidazol-2-yl)hexane-1,5-diamine Chemical compound N=1C=C(C=2C=CC=CC=2)NC=1C(N)(CCCCN)CC1=CC=CC=C1 SALGAMBRFYHHKF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005618 Fries rearrangement reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 108700003203 N-methylglycinamide Proteins 0.000 description 1
- CPACYIUVYXTSRY-UHFFFAOYSA-N N1C(CNC(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 Chemical compound N1C(CNC(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPACYIUVYXTSRY-UHFFFAOYSA-N 0.000 description 1
- YDJWQSVCFRPUIM-UHFFFAOYSA-N N1C(CNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 Chemical compound N1C(CNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 YDJWQSVCFRPUIM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ZNJBPYXLVPCOQM-UHFFFAOYSA-N [1-methyl-4-(4-phenylphenyl)imidazol-2-yl]methanamine Chemical compound N1=C(CN)N(C)C=C1C1=CC=C(C=2C=CC=CC=2)C=C1 ZNJBPYXLVPCOQM-UHFFFAOYSA-N 0.000 description 1
- AJSVWOCYSPNHEA-UHFFFAOYSA-N [5-(4-fluorophenyl)-1h-imidazol-2-yl]methanamine Chemical compound N1C(CN)=NC(C=2C=CC(F)=CC=2)=C1 AJSVWOCYSPNHEA-UHFFFAOYSA-N 0.000 description 1
- ORFCQIIRINXSRB-UHFFFAOYSA-N [5-(4-phenylphenyl)-1h-imidazol-2-yl]methanamine Chemical compound N1C(CN)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 ORFCQIIRINXSRB-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- HQYMUNCIMNFLDT-UHFFFAOYSA-N benzyl n-(2-amino-2-oxoethyl)carbamate Chemical compound NC(=O)CNC(=O)OCC1=CC=CC=C1 HQYMUNCIMNFLDT-UHFFFAOYSA-N 0.000 description 1
- UDRCVZGXOKQHJG-XMMPIXPASA-N benzyl n-[(1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]carbamate Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)OCC=2C=CC=CC=2)=NC=1C1=CC=CC=C1 UDRCVZGXOKQHJG-XMMPIXPASA-N 0.000 description 1
- XPJUMSGQAUEVPX-UHFFFAOYSA-N benzyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-2-yl]carbamate Chemical group N=1C(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CNC=1C(C)(C)NC(=O)OCC1=CC=CC=C1 XPJUMSGQAUEVPX-UHFFFAOYSA-N 0.000 description 1
- DXJGOYKYERENGH-UHFFFAOYSA-N benzyl n-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]carbamate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CNC(=O)OCC=3C=CC=CC=3)SC=2)=C1 DXJGOYKYERENGH-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- OGDBYKXYIXUNQT-UHFFFAOYSA-N butane;sulfurochloridic acid Chemical compound CCCC.OS(Cl)(=O)=O OGDBYKXYIXUNQT-UHFFFAOYSA-N 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FQHRHANBYLJCLS-MRXNPFEDSA-N butyl n-[(1r)-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group N1C([C@@H](C)NC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 FQHRHANBYLJCLS-MRXNPFEDSA-N 0.000 description 1
- DPORWBIXTKXBCP-UHFFFAOYSA-N butyl n-[2-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=C3OCCOC3=CC=2)=C1 DPORWBIXTKXBCP-UHFFFAOYSA-N 0.000 description 1
- DLNGQHFKASDYRG-UHFFFAOYSA-N butyl n-[2-[5-(4-bromophenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(Br)=CC=2)=C1 DLNGQHFKASDYRG-UHFFFAOYSA-N 0.000 description 1
- KPMNSPMNLNWVLR-UHFFFAOYSA-N butyl n-[2-[5-(4-cyclohexylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C2CCCCC2)=C1 KPMNSPMNLNWVLR-UHFFFAOYSA-N 0.000 description 1
- SRAXTDZMQVUXQF-UHFFFAOYSA-N butyl n-[2-[5-(4-fluorophenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(F)=CC=2)=C1 SRAXTDZMQVUXQF-UHFFFAOYSA-N 0.000 description 1
- LQVXIUWCQWSCDW-UHFFFAOYSA-N butyl n-[2-[5-(4-phenoxyphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 LQVXIUWCQWSCDW-UHFFFAOYSA-N 0.000 description 1
- WBMLRFSUMKMYNQ-UHFFFAOYSA-N butyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-2-yl]carbamate Chemical group N1C(C(C)(C)NC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 WBMLRFSUMKMYNQ-UHFFFAOYSA-N 0.000 description 1
- DOAQWJGVIPNSAU-UHFFFAOYSA-N butyl n-[2-[5-(4-tert-butylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C(C)(C)C)=C1 DOAQWJGVIPNSAU-UHFFFAOYSA-N 0.000 description 1
- DALIGEUSSSFBSJ-UHFFFAOYSA-N butyl n-[2-[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCC)=NC(C=2C=CC(=CC=2)C(F)(F)F)=C1 DALIGEUSSSFBSJ-UHFFFAOYSA-N 0.000 description 1
- 150000001663 caesium Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- YECAJNWCKIRMJU-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1C[CH]C1 YECAJNWCKIRMJU-UHFFFAOYSA-N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- RZLJFTCRTBUCRP-UHFFFAOYSA-N cyclobutylmethyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound C1CCC1COC(=O)NCCC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 RZLJFTCRTBUCRP-UHFFFAOYSA-N 0.000 description 1
- FSDSKERRNURGGO-UHFFFAOYSA-N cyclohexane-1,3,5-triol Chemical compound OC1CC(O)CC(O)C1 FSDSKERRNURGGO-UHFFFAOYSA-N 0.000 description 1
- FDXTVNCSVXPTAP-UHFFFAOYSA-N cyclohexyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group C1CCCCC1OC(=O)NCCC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 FDXTVNCSVXPTAP-UHFFFAOYSA-N 0.000 description 1
- UHBZEAPZATVYKV-UHFFFAOYSA-N cyclohexylacetone Chemical compound CC(=O)CC1CCCCC1 UHBZEAPZATVYKV-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YPNRWWTZPKGYBX-UHFFFAOYSA-N cyclohexylmethyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound C1CCCCC1COC(=O)NCCC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 YPNRWWTZPKGYBX-UHFFFAOYSA-N 0.000 description 1
- OGENOWSZHSCFII-UHFFFAOYSA-N cyclohexylmethyl n-[2-[5-[4-(4-bromophenyl)phenyl]-1h-imidazol-2-yl]ethyl]carbamate Chemical compound C1=CC(Br)=CC=C1C1=CC=C(C=2N=C(CCNC(=O)OCC3CCCCC3)NC=2)C=C1 OGENOWSZHSCFII-UHFFFAOYSA-N 0.000 description 1
- QJHIBKAIVKVRHG-UHFFFAOYSA-N cyclopentanamine Chemical compound N[C]1[CH][CH][CH][CH]1 QJHIBKAIVKVRHG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- ZAUOTKKXBAYREM-UHFFFAOYSA-N ethyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group N1C(CCNC(=O)OCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 ZAUOTKKXBAYREM-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- WTVNABTWDZCYCN-UHFFFAOYSA-N hexane;hydrobromide Chemical compound Br.CCCCCC WTVNABTWDZCYCN-UHFFFAOYSA-N 0.000 description 1
- ROASJEHPZNKHOF-UHFFFAOYSA-N hexyl carbamate Chemical compound CCCCCCOC(N)=O ROASJEHPZNKHOF-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVILIVVBXHECLH-UHFFFAOYSA-N hexyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound N1C(CCNC(=O)OCCCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 KVILIVVBXHECLH-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- DJHWBDYRTHAZGM-UHFFFAOYSA-N methyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group N1C(CCNC(=O)OC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 DJHWBDYRTHAZGM-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MKJHQNPSJUWWHN-HSZRJFAPSA-N n'-[(1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]benzenecarboximidamide Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=N)C=2C=CC=CC=2)=NC=1C1=CC=CC=C1 MKJHQNPSJUWWHN-HSZRJFAPSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- YJSLEMJUVISYQF-UHFFFAOYSA-N n-[(1-benzyl-4-phenylimidazol-2-yl)methyl]-1-phenylmethanamine Chemical compound N=1C(C=2C=CC=CC=2)=CN(CC=2C=CC=CC=2)C=1CNCC1=CC=CC=C1 YJSLEMJUVISYQF-UHFFFAOYSA-N 0.000 description 1
- LVHYUHBDOVYPRE-HSZRJFAPSA-N n-[(1r)-2-(1h-indol-3-yl)-1-(4-phenyl-1,3-thiazol-2-yl)ethyl]benzamide Chemical compound C=1SC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)C=2C=CC=CC=2)=NC=1C1=CC=CC=C1 LVHYUHBDOVYPRE-HSZRJFAPSA-N 0.000 description 1
- FTJKCXUSWTYHAX-HSZRJFAPSA-N n-[(1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]benzamide Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)C=2C=CC=CC=2)=NC=1C1=CC=CC=C1 FTJKCXUSWTYHAX-HSZRJFAPSA-N 0.000 description 1
- UESHDWCDLVKERD-HXUWFJFHSA-N n-[(1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]pyrimidin-2-amine Chemical compound N([C@H](CC=1C2=CC=CC=C2NC=1)C=1NC=C(N=1)C=1C=CC=CC=1)C1=NC=CC=N1 UESHDWCDLVKERD-HXUWFJFHSA-N 0.000 description 1
- XXNNZCHXYDZISW-OAQYLSRUSA-N n-[(1r)-2-cyclohexyl-1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]ethyl]cyclohexanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@@H](CC2CCCCC2)NC2CCCCC2)=N1 XXNNZCHXYDZISW-OAQYLSRUSA-N 0.000 description 1
- XNNLYZMQHRBHBM-FQEVSTJZSA-N n-[(1s)-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propyl]butan-1-amine Chemical compound N1C([C@H](CC)NCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 XNNLYZMQHRBHBM-FQEVSTJZSA-N 0.000 description 1
- IXKKHVKJTHAJTN-QHCPKHFHSA-N n-[(1s)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]hexan-1-amine Chemical compound C=1NC([C@H](CC=2C3=CC=CC=C3NC=2)NCCCCCC)=NC=1C1=CC=CC=C1 IXKKHVKJTHAJTN-QHCPKHFHSA-N 0.000 description 1
- UQDNNXSEUDAHQV-UHFFFAOYSA-N n-[(4,5-diphenyl-1h-imidazol-2-yl)methyl]-1-phenylmethanamine Chemical compound N=1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)NC=1CNCC1=CC=CC=C1 UQDNNXSEUDAHQV-UHFFFAOYSA-N 0.000 description 1
- PXRLGMGRLBFALT-NRFANRHFSA-N n-[(s)-[5-(3-bromophenyl)-1h-imidazol-2-yl]-cyclohexylmethyl]cyclohexanamine Chemical compound BrC1=CC=CC(C=2N=C(NC=2)[C@@H](NC2CCCCC2)C2CCCCC2)=C1 PXRLGMGRLBFALT-NRFANRHFSA-N 0.000 description 1
- ZMZYUNIPFVIEJO-NRFANRHFSA-N n-[(s)-[5-[3,5-bis(trifluoromethyl)phenyl]-1h-imidazol-2-yl]-cyclohexylmethyl]cyclohexanamine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C=2N=C(NC=2)[C@@H](NC2CCCCC2)C2CCCCC2)=C1 ZMZYUNIPFVIEJO-NRFANRHFSA-N 0.000 description 1
- ASIZYAUMGZEBJK-NRFANRHFSA-N n-[(s)-cyclohexyl-(5-cyclohexyl-1h-imidazol-2-yl)methyl]cyclohexanamine Chemical compound C1CCCCC1N[C@H](C=1NC=C(N=1)C1CCCCC1)C1CCCCC1 ASIZYAUMGZEBJK-NRFANRHFSA-N 0.000 description 1
- ABAAFWPKEJYSOC-IBGZPJMESA-N n-[(s)-cyclohexyl-(5-phenyl-1h-imidazol-2-yl)methyl]cyclobutanamine Chemical compound C1CCC1N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)C1CCCCC1 ABAAFWPKEJYSOC-IBGZPJMESA-N 0.000 description 1
- SETOECLFBZLJJF-NRFANRHFSA-N n-[(s)-cyclohexyl-(5-phenyl-1h-imidazol-2-yl)methyl]cyclohexanamine Chemical compound C1CCCCC1N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)C1CCCCC1 SETOECLFBZLJJF-NRFANRHFSA-N 0.000 description 1
- COJYPBBBWRSJDO-QFIPXVFZSA-N n-[(s)-cyclohexyl-[4-(4-fluorophenyl)-1-methylimidazol-2-yl]methyl]cyclohexanamine Chemical compound N([C@H](C1=NC(=CN1C)C=1C=CC(F)=CC=1)C1CCCCC1)C1CCCCC1 COJYPBBBWRSJDO-QFIPXVFZSA-N 0.000 description 1
- SPWOSBGRYONYCJ-IBGZPJMESA-N n-[(s)-cyclohexyl-[5-(3,4-difluorophenyl)-1h-imidazol-2-yl]methyl]cyclobutanamine Chemical compound C1=C(F)C(F)=CC=C1C1=CNC([C@@H](NC2CCC2)C2CCCCC2)=N1 SPWOSBGRYONYCJ-IBGZPJMESA-N 0.000 description 1
- JDZPLJKAFUHKGB-NRFANRHFSA-N n-[(s)-cyclohexyl-[5-(3,4-difluorophenyl)-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound C1=C(F)C(F)=CC=C1C1=CNC([C@@H](NC2CCCCC2)C2CCCCC2)=N1 JDZPLJKAFUHKGB-NRFANRHFSA-N 0.000 description 1
- IXOUVPLLPSUURK-FQEVSTJZSA-N n-[(s)-cyclohexyl-[5-(3-fluoro-4-methoxyphenyl)-1h-imidazol-2-yl]methyl]cyclobutanamine Chemical compound C1=C(F)C(OC)=CC=C1C1=CNC([C@@H](NC2CCC2)C2CCCCC2)=N1 IXOUVPLLPSUURK-FQEVSTJZSA-N 0.000 description 1
- IMAXAFNHSLCPFJ-NRFANRHFSA-N n-[(s)-cyclohexyl-[5-(3-fluorophenyl)-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound FC1=CC=CC(C=2N=C(NC=2)[C@@H](NC2CCCCC2)C2CCCCC2)=C1 IMAXAFNHSLCPFJ-NRFANRHFSA-N 0.000 description 1
- IHINLYRCVVQGLD-VWLOTQADSA-N n-[(s)-cyclohexyl-[5-(4-cyclohexylphenyl)-1h-imidazol-2-yl]methyl]cyclobutanamine Chemical compound C1CCC1N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C1CCCCC1)C1CCCCC1 IHINLYRCVVQGLD-VWLOTQADSA-N 0.000 description 1
- PKBNPPPIYHBHMY-QFIPXVFZSA-N n-[(s)-cyclohexyl-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methyl]cycloheptanamine Chemical compound C1=CC(F)=CC=C1C1=CNC([C@@H](NC2CCCCCC2)C2CCCCC2)=N1 PKBNPPPIYHBHMY-QFIPXVFZSA-N 0.000 description 1
- LDHIDBULACTEFX-SFHVURJKSA-N n-[(s)-cyclohexyl-[5-(4-fluorophenyl)-1h-imidazol-2-yl]methyl]propan-2-amine Chemical compound C1([C@H](NC(C)C)C=2NC=C(N=2)C=2C=CC(F)=CC=2)CCCCC1 LDHIDBULACTEFX-SFHVURJKSA-N 0.000 description 1
- OLGQTEBALKCYNZ-QFIPXVFZSA-N n-[(s)-cyclohexyl-[5-(4-methylsulfonylphenyl)-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CNC([C@@H](NC2CCCCC2)C2CCCCC2)=N1 OLGQTEBALKCYNZ-QFIPXVFZSA-N 0.000 description 1
- QJJKGIWQRYOLFP-NRFANRHFSA-N n-[(s)-cyclohexyl-[5-[3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(NC=2)[C@@H](NC2CCCCC2)C2CCCCC2)=C1 QJJKGIWQRYOLFP-NRFANRHFSA-N 0.000 description 1
- LUYBVTAZAFFRSN-IBGZPJMESA-N n-[(s)-cyclohexyl-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]methyl]cyclobutanamine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CNC([C@@H](NC2CCC2)C2CCCCC2)=N1 LUYBVTAZAFFRSN-IBGZPJMESA-N 0.000 description 1
- XVYDIFLWJSJRFD-IBGZPJMESA-N n-[(s)-cyclohexyl-[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]methyl]cyclobutanamine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CNC([C@@H](NC2CCC2)C2CCCCC2)=N1 XVYDIFLWJSJRFD-IBGZPJMESA-N 0.000 description 1
- HBVHMLWDRYKJPS-UHFFFAOYSA-N n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]butane-1-sulfonamide Chemical compound N1C(CCNS(=O)(=O)CCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 HBVHMLWDRYKJPS-UHFFFAOYSA-N 0.000 description 1
- XBJFSTUGCOCCFF-UHFFFAOYSA-N n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]cyclohexanamine Chemical compound C1CCCCC1NCCC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 XBJFSTUGCOCCFF-UHFFFAOYSA-N 0.000 description 1
- OAAIYWDJOLLSBT-UHFFFAOYSA-N n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]hexan-1-amine Chemical compound N1C(CCNCCCCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 OAAIYWDJOLLSBT-UHFFFAOYSA-N 0.000 description 1
- ZYCSHKXFHJATLW-UHFFFAOYSA-N n-[[5-(3,5-ditert-butyl-4-hydroxyphenyl)-1h-imidazol-2-yl]methyl]-n-methyl-4-nitrobenzamide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=O)N(C)CC(NC=1)=NC=1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 ZYCSHKXFHJATLW-UHFFFAOYSA-N 0.000 description 1
- FUAAMQAMYDSPKW-UHFFFAOYSA-N n-[[5-(3-bromophenyl)-1h-imidazol-2-yl]methyl]cyclohexanamine Chemical compound BrC1=CC=CC(C=2N=C(CNC3CCCCC3)NC=2)=C1 FUAAMQAMYDSPKW-UHFFFAOYSA-N 0.000 description 1
- OTXANIXRWRMWTK-UHFFFAOYSA-N n-benzyl-1-(5-phenyl-1h-imidazol-2-yl)cyclohexan-1-amine Chemical compound C=1C=CC=CC=1CNC1(C=2NC=C(N=2)C=2C=CC=CC=2)CCCCC1 OTXANIXRWRMWTK-UHFFFAOYSA-N 0.000 description 1
- ZUSQPOCAWDPAND-UHFFFAOYSA-N n-benzyl-1-phenyl-n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]methanamine Chemical compound N=1C(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CNC=1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 ZUSQPOCAWDPAND-UHFFFAOYSA-N 0.000 description 1
- NBXPVHWLMLXRBY-UHFFFAOYSA-N n-benzyl-2-(5-phenyl-1h-imidazol-2-yl)propan-2-amine Chemical compound N=1C(C=2C=CC=CC=2)=CNC=1C(C)(C)NCC1=CC=CC=C1 NBXPVHWLMLXRBY-UHFFFAOYSA-N 0.000 description 1
- XDDDGAGJFLPLPC-UHFFFAOYSA-N n-benzyl-3-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propan-1-amine Chemical compound N=1C(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CNC=1CCCNCC1=CC=CC=C1 XDDDGAGJFLPLPC-UHFFFAOYSA-N 0.000 description 1
- JUUYMQSGXIKVPU-UHFFFAOYSA-N n-benzyl-n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]hexan-1-amine Chemical compound C=1C=CC=CC=1CN(CCCCCC)CC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 JUUYMQSGXIKVPU-UHFFFAOYSA-N 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- DKNGJISFWRUHBK-UHFFFAOYSA-N n-methyl-1-phenyl-n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]methanamine Chemical compound C=1C=CC=CC=1CN(C)CC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 DKNGJISFWRUHBK-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical class ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JLQFXZBEZFLRLG-UHFFFAOYSA-N propyl n-[2-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group N1C(CCNC(=O)OCCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 JLQFXZBEZFLRLG-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical class OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YANPBJSFTHUEAC-UHFFFAOYSA-N tert-butyl 2-[(2-amino-2-sulfanylideneethyl)amino]acetate Chemical compound CC(C)(C)OC(=O)CNCC(N)=S YANPBJSFTHUEAC-UHFFFAOYSA-N 0.000 description 1
- KYZYVGBBYFHROZ-UHFFFAOYSA-N tert-butyl n-(2-amino-2-sulfanylideneethyl)-n-methylcarbamate Chemical compound NC(=S)CN(C)C(=O)OC(C)(C)C KYZYVGBBYFHROZ-UHFFFAOYSA-N 0.000 description 1
- BBPZOYZHRBUIRS-UHFFFAOYSA-N tert-butyl n-[(1-benzyl-4-phenylimidazol-2-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=NC(C=2C=CC=CC=2)=CN1CC1=CC=CC=C1 BBPZOYZHRBUIRS-UHFFFAOYSA-N 0.000 description 1
- WWJKNEKKMXNEOG-QGZVFWFLSA-N tert-butyl n-[(1r)-1-(5-tert-butyl-1h-imidazol-2-yl)-2-(1h-indol-3-yl)ethyl]carbamate Chemical compound C1([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)OC(C)(C)C)=NC(C(C)(C)C)=CN1 WWJKNEKKMXNEOG-QGZVFWFLSA-N 0.000 description 1
- LZBCBTANKCOTAZ-HXUWFJFHSA-N tert-butyl n-[(1r)-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]butyl]carbamate Chemical group N1C([C@H](NC(=O)OC(C)(C)C)CCC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 LZBCBTANKCOTAZ-HXUWFJFHSA-N 0.000 description 1
- OPFXSHZAPQGHFM-OAQYLSRUSA-N tert-butyl n-[(1r)-2-(1h-indol-3-yl)-1-(1-methyl-4-phenylimidazol-2-yl)ethyl]carbamate Chemical compound N1=C([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)OC(C)(C)C)N(C)C=C1C1=CC=CC=C1 OPFXSHZAPQGHFM-OAQYLSRUSA-N 0.000 description 1
- QWEVSVIZUBGYOE-HXUWFJFHSA-N tert-butyl n-[(1r)-2-(1h-indol-3-yl)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]carbamate Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)OC(C)(C)C)=NC=1C1=CC=CC=C1 QWEVSVIZUBGYOE-HXUWFJFHSA-N 0.000 description 1
- MJZUPVKYQFLLKL-HXUWFJFHSA-N tert-butyl n-[(1r)-2-(1h-indol-3-yl)-1-[5-(4-nitrophenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical compound C=1NC([C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)OC(C)(C)C)=NC=1C1=CC=C([N+]([O-])=O)C=C1 MJZUPVKYQFLLKL-HXUWFJFHSA-N 0.000 description 1
- XQQYLZISXRTLCC-XMMPIXPASA-N tert-butyl n-[(1r)-2-cyclohexyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]ethyl]carbamate Chemical group C([C@@H](NC(=O)OC(C)(C)C)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)C1CCCCC1 XQQYLZISXRTLCC-XMMPIXPASA-N 0.000 description 1
- VQHHRICBFALAFP-OAHLLOKOSA-N tert-butyl n-[(1r)-3-methyl-1-(5-phenyl-1h-imidazol-2-yl)butyl]carbamate Chemical compound N1C([C@H](NC(=O)OC(C)(C)C)CC(C)C)=NC(C=2C=CC=CC=2)=C1 VQHHRICBFALAFP-OAHLLOKOSA-N 0.000 description 1
- VEJFGTBLVYLUPP-LJQANCHMSA-N tert-butyl n-[(1r)-3-phenyl-1-(5-phenyl-1h-imidazol-2-yl)propyl]carbamate Chemical compound C([C@@H](NC(=O)OC(C)(C)C)C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 VEJFGTBLVYLUPP-LJQANCHMSA-N 0.000 description 1
- LZTILXPFIFGUPV-RUZDIDTESA-N tert-butyl n-[(1r)-3-phenyl-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propyl]carbamate Chemical group C([C@@H](NC(=O)OC(C)(C)C)C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 LZTILXPFIFGUPV-RUZDIDTESA-N 0.000 description 1
- MRCFERHKBLHBSZ-SFHVURJKSA-N tert-butyl n-[(1s)-1-(4,5-diphenyl-1h-imidazol-2-yl)propyl]carbamate Chemical compound N1C([C@@H](NC(=O)OC(C)(C)C)CC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 MRCFERHKBLHBSZ-SFHVURJKSA-N 0.000 description 1
- YIPUWMSPQLYINU-IBGZPJMESA-N tert-butyl n-[(1s)-1-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propyl]carbamate Chemical group N1C([C@@H](NC(=O)OC(C)(C)C)CC)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 YIPUWMSPQLYINU-IBGZPJMESA-N 0.000 description 1
- OUVXCNJOXIZWNG-UHFFFAOYSA-N tert-butyl n-[(4,5-diphenyl-1h-imidazol-2-yl)methyl]-n-methylcarbamate Chemical compound N1C(CN(C)C(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OUVXCNJOXIZWNG-UHFFFAOYSA-N 0.000 description 1
- LIJZOCXZLJDJDW-UHFFFAOYSA-N tert-butyl n-[(5-phenyl-1h-imidazol-2-yl)methyl]carbamate Chemical compound N1C(CNC(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1 LIJZOCXZLJDJDW-UHFFFAOYSA-N 0.000 description 1
- URCVUGKBSYAMPU-UHFFFAOYSA-N tert-butyl n-[1-(5-phenyl-1h-imidazol-2-yl)cyclohexyl]carbamate Chemical compound N=1C(C=2C=CC=CC=2)=CNC=1C1(NC(=O)OC(C)(C)C)CCCCC1 URCVUGKBSYAMPU-UHFFFAOYSA-N 0.000 description 1
- KETJWJDZZPIODY-UHFFFAOYSA-N tert-butyl n-[2-(5-phenyl-1h-imidazol-2-yl)propan-2-yl]carbamate Chemical compound N1C(C(C)(C)NC(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1 KETJWJDZZPIODY-UHFFFAOYSA-N 0.000 description 1
- ZUENNJPQOJLFIS-UHFFFAOYSA-N tert-butyl n-[3-[5-(4-phenylphenyl)-1h-imidazol-2-yl]propyl]carbamate Chemical group N1C(CCCNC(=O)OC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 ZUENNJPQOJLFIS-UHFFFAOYSA-N 0.000 description 1
- IRPIKPGPAKUJEO-UHFFFAOYSA-N tert-butyl n-[6-(5-phenyl-1h-imidazol-2-yl)hexyl]carbamate Chemical compound N1C(CCCCCCNC(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1 IRPIKPGPAKUJEO-UHFFFAOYSA-N 0.000 description 1
- QICDCCGRWFZMIN-UHFFFAOYSA-N tert-butyl n-[[1-methyl-4-(4-phenylphenyl)imidazol-2-yl]methyl]carbamate Chemical group N1=C(CNC(=O)OC(C)(C)C)N(C)C=C1C1=CC=C(C=2C=CC=CC=2)C=C1 QICDCCGRWFZMIN-UHFFFAOYSA-N 0.000 description 1
- WDNMTCPYOJPZBJ-UHFFFAOYSA-N tert-butyl n-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]-n-methylcarbamate Chemical compound S1C(CN(C)C(=O)OC(C)(C)C)=NC(C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 WDNMTCPYOJPZBJ-UHFFFAOYSA-N 0.000 description 1
- JYJLOGAEABLBQF-UHFFFAOYSA-N tert-butyl n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]carbamate Chemical group N1C(CNC(=O)OC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 JYJLOGAEABLBQF-UHFFFAOYSA-N 0.000 description 1
- USINPNMJWJJQNE-UHFFFAOYSA-N tert-butyl n-benzyl-n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]carbamate Chemical group C=1C=CC=CC=1CN(C(=O)OC(C)(C)C)CC(NC=1)=NC=1C(C=C1)=CC=C1C1=CC=CC=C1 USINPNMJWJJQNE-UHFFFAOYSA-N 0.000 description 1
- VFMFHHGHSYWVPM-UHFFFAOYSA-N tert-butyl n-methyl-n-[(5-methyl-4-phenyl-1h-imidazol-2-yl)methyl]carbamate Chemical compound N1C(CN(C)C(=O)OC(C)(C)C)=NC(C=2C=CC=CC=2)=C1C VFMFHHGHSYWVPM-UHFFFAOYSA-N 0.000 description 1
- RQVBMYXJWQXLOL-UHFFFAOYSA-N tert-butyl n-methyl-n-[[5-(4-phenylphenyl)-1h-imidazol-2-yl]methyl]carbamate Chemical group N1C(CN(C)C(=O)OC(C)(C)C)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 RQVBMYXJWQXLOL-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to the use of compounds of general formula (I) for preparing a medicament intended to inhibit monoamine oxydases (MAO) and/or lipidic peroxidation and/or to act as modulators of the sodium channels.
- a subject of the invention is also, as medicaments, the compounds of general formula (II) defined hereafter.
- it relates to new compounds of general formula (III).
- the advantage of a combination of the inhibitory activities of MAO and inhibition of lipidic peroxidation is for example well illustrated in Parkinson's disease.
- This pathology is characterized by a loss of dopaminergic neurons of the nigrostriatal route the cause of which would in part be linked to an oxidizing stress due to ROS's.
- the exogenic dopamine from L Dopa is used in therapeutics in order to maintain sufficient levels of dopamine.
- MAO inhibitors are also used with L Dopa to avoid its metabolic degradation but do not act on the ROS's. Compounds which act both on MAO's and ROS's will therefore have a certain advantage.
- the character of the modulator of the sodium channels is very useful for therapeutic indications such as:
- the European Patent Application EP 432 740 describes derivatives of hydroxyphenylthiazoles, which can be used in the treatment of inflammatory diseases, in particular rheumatic diseases. These derivatives of hydroxyphenylthiazoles show properties of trapping free radicals and inhibitors of the metabolism of arachidonic acid (they inhibit lipoxygenase and cyclooxygenase).
- R1 represents one of the aryl, heteroaryl, aralkyl or cycloalkyl radicals optionally substituted by one to three substituents chosen independently from a halogen atom, the CF 3 , CN, OH, alkyl or alkoxy radical, SO 2 R9 with R9 representing NH 2 or NHCH 3
- X represents NR2, R2 representing H or alkyl
- Y represents N or CR3
- Z represents CR3 or N; on the condition however that Y and Z are not both CR3 or N at the same time
- R3 represents H, alkyl, halogen, hydroxyalkyl or phenyl optionally substituted by 1 to 3 substituents chosen from H, CF 3 , CN, SO 2 NH 2 , OH, alkyl or alkoxy
- m represents 0, 1 or 2
- R4 represents H or alkyl; when Z represents CR3, then R3 and R4 can also represent together —
- R1 represents in particular an alkyl, optionally substituted phenyl or optionally substituted heterocyclic aryl radical
- R2 represents H or phenylalkyl
- R4 represents H, quinolyl, 3-4-methylenedioxyphenyl or one of the phenyl or pyridyl radicals optionally substituted, by a radical or radicals chosen in particular from alkyl, alkoxy, alkylthio, optionally protected hydroxy, amino, alkylamino, dialkylamino
- R5 represents H or an imidazolyl, phenyl, nitrophenyl, phenylalkyl radical, or also a —CO—N(R7)(R8) radical, in which R7 and R8 represent independently H, phenyl, phenylalkyl, alkyl or alkoxy; or R4 and R5 in combination form a
- the compounds corresponding to general formula (I) in racemic, enantiomeric form or any combination of these forms in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (I) corresponds exclusively to one of the following sub-formulae: in which A represents either a radical in which R 3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical, or a radical in which R 4 , R 5 , R 6 , R 7 and R 8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR 10 R 11 radical, R 10 and R 11 representing, independently, a hydrogen atom, an alkyl radical or a —COR 12 group, or R 10 and R 11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from
- ⁇ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms
- —R 34 and R 35 representing, independently, a hydrogen atom or an alkyl radical
- R 36 and R 37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR 10 R 11 radicals,
- R 10 and R 11 representing, independently, a hydrogen atom, an alkyl radical or a —COR 12 group, or R 10 and R 11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
- R 12 representing a hydrogen atom or an alkyl, alkoxy or NR 13 R 14 radical
- A represents an alkyl, cycloalkyl or cycloalkylalkyl radical
- X represents S or NR 38 .
- R 38 representing a hydrogen atom or an alkyl, cyanoalkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical
- Y represents O or S
- R 1 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH 2 ) g -Z 1 R 39 , —(CH 2 ) g —COR 40 , —(CH 2 ) g —NHCOR 70 , aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radicals itself being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, amino
- Z 1 and Z 2 representing a bond, —O—, —NR 41 — or —S—,
- R 39 and R 41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl or cyanoalkyl radical
- R 40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR 42 R 43 radical,
- R 42 and R 43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- R 2 represents a hydrogen atom, an alkyl aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl or —(CH 2 ) g —NHCOR 71 radical, or also one of the aralkyl or heteroarylalkyl radicals optionally substituted on the aryl or heteroaryl group by one or more of the groups chosen independently from the group composed of a halogen atom and an alkyl, alkoxy, hydroxy, cyano, nitro, amino, alkylamino or dialkylamino radical,
- R 70 and R 71 representing independently an alkyl or alkoxy radical
- B represents a hydrogen atom, an alkyl radical, a —(CH 2 ) g -Z 3 R 44 radical or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical,
- Z 3 representing a bond, —O—, —NR 45 — or —S—,
- R 44 and R 45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxy, allenyl, allenylalkyl or cyanoalkyl radical;
- ⁇ represents one of the NR 46 R 47 or OR 48 radicals, in which:
- R 46 and R 47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, (CH 2 ) g -Z 4 R 50 , —(CH 2 ) k —COR 51 , —(CH 2 ) k —COOR 51 , —(CH 2 ) k —CONHR 51 or —SO 2 R 51 radical, or also a radical chosen from the aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl and in particular pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl
- Z 4 and Z 5 representing a bond, —O—, —NR 52 — or —S—,
- R 46 and R 47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R 53 )—, —NR 54 —, —O—, —S— and —CO—, said heterocycle being able to be for example an azetidine, a piperazine, a homopiperazine, a 3,5-dioxopiperazine, a piperidine, a pyrrolidine, a morpholine or a thiomorpholine,
- R 50 and R 52 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
- R 51 representing, independently each time that they occur, a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical has 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, alkoxyalkyl or NR 58 R 59 radical, or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,
- R 58 and R 59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
- R 53 and R 54 representing, independently, a hydrogen atom or a —(CH 2 ) k -Z 7 R 60 or —(CH 2 ) k —COR 61 radical,
- Z 7 representing a bond, —O—, —NR 62 — or —S—,
- R 60 and R 62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH 2 ) k -Z 8 R 63 and —(CH 2 ) k —COR 64 radicals,
- R 61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR 65 R 66 radical,
- R 65 and R 66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- Z 8 representing a bond, —O—, —NR 67 — or —S—,
- R 63 and R 67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- R 64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR 68 R 69 radical,
- R 68 and R 69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- R 48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical
- A represents the 4-hydroxy-2,3-di-tertiobutyl-phenyl radical
- these compounds have at least two of the activities mentioned above.
- they inhibit both the MAO's and trap the ROS's or they will have both an antagonist activity vis-à-vis the sodium channels and a trapping activity on the ROS's.
- the compounds of general formula (I) even combine the three activities.
- alkyl unless otherwise specified, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms.
- cycloalkyl when no further detail is given, is meant a monocyclic carbon system containing 3 to 7 carbon atoms.
- alkenyl when no further detail is given, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and having at least one unsaturation (double bond).
- alkynyl when no further detail is given, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and having at least one double unsaturation (triple bond).
- allenyl is meant the —CH ⁇ C ⁇ CH 2 radical.
- carbocyclic or heterocyclic aryl is meant a carbocyclic system (in particular, the phenyl radical which can be noted Ph in an abbreviated fashion) or heterocyclic system comprising at least one aromatic ring, a system being called heterocyclic when at least one of the rings which comprises it contains a heteroatom (O, N or S).
- heterocycle is meant a mono- or polycyclic system, said system comprising at least one heteroatom chosen from O, N and S and being saturated, partially or totally unsaturated or aromatic.
- heteroaryl is meant a heterocycle as defined previously in which at least one of the rings which comprises it is aromatic.
- haloalkyl is meant an alkyl radical at least one of hydrogen atoms of which (and optionally all) is replaced by a halogen atom.
- an optionally substituted radical is meant unless otherwise specified a radical comprising one or more substituents chosen independently from the group composed of a halogen atom and the alkyl and alkoxy radicals.
- alkylthio, alkoxy, haloalkyl, alkoxyalkyl, trifluoromethylalkyl, cycloalkylalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, allenylalkyl, cyanoalkyl and aralkyl radicals is meant respectively the alkylthio, alkoxy, haloalkyl, alkoxyalkyl, trifluoromethylalkyl, cycloalkylalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, allenylalkyl, cyanoalkyl and aralkyl radicals the alkyl radical (the alkyl radicals) of which have the meaning(s) indicated previously.
- heterocycle is meant in particular the thiophene, piperidine, piperazine, quinoline, indoline and indole radicals.
- linear or branched alkyl having 1 to 6 carbon atoms is meant in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals.
- halogen is meant the fluorine, chlorine, bromine or iodine atoms.
- the compounds according to the invention are such that they correspond to general formula (I): in racemic, enantiomeric form or any combination of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (I) corresponds exclusively to one of the following sub-formulae: in which A represents either a radical in which R 3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical, or a radical in which R 4 , R 5 , R 6 , R 7 and R 8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR 10 R 11 radical, R 10 and R 11 representing, independently, a hydrogen atom or an alkyl radical R 9 represents a hydrogen atom or an alkyl radical, and W doesn't exist, or represents a bond, or —O—, —S— or —NR 18 —, in which R 18 represents a hydrogen
- the Q radical is preferably found in para position with respect to the heterocycle Het.
- the compounds of general formula (I) or their salts are more especially intended to have an inhibitory activity on MAO's and/or ROS's and they will therefore be preferably such that:
- A represents
- R 3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical
- R 4 , R 5 , R 6 , R 7 and R 8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy or NR 10 R 11 radical
- R 10 and R 11 representing, independently, a hydrogen atom or an alkyl radical, or R 10 and R 11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine
- R 9 represents a hydrogen atom or an alkyl radical
- W doesn't exist, or represents a bond, or —O—, —S
- the compounds of general formula (I) when they are intended to have an inhibitory activity on MAO's and/or ROS's, will be such that:
- A represents
- R 3 represents a hydrogen atom
- R 4 , R 5 , R 6 , R 7 and R 8 represent, independently, a hydrogen atom, or an alkyl or alkoxy radical
- R 9 represents a hydrogen atom
- W doesn't exist, or represents a bond, or —O—, —S— or —NR 18 —, in which R 18 represents a hydrogen atom or an alkyl radical; or a radical in which Q represents —OR 22 , —SR 22 or a phenyl radical substituted by an OH radical and optionally one or more of the additional substituents chosen independently from a halogen atom and an OH, alkyl or alkoxy radical.
- R 22 representing a hydrogen atom or an alkyl radical
- R 19 , R 20 and R 21 represent, independently, a hydrogen, a halogen, the OH or SR 26 group, or an alkyl or alkoxy radical
- R 26 representing a hydrogen atom or an alkyl radical, or a radical in which R 32 represents a hydrogen atom or an alkyl radical
- the said compounds of general formula (I) (or their salts) more especially intended to have an inhibitory activity on MAO's and the ROS's, the said compounds having at least one of the following characteristics will generally be preferred:
- the compounds of Examples 1 to 30, 210, 291, 316, 319 to 323, 329 to 336 and 346 to 349 are preferred when an inhibitory activity on MAO's and/or the ROS's is sought in the first place.
- the compounds of Examples 1, 3, 6, 22, 24, 26 to 29, 323 and 332 are preferred when an inhibitory activity on MAO's and/or the ROS's is sought in the first place.
- the compounds of general formula (I) or their pharmaceutically acceptable salts are more especially intended to have an modulating activity on the sodium channels and they are then preferably such that they correspond to general sub-formulae (I), and (I) 2 and that:
- A represents
- Q represents H, —OR 22 , SR 22 or a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom, an alkyl or alkoxy radical, and a group of two substituents together representing a methylenedioxy or ethylenedioxy radical, or Q represents a —COPh, —OPh, —SPh, —SO 2 Ph or —CH 2 Ph radical, said —COPh, —OPh, —SPh, —SO 2 Ph or —CH 2 Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen independently from an alkyl or alkoxy radical and a halogen atom, R 22 representing a hydrogen atom or an alkyl radical, and R 19 , R 20 and R 21 represent, independently, a hydrogen, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro, cycloalkyl,
- A represents the radical in which Q represents H, —OR 22 , —SR 22 , or a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical, or also Q represents a —COPh, —OPh, —SPh, —SO 2 Ph or —CH 2 Ph radical, said —COPh, —OPh, —SPh, —SO 2 Ph or —CH 2 Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen from an alkyl or alkoxy radical and a halogen atom, R 22 representing a hydrogen atom or an alkyl radical, and R 19 , R 20 and R 21 represent, independently, a hydrogen,
- R 1 and R 2 will preferably represent hydrogen atoms.
- the compounds of Examples 1, 3, 6, 7, 9 to 11, 13, 15 to 17, 20, 24, 26, 28 to 318, 321, 324 to 330 and 337 to 345 are preferred when a modulating activity on the sodium channels is sought in the first place.
- Het is such that the compounds of general formula (I) correspond to one of the general sub-formulae (I), and (I), in which X represents NH or S or general sub-formula (I) 3 in which Y represents O;
- A represents a radical in which Q represents OH, two of the R 19 , R 20 and R 21 radicals represent an alkyl radical and the third represents a hydrogen atom, or in which Q represents a phenyl radical substituted by an OH radical and one or more radicals chosen independently from alkyl radicals;
- B represents a hydrogen atom; n represents 0 or 1; R 1 and R 2 both represent a hydrogen atom; and
- ⁇ represents an NR 46 R 47 radical in which R 46 represents a hydrogen atom or an alkyl, alkynyl, hydroxyalkyl or cyanoalkyl radical and R 47 represents a hydrogen atom or an alkyl radical or also R 46 and R 47 form together with the nitrogen atom which carries them a non-aromatic heterocycle with 5 to 7 members, the additional members being chosen from —CH 2 — and —NH—; can be used to prepare a medicament intended both to inhibit MAO's and lipidic peroxidation and to modulate the sodium channels.
- the compounds of general formula (I) which can be used to prepare a medicament intended both to inhibit MAO's and lipidic peroxidation and to modulate the sodium channels will be such that:
- Het is such that the compounds of general formula (I) correspond to general sub-formula (I), in which X represents S or to general sub-formula (I) 3 in which Y represents O;
- A represents a radical in which Q represents OH, two of the radicals R 19 , R 20 and R 21 represent an alkyl radical and the third represents a hydrogen atom; B represents a hydrogen atom; n represents 0 or 1; R 1 and R 2 both represent a hydrogen atom; and ⁇ represents an NR 46 R 47 radical in which R 46 represents a hydrogen atom or an alkyl, hydroxyalkyl or cyanoalkyl radical and R 47 represents a hydrogen atom or an alkyl radical or also R 46 and R 47 form together with the nitrogen atom which carries them an N-piperazinyl radical.
- n will preferably represent 0 when Het is such that the compounds of general formula (I) correspond to general sub-formula (I), in which X represents S and preferably 1 when Het is such that the compounds of general formula (I) correspond to general sub-formula (I) 3 in which Y represents O.
- Examples 1, 3, 6, 24, 26, 28 and 29 (sometimes described in the form of salts) or their pharmaceutically acceptable salts will be preferred if one wishes to prepare a medicament intended both to inhibit MAO's and lipidic peroxidation and to modulate the sodium channels.
- the invention also offers, as medicaments, the compounds of general formula (II) in racemic, enantiomeric form or any combinations of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (II) correspond exclusively to one of the following sub-formulae: in which A represents either a radical in which R 3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical, or a radical in which R 4 , R 5 , R 6 , R 7 and R 8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR 10 R 11 radical, R 10 and R 11 representing, independently, a hydrogen atom, an alkyl radical or a —COR 12 group, or R 10 and R 11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms
- A represents a radical in which Q represents OH and two of the R 19 , R 20 and R 21 radicals represent alkyl radicals.
- Het represents an imidazole ring.
- the medicaments of general formula (II) will be chosen from the compounds described (sometimes in the form of salts) in Examples 1 to 35, 52, 57, 61, 80, 82, 83, 85 to 87, 90, 94, 113, 115, 123, 127, 130, 132, 134, 138, 139, 147, 152, 154, 161, 164, 169, 171 to 173, 176 to 180, 203, 237 to 239, 243 to 247, 249, 251, 255, 258 to 262, 264 to 271, 273 to 275 and 277 to 349, or the pharmaceutically acceptable salts of these compounds.
- the medicaments of general formula (II) will be chosen from the compounds described (sometimes in the form of salts) in Examples 1, 3, 6, 7, 11, 17, 24, 26 to 35, 57, 61, 82, 83, 85 to 87, 94, 113, 123, 130, 132, 134, 138, 139, 152, 154, 164, 169, 171 to 173, 176 to 178, 203, 237 to 239, 243 to 247, 249, 955, 258, 259, 261, 262, 264 to 271, 273 to 275, 277 to 281, 283 to 288, 293 to 313, 321, 323, 324, 332 and 338 to 340, or the pharmaceutically acceptable salts of these compounds.
- the invention also relates, as new industrial products, to the compounds of general formula (III) in racemic, enantiomeric form or any combinations of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (III) corresponds exclusively to one of the following sub-formulae: in which A represents either a radical in which R 3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical, or a radical in which R 4 , R 5 , R 6 , R 7 and R 8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR 10 R 11 radical, R 10 and R 11 representing, independently, a hydrogen atom, an alkyl radical or a —COR 12 group, or R 10 and R 11 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatom
- R 15 representing a hydrogen atom or an alkyl, alkoxy or NR 16 R 17 radical
- R 16 and R 17 representing, independently, a hydrogen atom or an alkyl radical, or R 16 and R 17 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, and W doesn't exist, or represents a bond, or —O—, —S— or —NR 18 —, in which R 18 represents a hydrogen atom or an alkyl radical; or a radical in which Q represents H, —OR 22 , —SR 22 , —NR 23 R 24 , a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom, an OH, cyano, nitro, alkyl, alkoxy or —NR 10 R 11 radical and a group of two substitu
- the compounds of general formula (III) will be both ROS and MAO inhibitors and have at least one of the following characteristics:
- the compounds of general formula (III) will be modulators of the sodium channels and preferably have one of the following two characteristics:
- the compounds of general formula (III) which are modulators of the sodium channels are such that Het represents an imidazole ring (i.e. that they correspond to one of general formulae (III) 1 or (III) 2 in which X represents an NR 38 radical in which R 38 is as defined previously).
- the compounds of general formula (III) will be preferably chosen from the compounds described (sometimes in the form of salts) in Examples 1 to 7, 9, 10, 24, 26 to 35, 52, 57, 61, 80, 82, 83, 85 to 87, 90, 94, 113, 115, 123, 127, 130, 132, 134, 138, 139, 147, 152, 154, 161, 164, 169, 171 to 173, 176 to 180, 203, 237 to 239, 243 to 247, 249, 251, 255, 258 to 262, 264 to 271, 273 to 275, 277 to 333 and 335 to 349, or the salts of these compounds.
- the compounds of general formula (III) will be chosen from the compounds described (sometimes in the form of salts) in Examples 1, 3, 6, 7, 24, 26 to 35, 57, 61, 82, 83, 85 to 87, 94, 113, 123, 130, 132, 134, 138, 139, 152, 154, 164, 169, 171 to 173, 176 to 178, 203, 237 to 239, 243 to 247, 249, 255, 258, 259, 261, 262, 264 to 271, 273 to 275, 277 to 281, 283 to 288, 293 to 313, 321, 323, 324, 332 and 338 to 340, or the salts of these compounds.
- the compounds according to the present invention can contain asymmetrical carbon atoms.
- the compounds according to the present invention have two possible enantiomeric forms, i.e. the “R” and “S” configurations.
- the present invention includes the two enantiomeric forms and all combinations of these forms, including the racemic “RS” mixtures.
- RS racemic
- the invention also relates to of the pharmaceutical compositions containing, as active ingredient, a compound of general formula (II) or a pharmaceutically acceptable salt of a compound general formula (II), as well as the use of the compounds of general formula (II) for preparing a medicament intended to inhibit the monoamine oxydases, in particular monoamine oxydase B, to inhibit lipidic peroxidation, to have a modulatory activity on the sodium channels or to have two of the three or all three aforementioned activities.
- a compound of general formula (II) or a pharmaceutically acceptable salt of a compound general formula (II) as well as the use of the compounds of general formula (II) for preparing a medicament intended to inhibit the monoamine oxydases, in particular monoamine oxydase B, to inhibit lipidic peroxidation, to have a modulatory activity on the sodium channels or to have two of the three or all three aforementioned activities.
- the invention relates moreover, as medicaments, to the compounds of general formula (III) or their pharmaceutically acceptable salts. Similarly it relates to the pharmaceutical compositions containing, as active ingredient, a compound of general formula (III) or a pharmaceutically acceptable salt of a compound of general formula (III), as well as to the use of the compounds of general formula (III) for preparing a medicament intended to inhibit monoamine oxydases, in particular monoamine oxydase B, to inhibit lipidic peroxidation, to have a modulatory activity on the sodium channels or to have two of the three or all three of the aforementioned activities.
- the compounds of general formula (I), (II) or (III) can be used for preparing a medicament intended to treat one of the following disorders or one of the following diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depressions, psychoses, migraine or pains and in particular neuropathic pains.
- salt in particular the addition salts with inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or with organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate and stearate.
- inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate
- organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate and stearate.
- bases such as sodium or potassium hydroxide.
- Salt selection for basic drugs Int. J. Pharm . (1986), 33, 201-217.
- the pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories.
- Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
- compositions containing a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups.
- Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, similarly their mixtures, in varying proportions, in water.
- the administration of a medicament according to the invention can be done by topical, oral, parenteral route, by intramuscular injection, etc.
- the administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg to 10 g according to the type of active compound used.
- the compounds of general formula (I) can be prepared by the processes described below.
- the compounds of general formula (I) can be prepared by the 8 synthesis routes illustrated below (Diagram 1) starting from the intermediates of general formula (IV), (V), (VI), (VII), (VIII), (IX), (X) and (I) ⁇ in which A, B, Q, R 1 , R 2 , Het and n are as defined above, L is a parting group such as for example a halogen, Alk is an alkyl radical, Gp is a protective group for an amine function, for example a 2-(trimethylsilyl)ethoxymethyl (SEM) group, and Gp′ a protective group for an alcohol function, for example a group of benzyl, acetate or also silyl type such as tert-butyldimethylsilyl, and finally A represents a bond or a —(CH 2 ) x —, —CO—(CH 2 ) x —, —(CH 2 ) y —O— or —C( ⁇ NH)—
- the protected amines of general formula (IV) are accessible by a general synthesis route described in Biorg. and Med. Chem. Lett., 1993, 3, 915 and Tetrahedron Lett., 1993. 34, 1901 and more particularly in the PCT Patent Application WO 98/58934.
- ⁇ represents an alkyl, cycloalkylalkyl, arylalkyl, aryl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl or hydroxyalkyl radical and ⁇ ′ represents an alkyl, cycloalkylalkyl, arylalkyl or aryl radical when g or k do not represent 0, or ⁇ ′ represents an alkyl, cycloalkylalkyl, arylalkyl radical or an aryl radical preferably deactivated (i.e.
- a reducing agent such as sodium triacetoxyborohydride or sodium borohydride
- a lower aliphatic alcohol such as methanol
- the compounds of general formula (V) are converted to the corresponding compounds of general formula (I) by reaction with the halogenated derivatives of general formula (XI) in a solvent such as acetonitrile, dichloromethane or acetone and in the presence of a base such as for example triethylamine or potassium carbonate at a temperature comprised between ambient temperature and the reflux temperature of the solvent.
- a solvent such as acetonitrile, dichloromethane or acetone
- a base such as for example triethylamine or potassium carbonate
- the derivatives of general formula (V) are in particular accessible by a general synthesis route described in Biorg. and Med. Chem. Lett., 1993, 3, 915 and Tetrahedron Lett., 1993. 34, 1901, and more particularly in the Patent Application WO 98/58934.
- R 46 ⁇ H the compounds of general formula (V) can be prepared, for example, according to a protocol described in the Patent Application WO 98/58934 (using the appropriate amino acid in place of N—Boc-sarcosinamide).
- R 47 represents a cycloalkyl radical
- the amines of general formula (I), Diagram 3a, in which A, B, R 1 , R 2 , R 46 , Het and n are as defined above and i represents an integer from 0 to 4 are prepared by condensation of the amines of general formula (V) with the cycloalkylketones of general formula (XIV) in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium borohydride in a lower aliphatic alcohol such as methanol and optionally in the presence of molecular sieves at ambient temperature.
- a reducing agent such as sodium triacetoxyborohydride or sodium borohydride in a lower aliphatic alcohol such as methanol
- Route 3 Het is Oxazole or Thiazole, R 1 and R 2 are both H and ⁇ is OH.
- the alcoholic derivatives of general formula (I), Diagram 4, in which A, B, Het and n are as defined above and R 1 and R 2 are hydrogen atoms are obtained by reduction of the acids or esters of general formula (VI) (accessible by a general synthesis route described in J. Med. Chem., 1996, 39, 237-245 and the PCT Patent Application WO 99/09829).
- This reduction can, for example, be carried out by the action of boron hydride or lithium aluminium hydride or also diisobutylaluminium hydride in an aprotic polar solvent such as tetrahydrofuran.
- Route 4 Het is Oxazole or Thiazole and ⁇ is NR 46 R 47 .
- the amines of general formula (I), Diagram 5, in which A, B, R 1 , R 2 , R 46 , R 47 , Het, and n are as defined above, are prepared by condensation of the primary or secondary amines of general formula R 46 —NHR 47 with the compounds of general formula (VII) (in which L preferably represents a halogen atom Hal, but can also represent a mesylate or tosylate group) according to a general synthesis route described in J. Med. Chem., 1996, 39, 237-245 and the PCT Patent Application WO 99/09829 or the U.S. Pat. No. 4,123,529.
- This synthesis route can in particular be used when R 46 and R 47 taken together form with the nitrogen atom which carries them a non-aromatic heterocycle with 4 to 8 members.
- the reaction typically takes place in an anhydrous solvent (for example dimethylformamide, dichloromethane, tetrahydrofuran or acetone) in the presence of a base (for example Na 2 CO 3 or K 2 CO 3 in the presence of triethylamine), and preferably while heating.
- Route 5 Het is Imidazole and ⁇ is a Radical of Carbamate Type
- the acids of general formula (VIII) can be cyclized in the form of derivatives of imidazoles of general formula (I), Diagram 6, by the addition of caesium carbonate followed by a condensation with an ⁇ -halogenoketone of formula A-CO—CH(B)—[Br, Cl] followed by the addition of a large excess of ammonium acetate (for example 15 or 20 equivalents per equivalent of acid of general formula (VIII)).
- This reaction is preferably carried out in a mixture of xylenes and while heating (one can also, if appropriate, simultaneously eliminate the water formed during the reaction).
- Route 6 Het is Imidazole, Oxazole or Thiazole and ⁇ is NR 46 R 47
- ⁇ is an NR 46 R 47 radical in which R 47 is a radical comprising a termination of aminophenylene, alkylaminophenylene or dialkylaminophenylene type
- the compounds of general formula (I) in which A, B, Het, n, R 1 , R 2 and R 46 are as defined above and ⁇ represents a bond or a —(CH 2 ) x —, —CO—(CH 2 ) x —, —(CH 2 ) y —O— or —C( ⁇ NH)— radical, x and y being integers from 0 to 6, can be obtained
- Diagram 7 by reduction of the compound of general formula (IX), for example by the action of hydrogen in the presence of a catalyst of palladium on carbon type in a solvent such as for example methanol, ethanol, dichloromethane or tetrahydrofuran.
- Reduction of the nitro function can also be carried out, for example, by heating the product in an appropriate solvent such as ethyl acetate with a little ethanol in the presence of SnCl 2 ( J. Heterocyclic Chem . (1987), 24, 927-930; Tetrahedron Letters (1984), 25 (8), 839-842) or in the presence of SnCl 2 /Zn ( Synthesis . (1996), 9, 1076-1078), using NaBH 4 —BiCl 3 ( Synth. Com .
- an appropriate solvent such as ethyl acetate with a little ethanol
- SnCl 2 J. Heterocyclic Chem . (1987), 24, 927-930; Tetrahedron Letters (1984), 25 (8), 839-842
- SnCl 2 /Zn Synthesis . (1996), 9, 1076-1078
- R 47 is a radical of aminophenylene, alkylaminophenylene or dialkylaminophenylene type (Alk and Alk′ are identical or different alkyl radicals)
- the compound of general formula (IX) is reduced in order to produce the aniline derivative of general formula (I) and optionally mono- or di-alkylated according to standard reactions known to a person skilled in the art.
- the mono-alkylation is carried out by reducing amination with an aldehyde or by a nucleophilic substitution by reaction with an equivalent of halogenoalkyl Alk-Hal.
- a second alkylation can then be carried out if appropriate using a halogenoalkyl Alk′-Hal.
- the deprotection can be carried out, for example, by adding tetra-tert-butylammonium fluoride in a solvent such as tetrahydrofuran.
- a solvent such as for example methanol, ethanol, dichloromethane or tetrahydrofuran.
- the deprotection can be carried out, for example, using sodium or potassium carbonate in an alcoholic solvent such as methanol.
- a solvent such as dichloromethane, acetonitrile, anhydrous tetrahydrofuran or anhydrous ether
- a base such as potassium or sodium carbonate, sodium hydride or triethylamine.
- the acid of general formula (V.iii), in which Gp represents a protective group for an amine function, for example a protective group of carbamate type, is treated, Diagram 3.2, with Cs 2 CO 3 in a solvent such as methanol or ethanol.
- the ⁇ -halogeno-ketone of general formula (V.ii) in an inert solvent such as dimethylformamide is added to the caesium salt recovered.
- the intermediate ketoester is cyclized by heating to reflux in xylene (mixture of isomers) in the presence of a large excess of ammonium acetate (15 or 20 equivalents for example) in order to produce the imidazole derivative of general formula (V.iv) (the water formed being optionally eliminated during the reaction).
- the protected amine function is then deprotected under standard conditions in a strong acid medium (for example: trifluoroacetic acid or HCl in an organic solvent when it is a protective group of carbamate type), releasing the amine of general formula (V).
- a strong acid medium for example: trifluoroacetic acid or HCl in an organic solvent when it is a protective group of carbamate type
- the indoline or tetrahydroquinoline (T represents —CH 2 — or —(CH 2 ) 2 —) is protected using chloroacetyl chloride in order to produce the compound of general formula (XVII) which is subjected to a Friedel-Crafts reaction (substituted chloroacetyl chloride of general formula (XVIII), in which B has the meaning, indicated previously, in a solvent such as carbon disulphide and in the presence of aluminium chloride) in order to produce the compound of general formula (XIX).
- a Friedel-Crafts reaction substituted chloroacetyl chloride of general formula (XVIII), in which B has the meaning, indicated previously, in a solvent such as carbon disulphide and in the presence of aluminium chloride
- the compound of general formula (XIX) is hydrolyzed in the presence of acid, for example an acetic acid/HCl mixture, in order to produce the compounds of general formula (V.ii) in the form of a mixture of meta and para isomers.
- acid for example an acetic acid/HCl mixture
- isomers can be separated by fractioned crystallization from a solvent such as glacial acetic acid.
- a person skilled in the art will know how to adapt the syntheses described previously to the case where A represents an indolinyl or tetrahydroquinolyl radical in which R 33 does not represent H.
- R 33 represents an alkyl or aralkyl radical, the protection and deprotection stages will be unnecessary.
- the carbazole of general formula (XXIII) is protected using acetic anhydride in order to produce the compound of general formula (XXIV), which is subjected to a Friedel-Crafts reaction (substituted chloroacetyl chloride of general formula (XVIII) as defined previously in a solvent such as carbon disulphide and in the presence of aluminium chloride) in order to produce the compound of general formula (XXV).
- a Friedel-Crafts reaction substituted chloroacetyl chloride of general formula (XVIII) as defined previously in a solvent such as carbon disulphide and in the presence of aluminium chloride
- the acyl group protecting the amine function is hydrolyzed in the presence of acid, for example an AcOH/HCl mixture, in order to produce the compound of general formula (V.ii).
- A represents a carbazolyl radical in which R 9 represents alkyl or a —COR 15 group (case not shown in Diagram 3.8)
- the initial acylation stage is unnecessary and the last two stages of Diagram 3.8 allow the compounds of general formula (V.ii) to be obtained.
- the intermediates of general formula (V.ii) in which A represents a phenothiazinyl radical can be prepared according to a protocol which is slightly modified with respect to that described for the phenothiazinyl radical in Arzneistoffmaschine (1962), 12, 48, which is summarized in Diagram 3.9 hereafter (see also the examples).
- the phenothiazine of general formula (XXVI) is protected using chloroacetyl chloride in order to produce the compound of general formula (XXVII), which is then subjected to a Friedel-Crafts reaction (compound of general formula (XVIII) in a solvent such as carbon disulphide in the presence of aluminium chloride) in order to produce the compound of general formula (XXVIII).
- the intermediates of general formula (V.i)a and (V.ii)a in which A represents a phenylaminophenyl radical can be prepared according to a protocol which is slightly modified with respect to that described for the phenylaminophenyl radical in Chem Ber . (1986), 119, 3165-3197. This protocol is summarized in Diagram 3.10 hereafter.
- the compounds of general formula (V.i) are prepared from the compounds of general formula (XXXII) by a substitution reaction with a Grignard reagent, MeMgCl ( J. Het. Chem . (1990), 27, 1709-1712) or with MeLi ( J. Med. Chem . (1992), 35, 13).
- a Grignard reagent MeMgCl ( J. Het. Chem . (1990), 27, 1709-1712) or with MeLi ( J. Med. Chem . (1992), 35, 13).
- the bromoacetophenones of general formula (V.ii) are now accessible from the acetophenone of general formula (V.i) under previously described conditions.
- the compound of general formula (V.ii) in which R 32 represents a hydrogen atom or an alkyl radical can be prepared according to a process in only 3 stages (cf. Diagram 3.12—see also the examples).
- the bromination in the last stage of the compound of general formula (V.i) in order to produce the compound of general formula (V.ii) will preferably be carried out according to J. Am. Chem. Soc. (1999), 121, 24.
- 2,6-diisopropylphenol is acetylated according to methods known to a person skilled in the art, for example by reacting it with acetic acid in the presence of trifluoroacetic acid anhydride or with acetyl chloride in the presence of a base such as for example K 2 CO 3 .
- the acetylated homologue of 2,6-diisopropylphenol is then subjected to a Fries rearrangement in the presence of aluminium chloride in a solvent such as nitrobenzene in order to produce the compound of formula (V.i).
- the compound of formula (V.i) is acetylated in order to produce the compound of formula (V.i)b.
- the acids of general formula (XXXVI) are subjected to coupling with N,O-dimethylhydroxylamine ( Syn. Commun . (1995), 25, (8), 1255 ; Tetrahedron Lett . (1999), 40, (3), 411-414) in a solvent such as dimethylformamide or dichloromethane, in the presence of a base such as triethylamine with dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazol, in order to produce the intermediates of general formula (XXXVII).
- a base such as triethylamine with dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazol
- solvents such as ether or anhydrous tetrahydrofuran.
- the protected amino acids of general formula (XXXVIII) are obtained by protection of the corresponding amino acids by a group of carbamate type according to methods known to a person skilled in the art.
- the acids of general formula (XXXVIII) are then subjected to coupling with N,O-dimethylhydroxylamine ( Syn. Commun . (1995), 25, (8), 1255; Tetrahedron Lett .
- the bromo or chloroacetophenones of general formula (V.vii) are now accessible from the acetophenone of general formula (XLI) under the conditions previously described.
- the thiocarboxamides of general formula (V.v) can be obtained in three stages starting from the compounds of general formula (V.vi) as indicated in the Diagram 3.18 below.
- the amine function of the amino acid of general formula (V.vi) is firstly protected under standard conditions with tBu-O—CO—Cl or (tBu-O—CO) 2 O (or other protective groups known to a person skilled in the art), then the intermediate obtained is converted to its corresponding amide by methods described in the literature (cf. for example, J. Chem. Soc., Perkin Trans. 1, (1998), 20, 3479-3484 or the PCT Patent Application WO 99/09829).
- the carboxamide is converted to the thiocarboxamide of general formula (V.v), for example by reaction with Lawesson reagent in a solvent such as dioxane or tetrahydrofuran at a temperature preferably comprised between ambient temperature and the reflux temperature of the mixture, or also using (P 2 S 5 ) 2 under standard conditions for a person skilled in the art.
- a solvent such as dioxane or tetrahydrofuran
- the carboxamides of general formula (VII.ii) are treated under standard conditions in order to produce the thiocarboxamide of general formula (VII.iii), for example by Lawesson reagent or also using (P 2 S 5 ) 2 under standard conditions for a person skilled in the art.
- the acid of general formula (VII.i) is activated by the action of 1,1′-carbonyldiimidazole then treated with methylamine in an aprotic polar solvent such as for example tetrahydrofuran.
- the carboxamide intermediate obtained is converted to the thiocarboxamide of general formula (VI.i) under standard conditions, for example using Lawesson reagent or also using (P 2 S 5 ) 2 under standard conditions for a person skilled in the art.
- the thiocarboxamide of general formula (VII.iii) or (VI.i) is then reacted with the compound of general formula (VI.ii), for example while heating at reflux in a solvent such as benzene, dioxane or dimethylformamide.
- the ester of general formula (VI.iii) obtained can then be saponified by the action of a base such as for example potash in alcoholic medium or LiOH in tetrahydrofuran in order to produce the acid of general formula (VI).
- the acids of general formula (VI) derived from oxazoles can be prepared according to a procedure represented in Diagram 4.2 below.
- the carboxamides of general formula (VII.ii) are reacted with the compound of general formula (VI.ii) while heating, for example at reflux, in the absence or in the presence of a solvent such as dimethylformamide.
- the ester of general formula (VI.iv) obtained can then be saponified by the action of a base such as for example potash in alcoholic medium or LiOH in tetrahydrofuran in order to produce the acid of general formula (VI).
- the acids of general formula (VI) derived from isoxazolines can be prepared as follows: the commercial aldehydes of general formula (VI.v) are reacted with hydroxylamine hydrochloride.
- the oxime of general formula (VI.vi) thus obtained is activated in the form of oxime chloride, of general formula (VI.vii), by reaction with N-chlorosuccinimide in DMF before reacting with the esters of general formula (VI.viii) (in which Alk represents an alkyl radical) in order to produce the isoxazoline derivatives according to an experimental protocol described in the literature ( Tetrahedron Lett., 1996, 37 (26), 4455; J. Med. Chem., 1997, 40, 50-60 and 2064-2084).
- Saponification of the isoxazolines of general formula (VI.ix) is then carried out in a standard fashion (for example by the action of KOH in an alcoholic solvent or LiOH in a solvent such as tetrahydrofuran) in order to produce the acid derivative of general formula (VI).
- the non-commercial unsaturated esters of general formula (VI.x) can be prepared according to the methods described in the literature ( J. Med. Chem., 1987, 30, 193; J. Org. Chem., 1980, 45, 5017).
- the thiazoles of general formula (VII) intended for the preparation of compounds of general formula (I) 3 can be prepared according to the method summarized in Diagram 5.2.
- the carboxamide of general formula (VII.ii) is converted to the corresponding thiocarboxamide of general formula (VII.iii) in the presence of Lawesson reagent in a solvent such as dioxane or benzene at a temperature preferably comprised between ambient temperature and that of reflux of the mixture.
- the thiocarboxamide of general formula (VII.iii) is then treated with the ⁇ -halogenoketoester of general formula (VII.iv) in which Alk represents an alkyl radical (for example methyl, ethyl or tert-butyl), in order to produce the ester of general formula (VII.v), which is reduced to the corresponding alcohol of general formula (VII.vi), for example by the action of lithium aluminium hydride or diisobutylaluminium hydride in a solvent such as tetrahydrofuran.
- Alk represents an alkyl radical (for example methyl, ethyl or tert-butyl)
- the thiazoles of general formula (VII) intended for the preparation of compounds of general formula (I), can be prepared according to the method summarized in Diagram 5.3.
- the cyano derivative of general formula (VII.vii) in which Gp′ is a protective group for an alcohol function (for example a benzyl or —CO- ⁇ group in which ⁇ represents alkyl, for example methyl or tert-butyl) is converted to the corresponding thiocarboxamide of general formula (VII.viii) by the action of H 2 S in a solvent such as ethanol in the presence of triethanolamine at a temperature preferably comprised between ambient temperature and that of reflux of the mixture.
- the thiocarboxamide of general formula (VII.viii) is then treated with the ⁇ -halogenoketone of general formula (VII.ix) in order to produce the compound of general formula (VII.x), which is deprotected in order to produce the corresponding alcohol of general formula (VII.xi) according to methods known to a person skilled in the art (for example when Gp′ is a protective group of acetate type, this is removed in situ by the action of an aqueous solution of sodium carbonate).
- the oxazoles of general formula (VII) intended for the preparation of compounds of general formula (I) 3 can be prepared according to the method summarized in Diagram 5.4.
- the carboxamide of general formula (VII.ii) is treated with the ⁇ -halogenoketoester of general formula (VII.iv) in which Alk represents an alkyl radical (for example methyl, ethyl or tert-butyl), in order to produce the ester/acid of general formula (VII.xii).
- R 1 and R 2 both represent H
- the protected amino acids of general formula (VIII) are either commercial, or obtained by protection of commercial amino acids by a group of carbamate type according to the methods known to a person skilled in the art.
- the expected product is obtained after chromatography on a silica column (eluent: 20% ethyl acetate in heptane) in the form of an oil which crystallizes very slowly in a refrigerator with a yield of 28%. Melting point: 126.5-127.3° C.
- Example 8 0.8 ml of paraformaldehyde and 0.10 g of 20% palladium on carbon is added to a solution of 0.5 g (1.1 mmol) of Example 8 in 20 ml of ethanol. The medium is placed under hydrogen for 4 hours. The catalyst is filtered out and the solvent evaporated to dryness. The expected product is obtained after chromatography on a silica column (eluent: 3% ethanol in dichloromethane). The expected compound is obtained in the form of a brown oil with a yield of 54%.
- the compound is produced according to an experimental protocol described in the Patent Application WO 98/58934 (see preparation of intermediates 26.1 and 26.2), using Z-Gly-NH 2 in place of the N—Boc sarcosinamide.
- the expected compound is obtained in the form of a pale yellow oil with a yield of 99%.
- Example 13 The experimental protocol used is identical to that described for Example 13, the compound of Example 14 being used as starting product in place of the compound of Example 12. A yellow gum is obtained with a yield of 83%.
- Example 23 The compound of Example 23 can be obtained according to the procedures described in the PCT Patent Application WO 99/09829.
- the compound of Example 23 is converted to brominated derivative, intermediate 3, according to the procedure indicated in Diagram 1(c) of the PCT Application WO 99/09829. Then the brominated derivative (0.5 g; 1.31 mmol) is added to a solution of N-methylpropargylamine 0.34 ml (3.94 mmol) and potassium carbonate (1.11 g) in dimethylformamide (20 ml). After overnight stirring at 80° C., the reaction mixture is concentrated under vacuum and the residue is diluted with dichloromethane and 50 ml of a saturated solution of NaCl. After stirring and decantation, the organic phase is separated and dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 50% ethyl acetate in heptane). After evaporation, the pure fractions produce a yellow oil with a yield of 24%.
- a stream of HCl gas is passed bubblewise into a solution at 0° C. of intermediate 29.1 (0.450 g; 9.27 mmol) in ethyl acetate (30 ml). The mixture is left to return to ambient temperature overnight.
- a stream of argon is passed through the reaction mass, then the powder obtained is filtered and washed with ethyl acetate then with ether in order to produce a white solid with a yield of 70%. Melting point: >200° C.
- this compound can be obtained according to a similar method, but using 2-chloro-1-(10H-phenothiazin-2-yl)ethanone instead of 2-bromo-1-(10H-phenothiazin-2-yl)ethanone:
- a solution containing ⁇ -alanine (8.9 g; 0.1 mol) and 100 ml of a 1N solution of sodium hydroxide is cooled down to 10° C.
- n-butyl chloroformate (13.66 g; 0.1 mol) and 50 ml of a 2N solution of sodium hydroxide are added simultaneously.
- approximately 10 ml of a solution of concentrated hydrochloric acid (approximately 11 N) is added in order to adjust the pH to 4-5.
- the oil obtained is extracted with ethyl acetate (2 ⁇ 50 ml), washed with water then dried over magnesium sulphate.
- the product crystallizes from isopentane in the form of a white powder (yield of 68%). Melting point: 50.5° C.
- a mixture of N-(butoxycarbonyl)- ⁇ -alanine (prepared in Stage 31.1; 5.67 g; 0.03 mol) and caesium carbonate (4.89 g; 0.015 mol) in 100 ml of ethanol is stirred at 23° C. for 1 hour.
- the ethanol is eliminated by evaporation under reduced pressure in a rotary evaporator.
- the mixture obtained is dissolved in 100 ml of dimethylformamide then 4-phenyl-bromoacetophenone (8.26 g; 0.03 mol) is added. After stirring for 16 hours, the solvent is evaporated off under reduced pressure.
- the mixture obtained is taken up in ethyl acetate then the caesium bromide is filtered.
- the ethyl acetate of the filtrate is evaporated and the reaction oil is taken up in a mixture of xylene (100 ml) and ammonium acetate (46.2 g; 0.6 mol).
- the reaction medium is heated at reflux for approximately one hour and 30 minutes then, after cooling down, a mixture of ice-cooled water and ethyl acetate is poured into the reaction medium.
- the organic phase is washed with a saturated solution of sodium bicarbonate, dried over magnesium sulphate then evaporated under vacuum.
- the solid obtained is filtered then washed with ether in order to produce a light beige-coloured powder (yield of 50%). Melting point: 136.7° C.
- tert-butyl 2-(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate (4.8 g; 0.013 mol) is stirred in 120 ml of a solution of ethyl acetate saturated in hydrochloric acid for 2 hours 30 minutes at a temperature of 55° C.
- the solid obtained is filtered and washed with ether.
- a light beige-coloured powder is obtained with a yield of 89%.
- a mixture containing valeric acid (0.24 ml; 0.002 mol), dicyclohexylcarbodiimide (2.2 ml; 1M solution in methylene chloride) and 1-hydroxybenzotriazole hydrate (336 mg; 0.0022 mol) in 15 ml of dimethylformamide (DMF) is stirred at 23° C. for thirty minutes.
- the 2-(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylamine prepared previously is added then the mixture is stirred for 48 hours at 23° C.
- the dicyclohexylurea formed is filtered then the DMF is evaporated off under reduced pressure.
- This compound is obtained according to an operating method similar to the preparation of the compound of Stage 31.2 of Example 31 using Boc-aminocyclohexylglycine (9.4 g; 0.036 mol) in place of the N-(butoxycarbonyl)- ⁇ -alanine and parafluorobromoacetophenone (7.9 g; 0.036 mol) in place of the 4-phenyl-bromoacetophenone.
- Boc-aminocyclohexylglycine (9.4 g; 0.036 mol) in place of the N-(butoxycarbonyl)- ⁇ -alanine and parafluorobromoacetophenone (7.9 g; 0.036 mol) in place of the 4-phenyl-bromoacetophenone.
- a white-coloured powder is obtained with a yield of 53%.
- This compound is prepared according to an operating method similar to that of Stage 32.2 of Example 32 using tert-butyl(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methylcarbamate (7.5 g; 0.02 mol) as starting compound.
- a white-coloured powder is obtained with a yield of 92%.
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31, using 2-[(tert-butoxycarbonyl)amino]octanoic acid (8.1 g; 0.0314 mol) in place of the N-(butoxycarbonyl)- ⁇ -alanine and 2-bromo-1-cyclohexylethanone (6.4 g; 0.0314 mol) in place of the 4-phenyl-bromoacetophenone.
- An oil is obtained which is sufficiently pure to be used in the following reaction (yield of 88%).
- This compound is obtained according to an operating method similar to that of Stage 32.2 of Example 32 using as starting compound tert-butyl 1-(4-cyclohexyl-1H-imidazol-2-yl)heptylcarbamate (prepared in Stage 6.3; 10 g; 0.0275 mol).
- a yellow solid is obtained in the form of a paste (yield of 37%).
- This compound is obtained according to an operating method similar to that of Stage 35.3 of Example 35 using as starting amine 1-(4-cyclohexyl-1H-imidazol-2-yl)-1-heptanamine (obtained in Stage 6.4; 2.5 g; 0.074 mol) and as ketone, cyclohexanone (1 ml; 0.0097 mol).
- a silica column eluent: ethyl acetate—heptane/7-3 with CH 2 Cl 2 -MeOH/95-05
- a white-coloured powder is obtained with a yield of 12%. Melting point: 172-174° C.
- a solution of diisopropylamine (13.2 ml; 0.094 mol) in 130 ml of tetrahydrofuran (THF) is cooled down to ⁇ 40° C.
- n-butyllithium 37 ml of a 2.5 M solution in hexane; 0.094 mol
- the temperature is allowed to rise to 0° C.
- Boc-glycine (5 g; 0.028 mol) in solution in 30 ml of THF is introduced into the mixture.
- the reaction medium is left for ten minutes at this temperature then 1-bromo-4-methylpentane (7.9 ml; 0.056 mol) in solution in 20 ml of THF is added rapidly.
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31 using 2-[(tert-butoxycarbonyl)amino]-6-methylheptanoic acid (3.5 g; 0.0135 mol) in place of the N-(butoxycarbonyl)- ⁇ -alanine and 3-bromophenacyl bromide (3.75 g; 0.0135 mol) in place of the 4-phenyl-bromoacetophenone.
- a white powder is obtained with a yield of 63%. Melting point: 134-136° C.
- This compound is obtained according to an operating method similar to that of Stage 32.2 of Example 32 using as starting compound tert-butyl 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexylcarbamate (obtained in Stage 37.2; 3.5 g; 0.008 mol).
- a white-coloured powder is obtained with a yield of 97%. Melting point: 200-202° C.
- This compound is obtained according to an operating method similar to that of Stage 35.3 of Example 35 using as starting amine, 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine (obtained in Stage 7.3; 0.8 g; 0.0019 mol) and as ketone, cyclohexanone (0.32 ml; 0.0023 mol).
- a white-coloured powder is obtained with a yield of 38%. Melting point: 236-238° C.
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31 using 2-[(tert-butoxycarbonyl)amino]octanoic acid (6.2 g; 0.024 mol) in place of the N-(butoxycarbonyl)- ⁇ -alanine and 2-bromo-4-fluoroacetophenone (5.2 g; 0.024 mol) in place of the 4-phenyl-bromoacetophenone.
- a white powder is obtained (yield: 58%) which is sufficiently pure to be used as it is for the following stage.
- This compound is obtained according to an operating method similar to that of Stage 32.2 of Example 32 using as starting compound tert-butyl 1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptylcarbamate (5.2 g; 0.014 mol). After purification on a silica column (eluent: CH 2 Cl 2 -MeOH—NH 4 OH/89-10-1), a grey-coloured powder is obtained (yield of 72%). Melting point: 148-150° C.
- This compound is obtained according to an operating method similar to that of Stage 35.3 of Example 35 using as starting amine, 1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-heptanamine (0.5 g; 0.0014 mol) and as ketone, cyclohexanone (0.17 ml; 0.0014 mol).
- a white-coloured powder is obtained with a yield of 15%.
- Triethylamine (0.83 ml; 0.006 mol) is added at 23° C. to a solution containing (1R)-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine (0.7 g; 0.002 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) in 15 ml of acetonitrile. The mixture is stirred for one hour at 23° C. then benzyl chloride (0.23 ml; 0.002 mol) is added. Stirring is maintained for 16 hours.
- the reaction mixture is concentrated using a rotary evaporator and the oil obtained is taken up in ethyl acetate and water.
- the aqueous phase is extracted with ethyl acetate and washed with water then with a saturated solution of sodium chloride.
- the solvents are evaporated off under vacuum.
- a silica column eluent: AE-heptane/7-3
- a deep beige-coloured solid is obtained in the form of a paste (yield of 5% c). Free base. Melting point: 60-62° C.
- N-benzyl(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)methanamine (1 g; 0.0024 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 15 ml of dimethylformamide. Potassium carbonate (1 g; 0.0073 mol) is added at 23° C. then hexane bromide (0.34 ml; 0.0024 mol) is added fairly slowly. The reaction mixture is brought to about 70° C. for 3 hours before being poured into ice-cooled water. The mixture is extracted with ethyl acetate and the organic phase is washed with water.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
- The present invention relates to the use of compounds of general formula (I) for preparing a medicament intended to inhibit monoamine oxydases (MAO) and/or lipidic peroxidation and/or to act as modulators of the sodium channels. A subject of the invention is also, as medicaments, the compounds of general formula (II) defined hereafter. Moreover it relates to new compounds of general formula (III).
- The compounds mentioned above often present 2 or 3 of the activities mentioned above, which confer advantageous pharmacological properties on them.
- In fact, taking into account the potentiel role of the MAO's and ROS's (“reactive oxygen species”, at the origin of lipidic peroxidation) in physiopathology, the new described derivatives corresponding to general formula (I) can produce beneficial or favorable effects in the treatment of pathologies where these enzymes and/or these radicular species are involved. In particular:
-
- disorders of the central or peripheral nervous system such as for example neurological diseases where Parkinson's disease, cerebral or spinal cord traumatisms, cerebral infarction, sub arachnoid hemorrhage, epilepsy, ageing, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, peripheral neuropathies, pain can in particular be mentioned;
- schizophrenia, depressions, psychoses;
- disorders of the memory and the humour;
- pathologies such as for example migraine;
- behavioural disorders, bulimia and anorexia;
- auto-immune and viral diseases such as for example lupus, AIDS, parasitic and viral infections, diabetes and its complications, multiple sclerosis.
- addiction to toxic substances;
- proliferative and inflammatory pathologies;
- and more generally all the pathologies characterised by an excessive production of ROS's and/or participation of MAO's.
- In all of these pathologies, experimental evidence exists which demonstrates the involvement of ROS's (Free Radic. Biol. Med. (1996) 20, 675-705; Antioxid. Health. Dis. (1997) 4 (Handbook of Synthetic Antioxidants), 1-52) as well as the involvement of MAO's (Goodman & Gilman's: The pharmacological basis of therapeutics, 9th ed., 1995, 431-519).
- The advantage of a combination of the inhibitory activities of MAO and inhibition of lipidic peroxidation is for example well illustrated in Parkinson's disease. This pathology is characterized by a loss of dopaminergic neurons of the nigrostriatal route the cause of which would in part be linked to an oxidizing stress due to ROS's. The exogenic dopamine from L Dopa is used in therapeutics in order to maintain sufficient levels of dopamine. MAO inhibitors are also used with L Dopa to avoid its metabolic degradation but do not act on the ROS's. Compounds which act both on MAO's and ROS's will therefore have a certain advantage.
- Moreover, the character of the modulator of the sodium channels is very useful for therapeutic indications such as:
-
- the treatment or prevention of pain, and in particular:
- post-operative pain,
- migraine,
- neuropathic pain such as trigeminal neuralgia, post-herpetic pain, diabetic neuropathies, glossopharyngeal neuralgias, secondary radiculopathies and neuropathies associated with metastatic infiltrations, adiposis dolorosa and pain associated with burns,
- central pain as a result of vascular cerebral accidents, thalamic lesions and multiple sclerosis, and
- chronic inflammatory pain or pain linked to a cancer;
- the treatment of epilepsy;
- the treatment of disorders linked to neurodegeneration, and in particular:
- vascular cerebral accidents,
- cerebral traumatism, and
- neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis;
- the treatment of bipolar disorders and irritable colon syndrome.
- the treatment or prevention of pain, and in particular:
- The concrete advantages of the presence in a compound of at least one of these activities is therefore clearly apparent from the above.
- The European Patent Application EP 432 740 describes derivatives of hydroxyphenylthiazoles, which can be used in the treatment of inflammatory diseases, in particular rheumatic diseases. These derivatives of hydroxyphenylthiazoles show properties of trapping free radicals and inhibitors of the metabolism of arachidonic acid (they inhibit lipoxygenase and cyclooxygenase).
- Other derivatives of hydroxyphenylthiazoles or hydroxyphenyloxazoles are described in the PCT Patent Application WO 99/09829. These have analgesic properties.
- A certain number of derivatives of imidazoles with close or identical structures to those of the compounds corresponding to general formula (I) according to the invention have moreover been described by the Applicant in the PCT Patent Application WO 99/64401 as agonists or antagonists of somatostatin. However, said derivatives of imidazoles have therapeutic properties in fields different from those indicated above (suppression of the growth hormone and the treatment of acromegalia, treatment of the recurrence of stenosis, inhibition of the secretion of gastric acid and prevention of gastro-intestinal bleeding in particular).
- Moreover, the compounds of general formula (A1)
in which
R1 represents one of the aryl, heteroaryl, aralkyl or cycloalkyl radicals optionally substituted by one to three substituents chosen independently from a halogen atom, the CF3, CN, OH, alkyl or alkoxy radical, SO2R9 with R9 representing NH2 or NHCH3,
X represents NR2, R2 representing H or alkyl;
Y represents N or CR3;
Z represents CR3 or N;
on the condition however that Y and Z are not both CR3 or N at the same time;
R3 represents H, alkyl, halogen, hydroxyalkyl or phenyl optionally substituted by 1 to 3 substituents chosen from H, CF3, CN, SO2NH2, OH, alkyl or alkoxy;
m represents 0, 1 or 2;
R4 represents H or alkyl;
when Z represents CR3, then R3 and R4 can also represent together —(CH2)n1— with n1 an integer from 2 to 4 or R2 and R4 can also represent together —(CH2)n2— with n2 an integer from 2 to 4;
R5 and R6 represent independently H, alkyl, alkoxy, aryl or aralkyl;
NR5R6 can also represent together (in particular): -
- the optionally substituted 2-(1,9,3,4-tetrahydroquinolyl)radical,
- a
radical in which R7 represents one of the phenyl, benzyl or phenethyl radicals in which the phenyl ring can be substituted; - a
radical in which p is an integer from 1 to 3,
W is N and R8 represents H, CF3, one of the phenyl, pyridyl or pyrimidinyl radicals optionally substituted once to twice by radicals chosen from halogen, OH, alkyl or alkoxy, or
W is CH and R8 represents phenyl optionally substituted or aralkyl optionally substituted on the aryl group;
have been described in the PCT Patent Application WO 96/16040 as partial agonists or antagonists of the dopamine sub-receptors of the brain or as prodrug forms of such partial agonists or antagonists. Therefore these compounds would have useful properties in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain disorders of movement such as Parkinson's disease.
- It has also been described in the PCT Patent Application WO 98/27108 that certain amides of general formula (A2)
in which:
R1 represents in particular an alkyl, optionally substituted phenyl or optionally substituted heterocyclic aryl radical;
R2 represents H or phenylalkyl;
R4 represents H, quinolyl, 3-4-methylenedioxyphenyl or one of the phenyl or pyridyl radicals optionally substituted, by a radical or radicals chosen in particular from alkyl, alkoxy, alkylthio, optionally protected hydroxy, amino, alkylamino, dialkylamino;
R5 represents H or an imidazolyl, phenyl, nitrophenyl, phenylalkyl radical, or also a —CO—N(R7)(R8) radical, in which R7 and R8 represent independently H, phenyl, phenylalkyl, alkyl or alkoxy;
or R4 and R5 in combination form a group of formula —CH═CH—CH═CH—;
Y is a phenylene radical substituted by a phenyl, phenoxy or phenylalkoxy radical, or a group of formula —CH(R3)-, in which R3 represents H or a radical of formula —(CH2)n—R6, in which R6 represents an optionally protected hydroxy, acyl, carboxy, acylamino, alkoxy, phenylalkoxy, alkylthio, optionally substituted phenyl, optionally substituted pyridyl, pyrazinyl, pyrimidinyl, furyl, imidazolyl, naphthyl, N-alkylindolyl or 3,4-methylenedioxyphenyl radical and n is an integer from 0 to 3;
R2 and R3 taken together with the carbon atoms which carry them can form a phenyl group;
X represents S or NR9;
R9 representing H, an alkyl or cycloalkyl radical, or also a benzyl radical optionally substituted once on its phenyl part by H, alkyl or alkoxy;
are inhibitors of the NO synthases and can be used to treat diseases which include in particular cardiovascular or cerebral ischemia, cerebral hemorrhage, disorders of the central nervous system, Alzheimer's disease, multiple sclerosis, diabetes, hepatitis, migraine, rheumatoid arthritis and osteoporosis. - In a different field, the Applicant has itself previously described in the PCT Patent Application WO 98/58934 derivatives of amidines having the ability to inhibit NO synthases and/or lipidic peroxidation.
- The Applicant has now unexpectedly discovered that certain intermediates of the first stages of synthesis of the amidines described in the PCT Patent Application WO 98/58934, and more generally certain derivatives of heterocycles with five members, namely the products of general formula (I) defined hereafter, have at least one of the three properties chosen from the following properties (and often even two of these three properties even sometimes all three at the same time):
-
- MAO inhibition properties;
- lipidic peroxidation inhibition properties; and
- properties of modulating the sodium channels.
- These advantageous properties offer the advantage of opening up numerous uses for such compounds, in particular in the treatment of neurodegenerative diseases, and in particular those indicated previously, of pain or of epilepsy.
- According to the invention, the compounds corresponding to general formula (I)
in racemic, enantiomeric form or any combination of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (I) corresponds exclusively to one of the following sub-formulae:
in which
A represents
either a
radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR10R11 radical, R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical, R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, R9 represents a hydrogen atom, an alkyl radical or a —COR15 group,
R15 representing a hydrogen atom or an alkyl, alkoxy or NR16R17 radical,
R16 and R17 representing, independently, a hydrogen atom or an alkyl radical, or R16 and R17 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
either a
radical in which Q represents H, —OR22, —SR22—, —NR23R24, a phenyl radical optionally substituted by one or more substituents chosen independently from a halogen atom, an OH, cyano, nitro, alkyl, alkoxy or —NR10R11 radical and a group with two substituents representing together a methylenedioxy or ethylenedioxy radical, or also Q represents a —COPh, —SO2Ph or —CH2Ph radical, said —COPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen independently from an alkyl or alkoxy radical and a halogen atom,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, R12 representing a hydrogen atom, an alkyl or alkoxy or NR13R14 radical,
R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R22 representing a hydrogen atom, an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals,
R23 and R24 representing, independently, a hydrogen atom, an alkyl radical or a —CO—R25 radical,
R25 representing an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR15, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical,
R26 representing a hydrogen atom or an alkyl radical,
R27 and R28 representing, independently, a hydrogen atom, an alkyl radical or a —COR29 group, or R27 and R28 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
q representing an integer from 0 to 2,
R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
R29 representing a hydrogen atom, an alkyl, alkoxy or —NR30R31 radical,
R30 and R31 representing, independently, a hydrogen atom or an alkyl radical, or R30 and R31 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
or a
radical in which R32 represents a hydrogen atom or an alkyl radical, and T represents a —(CH2)m— radical with m=1 or 2,
or finally a
radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical, - Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms, —R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
- R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals,
- R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
- R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical,
- R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, and T represents a —(CH2)m— radical with m=1 or 2,
- or also A represents an alkyl, cycloalkyl or cycloalkylalkyl radical;
- X represents S or NR38,
- R38 representing a hydrogen atom or an alkyl, cyanoalkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical,
- Y represents O or S;
- R1 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH2)g-Z1R39, —(CH2)g—COR40, —(CH2)g—NHCOR70, aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radicals itself being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z2R39 or —(CH2)k—COR40 radicals,
- Z1 and Z2 representing a bond, —O—, —NR41— or —S—,
- R39 and R41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl or cyanoalkyl radical,
- R40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR42R43 radical,
- R42 and R43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- and R2 represents a hydrogen atom, an alkyl aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl or —(CH2)g—NHCOR71 radical, or also one of the aralkyl or heteroarylalkyl radicals optionally substituted on the aryl or heteroaryl group by one or more of the groups chosen independently from the group composed of a halogen atom and an alkyl, alkoxy, hydroxy, cyano, nitro, amino, alkylamino or dialkylamino radical,
- R70 and R71 representing independently an alkyl or alkoxy radical;
- or R1 and R2, taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members;
- B represents a hydrogen atom, an alkyl radical, a —(CH2)g-Z3R44 radical or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical,
- Z3 representing a bond, —O—, —NR45— or —S—,
- R44 and R45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxy, allenyl, allenylalkyl or cyanoalkyl radical;
- Ω represents one of the NR46R47 or OR48 radicals, in which:
- R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, (CH2)g-Z4R50, —(CH2)k—COR51, —(CH2)k—COOR51, —(CH2)k—CONHR51 or —SO2R51 radical, or also a radical chosen from the aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl and in particular pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen independently from halogen, alkyl, alkoxy, hydroxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
- Z4 and Z5 representing a bond, —O—, —NR52— or —S—,
- or R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R53)—, —NR54—, —O—, —S— and —CO—, said heterocycle being able to be for example an azetidine, a piperazine, a homopiperazine, a 3,5-dioxopiperazine, a piperidine, a pyrrolidine, a morpholine or a thiomorpholine,
- R50 and R52, representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
- R51 representing, independently each time that they occur, a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical has 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, alkoxyalkyl or NR58R59 radical, or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,
- R58 and R59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
- R53 and R54 representing, independently, a hydrogen atom or a —(CH2)k-Z7R60 or —(CH2)k—COR61 radical,
- Z7 representing a bond, —O—, —NR62— or —S—,
- R60 and R62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH2)k-Z8R63 and —(CH2)k—COR64 radicals,
- R61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR65R66 radical,
- R65 and R66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- Z8 representing a bond, —O—, —NR67— or —S—,
- R63 and R67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- R64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR68R69 radical,
- R68 and R69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
- and R48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical;
- g and p, each time that they occur, being independently integers from 1 to 6, and k and n, each time that they occur, being independently integers from 0 to 6;
- it being understood that when Het is such that the compound of general formula (I) corresponds to general sub-formula (I)4, then:
- A represents the 4-hydroxy-2,3-di-tertiobutyl-phenyl radical;
- B, R1 and R2 all represent H; and finally
- Ω represents OH;
- or pharmaceutically acceptable salts of the compounds of general formula (I);
- can be used for preparing a medicament intended to have at least one of the following three activities:
-
-
- to inhibit the monoamine oxydases, in particular monoamine oxydase B,
- to inhibit lipidic peroxidation,
- to have a modulating activity vis-à-vis the sodium channels.
- According to preferred variants of the invention, these compounds have at least two of the activities mentioned above. In particular, they inhibit both the MAO's and trap the ROS's or they will have both an antagonist activity vis-à-vis the sodium channels and a trapping activity on the ROS's. In certain cases, the compounds of general formula (I) even combine the three activities.
- This allows the compounds of general formula (I) to be of use in the treatment of the diseases mentioned previously such as being linked to MAO's, to lipidic peroxidation and to the sodium channels.
- By alkyl, unless otherwise specified, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms. By cycloalkyl, when no further detail is given, is meant a monocyclic carbon system containing 3 to 7 carbon atoms. By alkenyl, when no further detail is given, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and having at least one unsaturation (double bond). By alkynyl, when no further detail is given, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and having at least one double unsaturation (triple bond). By allenyl, is meant the —CH═C═CH2 radical. By carbocyclic or heterocyclic aryl, is meant a carbocyclic system (in particular, the phenyl radical which can be noted Ph in an abbreviated fashion) or heterocyclic system comprising at least one aromatic ring, a system being called heterocyclic when at least one of the rings which comprises it contains a heteroatom (O, N or S). By heterocycle, is meant a mono- or polycyclic system, said system comprising at least one heteroatom chosen from O, N and S and being saturated, partially or totally unsaturated or aromatic. By heteroaryl, is meant a heterocycle as defined previously in which at least one of the rings which comprises it is aromatic. By haloalkyl, is meant an alkyl radical at least one of hydrogen atoms of which (and optionally all) is replaced by a halogen atom.
- Moreover, by an optionally substituted radical is meant unless otherwise specified a radical comprising one or more substituents chosen independently from the group composed of a halogen atom and the alkyl and alkoxy radicals.
- By alkylthio, alkoxy, haloalkyl, alkoxyalkyl, trifluoromethylalkyl, cycloalkylalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, allenylalkyl, cyanoalkyl and aralkyl radicals, is meant respectively the alkylthio, alkoxy, haloalkyl, alkoxyalkyl, trifluoromethylalkyl, cycloalkylalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, allenylalkyl, cyanoalkyl and aralkyl radicals the alkyl radical (the alkyl radicals) of which have the meaning(s) indicated previously.
- By heterocycle, is meant in particular the thiophene, piperidine, piperazine, quinoline, indoline and indole radicals. By linear or branched alkyl having 1 to 6 carbon atoms, is meant in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals. Finally, by halogen, is meant the fluorine, chlorine, bromine or iodine atoms.
- Preferably, the compounds according to the invention are such that they correspond to general formula (I):
in racemic, enantiomeric form or any combination of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (I) corresponds exclusively to one of the following sub-formulae:
in which
A represents
either a
radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR10R11 radical,
R10 and R11 representing, independently, a hydrogen atom or an alkyl radical
R9 represents a hydrogen atom or an alkyl radical, and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
or a
radical in which Q represents H, —OR22, —SR22, —NR23R24, a phenyl radical optionally substituted by one or more substituents chosen independently from a halogen atom, an OH, cyano, nitro, alkyl, alkoxy or —NR10R11 radical and a group with two substituents representing together a methylenedioxy or ethylenedioxy radical, or also Q represents a —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph radical, said —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen independently from an alkyl or alkoxy radical and a halogen atom, R10 and R11 representing, independently, a hydrogen atom or an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R22 representing a hydrogen atom, an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals,
R23 and R24 representing, independently, a hydrogen atom, an alkyl radical or a —CO—R25 radical,
R25 representing an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical, R26 representing a hydrogen atom or an alkyl radical,
R27 and R28 representing, independently, a hydrogen atom, an alkyl radical or a —COR29 group, or R27 and R28 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
q representing an integer from 0 to 2,
R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
R29 representing a hydrogen atom, an alkyl, alkoxy or —NR30R31 radical,
R30 and R31 representing, independently, a hydrogen atom or an alkyl radical, or R30 and R31 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
or a
radical in which R32 represents a hydrogen atom or an alkyl radical, and T represents a —(CH2)m— radical with m=1 or 2,
or finally a
radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical,
Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms,
R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
and T represents a —(CH2)m— radical with m=1 or 2,
or also A represents an alkyl, cycloalkyl or cycloalkylalkyl radical;
X represents S or NR38,
R38 representing a hydrogen atom or an alkyl, cyanoalkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical,
Y represents O or S;
R1 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH—)g-Z1R39, —(CH2)g—COR40, —(CH2)g—NHCOR70, aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radicals itself being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z2R39 or —(CH2)k—COR40 radicals,
Z1 and Z2 representing a bond, —O—, —NR41— or —S—,
R39 and R41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl or cyanoalkyl radical,
R40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR42R43 radical,
R42 and R43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R2 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl or —(CH2)g—NHCOR71 radical, or also one of the aralkyl or heteroarylalkyl radicals optionally substituted on the aryl or heteroaryl group by one or more of the groups chosen independently from the group composed of a halogen atom and an alkyl, alkoxy, hydroxy, cyano, nitro, amino, alkylamino or dialkylamino radical,
R70 and R7 representing independently an alkyl or alkoxy radical;
or R1 and R2, taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members;
B represents a hydrogen atom, an alkyl radical, a —(CH2)g-Z3R44 radical or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical,
Z3 representing a bond, —O—, —NR45— or —S—,
R44 and R45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical;
Ω represents one of the NR46R47 or OR48 radicals, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH)g-Z4R50, —(CH2)k—COR51, —(CH2)k—COOR51, —(CH2)k—CONHR51 or —SO2R51 radical, or also a radical chosen from the aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl and in particular pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen independently from halogen, alkyl, alkoxy, hydroxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
Z4 and Z5 representing a bond, —O—, —NR52— or —S—,
or R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R53)—, —NR54—, —O—, —S— and —CO—, said heterocycle being able to be for example an azetidine, a piperazine, a homopiperazine, a 3,5-dioxopiperazine, a piperidine, a pyrrolidine, a morpholine or a thiomorpholine,
R50 and R52, representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxy, allenyl, allenylalkyl or cyanoalkyl radical,
R51 representing, independently each time that they occur, a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical has 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, alkoxyalkyl or NR58R59 radical, or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,
R58 and R59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R53 and R54 representing, independently, a hydrogen atom or a —(CH2)k-Z7R60 or —(CH2))k—COR61 radical,
Z7 representing a bond, —O—, —NR62— or —S—,
R60 and R62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH2)k-Z8R63 and —(CH2)k—COR64 radicals,
R61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR65R66 radical,
R65 and R66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
Z8 representing a bond, —O—, —NR67— or —S—,
R63 and R67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
R64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR68R69 radical,
R68 and R69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
g and p, each time that they occur, being independently integers from 1 to 6, and k and n, each time that they occur, being independently integers from 0 to 6;
and R48 represents a hydrogen atom or an alkyl alkynyl or cyanoalkyl radical;
it being understood that when Het is such that the compound of general formula (I) corresponds to general sub-formula (I)4, then:
A exclusively represents the 4-hydroxy-2,3-di-tertiobutyl-phenyl radical;
B represents H,
R1 and R2 both represent H; and finally
Ω represents OH;
or salts of said compounds - According to the invention, there will Generally be preferred the compounds of general formula (I) in which at least one of the following radicals is found:
-
- A representing:
- either the
- radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
- or the
- radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, the OH group or an alkyl or alkoxy radical,
- R9 represents a hydrogen atom or an alkyl radical,
- and W does not exist, or represents a bond, —O—, —S— or —NR18—, R18 representing a hydrogen atom or an alkyl radical;
- or the
- radical in which Q represents H, —OR22, —SR22 or a phenyl radical optionally substituted by one substituent or substituents chosen independently from a halogen atom, an OH, cyano, nitro, alkyl, alkoxy or —NR10R11 radical and a group of two substituents together representing a methylenedioxy or ethylenedioxy radical, or also Q represents an —OPh, —SPh, —SO2Ph or —CH2Ph radical, said —OPh, —SPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by a substituent or substituents chosen from an alkyl or alkoxy radical and a halogen atom,
- R10 and R11 representing, independently, a hydrogen atom or an alkyl radical;
- R22 representing a hydrogen atom, an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals,
- and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, S(O)qR56, —N(CO)R57, —CF3, —OCF3 or NR27R28 radical,
- R26 representing a hydrogen atom or an alkyl radical,
- R27 and R28 representing, independently, a hydrogen atom, an alkyl radical or a —COR29 group, or also R27 and R28 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2—, —NH— and —O—,
- R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
- q representing an integer from 0 to 2,
- R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
- R29 representing a hydrogen atom, an alkyl, alkoxy or —NR30R31 radical,
- R30 and R31 representing, independently, a hydrogen atom or an alkyl radical,
- or the
- radical in which R32 represents a hydrogen atom or an alkyl radical, and T represents the —(CH2)2— radical
- or finally the
- radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical,
- Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms,
- R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
- R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals,
- R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
- R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical,
- R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, such as for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
- and T represents the —(CH2)— radical;
- either the
- Ω representing:
- either the NR46R47 radical in which R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH2)k—COR51, —COOR51 or —SO2R51 radical or also a radical chosen from the aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl radicals and in particular pyridinyl, pyridinylalkyl or pyridinylcarbonyl, the aryl or heteroaryl group of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by a substituent or substituents chosen independently from halogen, alkyl, alkoxy, hydroxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
- R51 representing a hydrogen atom or an alkyl, alkenyl, alkynyl or alkoxyalkyl radical
- or the OH radical;
- A representing:
-
- Generally, all the preferences relating to sub-groups of compounds of general formula (I) presented below remain applicable with respect to the use of compounds of general formula (I) as defined previously for the preparation of medicaments intended to inhibit monoamine oxidases, in particular monoamine oxidase B, to inhibit lipidic peroxidation, to have a modulatory activity on the sodium channels or to have two of the three activities or the three activities mentioned previously.
- According to a particular variant of the invention, the compounds of general formula (I) or their salts are more especially intended to have an inhibitory activity on MAO's and/or ROS's and they will therefore be preferably such that:
- A represents
- either a
radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy or NR10R11 radical,
R10 and R11 representing, independently, a hydrogen atom or an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R9 represents a hydrogen atom or an alkyl radical,
and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
or a
radical in which Q represents —OR22—, —SR22, —NR23R24, a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom and an OH, cyano, nitro, alkyl, alkoxy or —NR10R11 radical,
R10 and R11 representing, independently, a hydrogen atom or an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R22 representing a hydrogen atom, an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals,
R23 and R24 representing, independently, a hydrogen atom or an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl, alkenyl, alkoxy or NR27R28 radical,
R26 representing a hydrogen atom or an alkyl radical,
R27 and R28 representing, independently, a hydrogen atom or an alkyl radical, or R27 and R28 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms; said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
or a
radical in which R32 represents a hydrogen atom or an alkyl radical,
and T represents a —(CH2)m— radical with m=1 or 2,
or finally a
radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical,
Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms,
R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals,
R10 and R11 representing, independently, a hydrogen atom or an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, and T represents a —(CH2)m— radical with m=1 or 2,
X represents S or NR38,
R38 representing a hydrogen atom or an alkyl or cyanoalkyl radical,
Y represents O or S;
R1 represents a hydrogen atom, an alkyl, cycloalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH2)g-Z1R39, —(CH2)g—COR40, aryl, aralkyl, arylcarbonyl, or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, or aralkylcarbonyl radicals being itself optionally substituted by a substituent or substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, —(CH2)k-Z2R39 or —(CH2)k—COR40 radicals,
Z1 and Z2 representing a bond, —O—, —NR41— or —S—,
R39 and R41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxy or cyanoalkyl radical,
R40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR42R43 radical,
R42 and R43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R2 represents a hydrogen atom or an alkyl radical
B represents a hydrogen atom or a —(CH2)g-Z3R44 radical,
Z3 representing a bond, —O—, —NR45— or —S—,
R44 and R45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical;
Ω represents one of the NR46R47 or OR48 radicals, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH2)g-Z4R50 pr —(CH2)k—COR51 radical, or also a radical chosen from the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more of the substituents chosen independently from halogen, alkyl, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
Z4 and Z5 representing a bond, —O—, —NR52— or —S—,
or R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R53)—, —NR54—, —O—, —S— and —CO—, said heterocycle being able to be for example an azetidine, a piperazine, a homopiperazine, a 3,5-dioxopiperazine, a piperidine, a pyrrolidine, a morpholine or a thiomorpholine,
R50 and R52, representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R51 representing, independently each time that they occur, a hydrogen atom, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl or NR58R59 radical,
R58 and R59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxy, allenyl, allenylalkyl or cyanoalkyl radical,
R53 and R54 representing, independently, a hydrogen atom or a —(CH2)k-Z7R60 or —(CH2)k—COR61 radical,
Z7 representing a bond, —O—, —NR62— or —S—,
R60 and R62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH—)k-Z8R63 and —(CH2)k—COR64 radicals,
R61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR65R66 radical,
R65 and R66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
Z8 representing a bond, —O—, —NR67— or —S—,
R63 and R67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
R64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR68R69 radical,
R68 and R69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical;
g and p, each time that they occur, being independently integers from 1 to 6, and k and n, each time that they occur, being independently integers from 0 to 6. - More preferentially, the compounds of general formula (I) (or their salts), when they are intended to have an inhibitory activity on MAO's and/or ROS's, will be such that:
- A represents
- either a
radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, or an alkyl or alkoxy radical,
R9 represents a hydrogen atom,
and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
or a
radical in which Q represents —OR22, —SR22 or a phenyl radical substituted by an OH radical and optionally one or more of the additional substituents chosen independently from a halogen atom and an OH, alkyl or alkoxy radical.
R22 representing a hydrogen atom or an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl or alkoxy radical,
R26 representing a hydrogen atom or an alkyl radical,
or a
radical in which R32 represents a hydrogen atom or an alkyl radical,
and T represents a —(CH2)m— radical with m=1 or 2,
or finally a
radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical,
Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms,
R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro or alkoxy radicals,
and T represents a —(CH2)m— radical with m=1 or 2,
X represents S or NR3,
R38 representing a hydrogen atom or an alkyl or cyanoalkyl radical,
Y represents O or S;
R1 represents a hydrogen atom, an alkyl, cycloalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH2)g-Z1R39, —(CH2)g—COR40, aryl, aralkyl, arylcarbonyl, or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, or aralkylcarbonyl radicals being itself optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, —(CH2)k-Z2R39 or —(CH2)k—COR40 radicals,
Z1 and Z2 representing a bond, —O—, —NR41— or —S—,
R39 and R41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl or cyanoalkyl radical,
R40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR42R43 radical,
R42 and R43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R2 represents a hydrogen atom or an alkyl radical
B represents a hydrogen atom or a —(CH2)g-Z3R44 radical,
Z3 representing a bond, —O—, —NR45— or —S—,
R44 and R45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical;
Ω represents one of the NR46R47 or OR48 radicals, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH2)g-Z4R50 or —(CH2)k—COR51 radical or also a radical chosen from the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more of the substituents chosen independently from halogen, alkyl, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
Z4 and Z5 representing a bond, —O—, —NR52— or —S—,
or R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group comprising —CH(R53)—, —NR54—, —O—, —S— and —CO—, said heterocycle being able to be for example an azetidine, a piperazine, a homopiperazine, a 3,5-dioxopiperazine, a piperidine, a pyrrolidine, a morpholine or a thiomorpholine,
R50 and R52, representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R51 representing, independently each time that they occur, a hydrogen atom, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl or NR58R59 radical,
R58 and R59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R53 and R54 representing, independently, a hydrogen atom or a —(CH2)k-Z7R60 or —(CH2)k—COR61 radical,
Z7 representing a bond, —O—, —NR62— or —S—,
R60 and R62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH2)k-Z8R63 and —(CH2)k—COR64 radicals,
R61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR65R66 radical,
R65 and R66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
Z8 representing a bond, —O—, —NR67— or —S—,
R63 and R67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
R64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR68R69 radical,
R68 and R69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical;
g and p, each time that they occur, being independently integers from 1 to 6, and k and n, each time that they occur, being independently integers from 0 to 6. - As regards the compounds of general formula (I) (or their salts) more especially intended to have an inhibitory activity on MAO's and the ROS's, the said compounds compounds having at least one of the following characteristics will generally be preferred:
-
- the compound corresponds to general sub-formula (I), or (I), in which X represents S, the compounds corresponds to general formula (I), in which Y represents O or the compound corresponds to general sub-formula (I)4;
- A represents the radical
- either the
- radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, or an alkyl or alkoxy radical,
- R9 represents a hydrogen atom,
- and W doesn't exist, or represents a bond, —O— or —S—,
- or the
- radical in which Q represents OH, two of the R19, R20 and R21 radicals' represent the radicals chosen independently from the alkyl, alkoxy, alkylthio, amino, alkylamino or dialkylamino radicals and the third represents a radical chosen from a hydrogen atom and the alkyl, alkoxy, alkylthio, amino, alkylamino or dialkylamino radicals, or in which Q represents a phenyl radical substituted by an OH radical and a radical or radicals chosen independently from a halogen atom and an OH, alkyl, alkoxy or —NR10R11 radical in which R10 and R11 represent independently a hydrogen atom or an alkyl radical,
- or also the
- radical
- or finally the
- radical in which T represents —CH2— and R33 represents a hydrogen atom, an aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical;
- either the
- B represents H;
- n represents 0 or 1;
- R1 and R2 both represent H;
- Ω represents
- preferably: an NR46R47 radical such that NR46R47 represents the N-piperazinyl radical or the N-piperazinyl radical optionally N-substituted by an alkyl radical or in which one of R46 and R47 represents H or a hydroxyalkyl, alkynyl or cyanoalkyl radical and the other represents H or an alkyl radical.
- or the OR48 radical in which R48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical.
- As regards the compounds of general formula (I) (or their salts) more especially intended to have an inhibitory activity on MAO's and the ROS's, the said compounds having at least one of the following characteristics will be quite particularly preferred:
-
- the compound corresponds to general sub-formula (I), or (I), in which X represents S or the compound corresponds to general formula (I), in which Y represents O;
- A represents the
- radical in which Q represents OH, two of the R19, R20 and R21 radicals represent an alkyl radical and the third represents H,
- or in which Q represents a phenyl radical substituted by an OH radical and one or more radicals chosen independently from the alkyl radicals;
- B represents H;
- n represents 0 or 1;
- R1 and R2 both represent H;
- Ω represents:
- preferably: an NR46R47 radical such that NR46R47 represents an N-piperazinyl radical or in which one of R46 and R47 represents H or a hydroxyalkyl, alkynyl or cyanoalkyl radical and the other represents H or an alkyl radical,
- or the OH radical.
- In particular, the compounds of Examples 1 to 30, 210, 291, 316, 319 to 323, 329 to 336 and 346 to 349 (sometimes described in the form of salts) or their pharmaceutically acceptable salts are preferred when an inhibitory activity on MAO's and/or the ROS's is sought in the first place. Even more preferentially, the compounds of Examples 1, 3, 6, 22, 24, 26 to 29, 323 and 332 (sometimes described in the form of salts), or their pharmaceutically acceptable salts, are preferred when an inhibitory activity on MAO's and/or the ROS's is sought in the first place.
- According to another variant of the invention, the compounds of general formula (I) or their pharmaceutically acceptable salts are more especially intended to have an modulating activity on the sodium channels and they are then preferably such that they correspond to general sub-formulae (I), and (I)2 and that:
- A represents
- either a
radical in which Q represents H, —OR22, SR22 or a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom, an alkyl or alkoxy radical, and a group of two substituents together representing a methylenedioxy or ethylenedioxy radical, or Q represents a —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph radical, said —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen independently from an alkyl or alkoxy radical and a halogen atom,
R22 representing a hydrogen atom or an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro, cycloalkyl, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical,
R27 and R28 representing, independently, a hydrogen atom or an alkyl radical or R27 and R28 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2—, —NH— and —O—,
R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
q representing an integer from 0 to 2,
R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy or NR10R11 radical,
R10 and R11 representing, independently, a hydrogen atom or an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle comprising 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
R9 represents a hydrogen atom or an alkyl radical,
and W does not exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
or a
radical in which R32 represents a hydrogen atom or an alkyl radical,
and T represents a —(CH2)m— radical with m=1 or 2,
or also A represents an alkyl, cycloalkyl or cycloalkylalkyl radical;
B represents a hydrogen atom, a linear or branched alkyl radical containing 1 to 6 carbon atoms or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, an alkyl or alkoxy radical, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical;
X represents NR38 or S,
R38 representing a hydrogen atom or an alkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical,
R1 and R2 represent, independently, a hydrogen atom, an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, aminoalkyl, —(CH2)g NH—CO—R70 radical or an aralkyl or heteroarylalkyl radical optionally substituted on the aryl or heteroaryl group by one or more groups chosen from the group composed of a halogen atom, an alkyl or alkoxy radical, a hydroxy, cyano or nitro radical and an amino, alkylamino or dialkylamino radical,
R70 representing, independently each time that it occurs, an alkyl or alkoxy radical;
R1 and R2 taken together can optionally form with the carbon atom which carries them a carbocycle with 3 to 7 members;
Ω represents OH or an NR46R47 radical, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl, —CO—NH—R51, —CO—O—R51 or —SO2—R72 radical or one of the heteroaryl, aralkyl, aryloxyalkyl or arylimino radicals optionally substituted on the heteroaryl or aryl group by one or more groups chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical,
R51 representing a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical contains 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkoxyalkyl radical or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical, and R72 representing an alkyl radical, or one of the phenyl or aralkyl radicals optionally substituted on the aromatic ring by one or more of the radicals chosen from a halogen atom, an alkyl or alkoxy radical;
g represents an integer from 1 to 6; and finally
n represents an integer from 0 to 6. - More preferentially, the compounds of general formula (I) (or their pharmaceutically acceptable salts) intended to have a modulating activity on the sodium channels corresponding to general sub-formulae (I), and (I)2 and will be such that:
A represents the
radical in which Q represents H, —OR22, —SR22, or a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical, or also Q represents a —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph radical, said —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen from an alkyl or alkoxy radical and a halogen atom,
R22 representing a hydrogen atom or an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro, cycloalkyl, —SO2NHR49, —CONHR55, —S(O)qR56—NH(CO)R57, —OCF3 or NR27R28 radical,
R27 and R28 representing, independently, a hydrogen atom or an alkyl radical or R27 and R28 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2—, —NH— and —O—,
R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
q representing an integer from 0 to 2,
R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
or also A represents an alkyl, cycloalkyl or cycloalkylalkyl radical,
B represents a hydrogen atom, a linear or branched alkyl radical containing 1 to 6 carbon atoms or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, an alkyl or alkoxy radical, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical;
X represents NR38 or S,
R38 representing a hydrogen atom or an alkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical,
R1 and R2 represent, independently, a hydrogen atom, an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, aminoalkyl, —(CH2)g—NH—CO—R70 radical or an aralkyl or heteroarylalkyl radical optionally substituted on the aryl or heteroaryl group by one or more groups chosen from the group composed of a halogen atom, an alkyl or alkoxy radical, a hydroxy, cyano or nitro radical and an amino, alkylamino or dialkylamino radical,
R70 representing, independently each time that it occurs, an alkyl or alkoxy radical;
R1 and R2 taken together can optionally form with the carbon atom which carries them a carbocycle with 3 to 7 members;
Ω represents the NR46R47 radical, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl, —CO—NH—R51, —CO—O—R51 or —SO2—R72 radical or one of the heteroaryl, aralkyl, aryloxyalkyl or arylimino radicals optionally substituted on the heteroaryl or aryl group by one or more groups chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical,
R51 representing a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical contains 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkoxyalkyl radical or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical, and R72 representing an alkyl radical, or one of the phenyl or aralkyl radicals optionally substituted on the aromatic ring by one or more of the radicals chosen from a halogen atom, an alkyl or alkoxy radical and finally;
n represents an integer from 0 to 6. - As regards the compounds of general formula (I) (or their salts) more especially intended to have a modulating activity on the sodium channels, said compounds of general sub-formula (I), or (I)2 will generally be preferred having at least one of the following characteristics:
-
- A represents:
- the
- radical in which Q represents a hydrogen atom, a halogen atom, the OH group, an alkoxy, alkylthio or phenyl radical optionally substituted by one or more radicals chosen from a halogen atom and an alkoxy radical,
- and R19, R20 and R21 represent, independently, a hydrogen atom, a halogen atom, the OH group or an alkyl, alkoxy, cyano, nitro, cycloalkyl, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical,
- R27 and R28 representing, independently, a hydrogen atom or an alkyl radical or R27 and R29 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2—, —NH— and —O—,
- R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
- q representing an integer from 0 to 2,
- R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical;
- or an alkyl, cycloalkyl or cycloalkylalkyl radical;
- the
- B represents H, alkyl, or phenyl;
- n represents 0 or 1;
- R1 and R2 are such that:
- R1 and R2 represent independently H, an alkyl, cycloalkyl radical and in particular cyclohexyl, cycloalkylalkyl, or also an aralkyl or heteroarylalkyl radical optionally substituted on the aryl or heteroaryl group by one or more groups chosen from the group comprising a halogen atom, an alkyl or alkoxy radical; in particular, R1 represents a linear or branched alkyl radical containing 2 to 6 carbon atoms, and preferably 4 to 6 carbon atoms, the cyclohexyl radical or the indolylmethyl radical optionally substituted and R2 represents H;
- or R1 and R2 taken together with the carbon atom which carries them a carbocycle with 3 to 7 members;
- Ω represents an OH radical or preferably an NR46R47 radical in which R46 represents H, an alkyl radical and in particular isopropyl, n-pentyl or n-hexyl, a cycloalkylalkyl radical, a cycloalkyl radical and in particular cyclobutyl, cyclopentyl or cyclohexyl, an alkylcarbonyl radical, an alkoxycarbonyl radical, a (cycloalkyl)oxycarbonyl radical, a cycloalkylalkoxycarbonyl radical, an alkylaminocarbonyl radical or also a benzyl radical optionally substituted by an alkoxy radical, and R47 represents H;
- X represents S or preferably the NR38 radical in which R38 represents a hydrogen atom or an alkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical.
- A represents:
- As regards the compounds of general formula (I) (or their salts) more particularly intended to have a modulatory activity on the sodium channels, said compounds of general sub-formula (I), or (I)2 comprising at least one of the following characteristics will be even more particularly preferred:
-
- A represents:
- the
- radical in which Q represents a hydrogen atom, a halogen atom or an alkoxy, alkylthio or phenyl radical optionally substituted by one or more radicals chosen from a halogen atom and an alkoxy radical,
- and R19, R20 and R21 represent, independently, a hydrogen atom, a halogen atom or an alkyl, alkoxy, cyano, cycloalkyl, —CF3 or NR27R28 radical,
- R27 and R28 representing, independently, a hydrogen atom or an alkyl radical or R27 and R28 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2— and —NH—;
- or a cycloalkyl radical;
- the
- B represents H;
- n represents 0 or 1;
- R1 represents H, an alkyl, cycloalkyl and in particular a cyclohexyl radical, and R2 represents H;
- Ω represents an NR46R47 radical in which R46 represents a cycloalkylalkyl radical, a cycloalkyl radical and in particular cyclobutyl or cyclohexyl, an alkoxycarbonyl radical, a (cycloalkyl)oxycarbonyl radical, a cycloalkylalkoxycarbonyl radical or also a benzyl radical optionally substituted by an alkoxy radical, and R47 represents H;
- X represents the NH radical.
- A represents:
- Furthermore, still for the compounds more particularly intended to have a modulatory activity on sodium channels, when n represents 1, R1 and R2 will preferably represent hydrogen atoms.
- In particular, the compounds of Examples 1, 3, 6, 7, 9 to 11, 13, 15 to 17, 20, 24, 26, 28 to 318, 321, 324 to 330 and 337 to 345 (sometimes described in the form of salts), or their pharmaceutically acceptable salts, are preferred when a modulating activity on the sodium channels is sought in the first place.
- More preferentially, the compounds of Examples 1, 6, 7, 11, 13, 15, 17, 20, 24, 31 to 38, 42, 43, 46 to 48, 53, 56, 57, 59 to 61, 64 to 80, 82 to 88, 9′ to 95, 97, 105, 106, 108, 110, 113, 117, 118, 121 to 123, 125, 128, 130 to 139, 142 to 145, 149, 151, 152, 154, 162 to 166, 168 to 178, 181, 183 to 186, 188, 190 to 196, 198 to 206, 208 to 210, 212 to 218, 220 to 231, 233 to 250, 252 to 259, 261 to 281, 283 to 288, 293 to 313, 324 and 338 to 340 (sometimes described in the form of salts), or their pharmaceutically acceptable salts, are preferred when a modulating activity on the sodium channels is sought in the first place.
- According to a more particular variant of the invention, the compounds of the invention of general formula (I) as defined previously in which:
- Het is such that the compounds of general formula (I) correspond to one of the general sub-formulae (I), and (I), in which X represents NH or S or general sub-formula (I)3 in which Y represents O;
- A represents a
radical in which Q represents OH, two of the R19, R20 and R21 radicals represent an alkyl radical and the third represents a hydrogen atom,
or in which Q represents a phenyl radical substituted by an OH radical and one or more radicals chosen independently from alkyl radicals;
B represents a hydrogen atom;
n represents 0 or 1;
R1 and R2 both represent a hydrogen atom;
and Ω represents an NR46R47 radical in which R46 represents a hydrogen atom or an alkyl, alkynyl, hydroxyalkyl or cyanoalkyl radical and R47 represents a hydrogen atom or an alkyl radical or also R46 and R47 form together with the nitrogen atom which carries them a non-aromatic heterocycle with 5 to 7 members, the additional members being chosen from —CH2— and —NH—;
can be used to prepare a medicament intended both to inhibit MAO's and lipidic peroxidation and to modulate the sodium channels. - More preferentially, the compounds of general formula (I) which can be used to prepare a medicament intended both to inhibit MAO's and lipidic peroxidation and to modulate the sodium channels will be such that:
- Het is such that the compounds of general formula (I) correspond to general sub-formula (I), in which X represents S or to general sub-formula (I)3 in which Y represents O;
- A represents a
radical in which Q represents OH, two of the radicals R19, R20 and R21 represent an alkyl radical and the third represents a hydrogen atom;
B represents a hydrogen atom;
n represents 0 or 1;
R1 and R2 both represent a hydrogen atom;
and Ω represents an NR46R47 radical in which R46 represents a hydrogen atom or an alkyl, hydroxyalkyl or cyanoalkyl radical and R47 represents a hydrogen atom or an alkyl radical or also R46 and R47 form together with the nitrogen atom which carries them an N-piperazinyl radical. - Still for the compounds of general formula (I) which can be used to prepare a medicament intended both to inhibit the MAO's and lipidic peroxidation and to modulate the sodium channels, n will preferably represent 0 when Het is such that the compounds of general formula (I) correspond to general sub-formula (I), in which X represents S and preferably 1 when Het is such that the compounds of general formula (I) correspond to general sub-formula (I)3 in which Y represents O.
- In particular, the compounds of Examples 1, 3, 6, 24, 26, 28 and 29 (sometimes described in the form of salts) or their pharmaceutically acceptable salts will be preferred if one wishes to prepare a medicament intended both to inhibit MAO's and lipidic peroxidation and to modulate the sodium channels.
- The invention also offers, as medicaments, the compounds of general formula (II)
in racemic, enantiomeric form or any combinations of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (II) correspond exclusively to one of the following sub-formulae:
in which
A represents
either a
radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR10R11 radical,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical,
R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R9 represents a hydrogen atom, an alkyl radical or a —COR15 group,
R15 representing a hydrogen atom or an alkyl, alkoxy or NR16R17 radical,
R16 and R17 representing, independently, a hydrogen atom or an alkyl radical, or R16 and R17 forming together with the nitrogen atom an optionally substituted heteroatom with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
or a
radical in which Q represents H, —OR22, —SR22, —NR23R24, a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom, an OH, cyano, nitro, alkyl, alkoxy or —NR10R11 radical and a group with two substituents together representing a methylenedioxy or ethylenedioxy radical, or also Q represents a —COPh, —SO2Ph or —CH2Ph radical, said —COPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen independently from an alkyl or alkoxy radical and a halogen atom,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —OR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R12 representing a hydrogen atom, an alkyl or alkoxy or NR13R14 radical,
R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R22 representing a hydrogen atom, an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals,
R23 and R24 representing, independently, a hydrogen atom, an alkyl radical or a —CO—R25 radical,
R25 representing an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF, —OCF3 or NR27R28 radical,
R26 representing a hydrogen atom or an alkyl radical,
R27 and R28 representing, independently, a hydrogen atom, an alkyl radical or a —COR29 group, or R27 and R28 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
q representing an integer from 0 to 2,
R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
R29 representing a hydrogen atom, an alkyl, alkoxy or —NR30R31 radical,
R30 and R31 representing, independently, a hydrogen atom or an alkyl radical, or R30 and R31 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
or a
radical in which R32 represents a hydrogen atom or an alkyl radical,
and T represents a —(CH2)m— radical with m=1 or 2,
or finally a
radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical,
Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms,
R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical,
R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
and T represents a —(CH2)m— radical with m=1 or 2,
or also A represents an alkyl, cycloalkyl or cycloalkylalkyl radical;
X represents S or NR38,
R38 representing a hydrogen atom or an alkyl, cyanoalkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical,
Y represents O or S;
R1 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH2)g-Z1R39, —(CH2)g—COR40, —(CH2)g—NHCOR70, aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radicals being itself optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z2R39 or —(CH2)k—COR40 radicals,
Z1 and Z2 representing a bond, —O—, —NR41— or —S—,
R39 and R41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl or cyanoalkyl radical,
R40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR42R43 radical,
R42 and R43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R2 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl or —(CH2)g—NHCOR71 radical, or also one of the aralkyl or heteroarylalkyl radicals optionally substituted on the aryl or heteroaryl group by one or more of the groups chosen independently from the group composed of a halogen atom and an alkyl, alkoxy, hydroxy, cyano, nitro, amino, alkylamino or dialkylamino radical,
R70 and R71 representing independently an alkyl or alkoxy radical;
or R1 and R2, taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members;
B represents a hydrogen atom, an alkyl radical, a —(CH2)g-Z3R44 radical or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical,
Z3 representing a bond, —O—, —NR45— or —S—,
R44 and R45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical;
Ω represents one of the NR46R47 or OR48 radicals, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH2)g-Z4R50, —(CH2)k—COR51, —(CH2)k—COOR51, —(CH2)k—CONHR51 or —SO2R51 radical, or also a radical chosen from the aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl and in particular pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more of the substituents chosen independently from halogen, alkyl, alkoxy, hydroxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
Z4 and Z5 representing a bond, —O—, —NR52— or —S—,
or R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R53)—, —NR54—, —O—, —S— and —CO—,
R50 and R52, representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R51 representing, independently each time that they occur, a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical contains 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, alkoxyalkyl or NR58R59 radical, or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more of the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,
R58 and R59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R53 and R54 representing, independently, a hydrogen atom or a —(CH2)k-Z7R60 or —(CH2)k—COR61 radical,
Z7 representing a bond, —O—, —NR62— or —S—,
R60 and R62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH2)k-Z8R63 and —(CH2)k—COR64 radicals,
R61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR65R66 radical,
R65 and R66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
Z8 representing a bond, —O—, —NR67— or —S—,
R63 and R67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical
R64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR68R69 radical,
R68 and R69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical;
g and p, each time that they occur, being independently integers from 1 to 6, and k and
n, each time that they occur, being independently integers from 0 to 6;
it being understood that when Het is such that the compound of general formula (II) corresponds to general sub-formula (II)4, then:
A represents the 4-hydroxy-2,3-di-tertiobutyl-phenyl radical;
B, R1 and R2 all represent H; and finally
Ω represents OH;
it also being understood that at least one of the following characteristics must be present: -
- Het is a thiazole, oxazole or isoxazoline ring, and
- A represents a
- radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
- or A represents a
- radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR10R11 radical, R10 and R11 representing, independently, a hydrogen atom or an alkyl radical
- R9 represents a hydrogen atom or an alkyl radical,
- and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical,
- or A represents a
- radical in which Q represents OH or Q represents a phenyl radical substituted by an OH radical and one or more of the radicals chosen independently from a halogen atom and an OH, alkyl, alkoxy or —NR10R11 radical in which R10 and R11 represent independently a hydrogen atom or an alkyl radical,
- or also A represents a
- radical in which R32 represents a hydrogen atom or an alkyl radical and T represents a —(CH2)m— radical with m=1 or 2,
- or finally A represents a
- radical in which the R33 radical represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-R36R37 radical, Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms, R34 and R35 representing, independently, a hydrogen atom or an alkyl radical, R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals, R10 and R11 representing, independently, a hydrogen atom, an alkyl radical, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms, said heterocycle being able to be for example azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine,
- and T represents a —(CH2)m— radical with m=1 or 2;
- Het is an imidazole ring,
- A represents a
- radical in which Q represents OH,
- and Ω represents NR46R47 in which R46 or R47 represents an aminophenyl, nitrophenyl, aminophenylcarbonyl, nitrophenylcarbonyl, aminophenylalkyl or nitrophenylalkyl radical;
- A represents a
- radical B represents a carbocyclic aryl radical optionally substituted 1 to 3 times by radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical, and one of R1 and R2 represents one of the optionally substituted arylalkyl or heteroarylalkyl radicals;
- A represents a cycloalkyl or cycloalkylalkyl radical;
- Ω represents NR46R47 and one of R46 and R47 represents an alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl or hydroxyalkyl radical;
- one of R1 and R2 represents a cycloalkyl or cycloalkylalkyl radical;
- none of R1 and R2 represents H;
- n=1 and A represents a biphenyl, phenoxyphenyl, phenylthiophenyl, phenylcarbonylphenyl or phenylsulphonylphenyl radical;
- when Het is a thiazole ring and Ω represents the OR48 radical in which R48 is a cyanoalkyl radical, then the cyano group is not attached to the carbon atom immediately adjacent to the oxygen atom;
or the pharmaceutically acceptable salts of the compounds of general formula (II).
- A represents a
- Het is a thiazole, oxazole or isoxazoline ring, and
- Generally, the medicaments of General formula (II) having one of the following additional characteristics are preferred:
- i. n=0,
-
-
- Het is an oxazole, thiazole or isoxazoline ring
- A represents a
- radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
- or A represents a
- radical in which R4, R5, R6, R7, R8 and R9 represent hydrogen atoms and W doesn't exist, or represents a bond, or —O—, —S— or —NR18— in which R18 represents a hydrogen atom or an alkyl radical,
- or A represents a
- radical in which Q represents OH and two of the R19, R20 and R21 radicals represent alkyl radicals,
- or in which Q represents a phenyl radical substituted by an OH radical and a radical or radicals chosen independently from a halogen atom and an OH, alkyl, alkoxy or —NR10R11 radical in which R10 and R11 represent independently a hydrogen atom or an alkyl radical,
- or also A represents a
- radical in which R32 represents a hydrogen atom or an alkyl radical and T represents —(CH2)2—,
- or finally A represents a
- radical in which T represents the —CH2— radical and the R33 radical represents a hydrogen atom or a -Σ-NR34R35 radical, Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms, and R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
- B represents H,
- R1 and R2 represent, independently, a hydrogen atom or an alkyl radical,
- and Ω represents an NR46R47 radical in which one of R46 and R47 represents an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl or hydroxyalkyl radical and the other represents a hydrogen atom or an alkyl radical; or
ii. n=0, - A represents a
- radical in which Q represents a hydrogen atom or an —OR22 or —SR22 radical in which R22 represents an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals, R19, R20 and R21 represent, independently, a hydrogen, a halogen, an SR26 radical, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical,
- R26 representing an alkyl radical,
- R27 and R28 representing, independently, a hydrogen atom or an alkyl radical or R27 and R28 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2—, —NH— and —O—,
- R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
- q representing an integer from 0 to 2,
- R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
- and one of R1 and R2 represents a cycloalkyl or cycloalkylalkyl radical or none of R1 and R2 represent a hydrogen atom; or finally
iii. n=1, - A represents an optionally substituted biphenyl radical or the cyclohexylphenyl radical,
- B represents a hydrogen atom,
- R1 and R2 each represent a hydrogen atom,
- and Ω represents an NR46R47 radical in which R46 represents a —COOR51 radical, R51 representing an alkyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl radical and R47 representing a hydrogen atom.
-
- In cases ii. and iii., it is preferred moreover that Het represents an imidazole ring.
- Preferably, the medicaments of general formula (II) will be chosen from the compounds described (sometimes in the form of salts) in Examples 1 to 35, 52, 57, 61, 80, 82, 83, 85 to 87, 90, 94, 113, 115, 123, 127, 130, 132, 134, 138, 139, 147, 152, 154, 161, 164, 169, 171 to 173, 176 to 180, 203, 237 to 239, 243 to 247, 249, 251, 255, 258 to 262, 264 to 271, 273 to 275 and 277 to 349, or the pharmaceutically acceptable salts of these compounds.
- More preferentially, the medicaments of general formula (II) will be chosen from the compounds described (sometimes in the form of salts) in Examples 1, 3, 6, 7, 11, 17, 24, 26 to 35, 57, 61, 82, 83, 85 to 87, 94, 113, 123, 130, 132, 134, 138, 139, 152, 154, 164, 169, 171 to 173, 176 to 178, 203, 237 to 239, 243 to 247, 249, 955, 258, 259, 261, 262, 264 to 271, 273 to 275, 277 to 281, 283 to 288, 293 to 313, 321, 323, 324, 332 and 338 to 340, or the pharmaceutically acceptable salts of these compounds.
- Moreover, the same preferences as those indicated for the compounds of general formula (I) are moreover applicable by analogy to the compounds of general formula (II).
- The invention also relates, as new industrial products, to the compounds of general formula (III)
in racemic, enantiomeric form or any combinations of these forms, in which Het is a heterocycle with 5 members comprising 2 heteroatoms and such that general formula (III) corresponds exclusively to one of the following sub-formulae:
in which
A represents
either a
radical in which R3 represents a hydrogen atom, the OH group or an alkoxy or alkyl radical,
or a
radical in which R4, R5, R6, R7 and R8 represent, independently, a hydrogen atom, a halogen, the OH group or an alkyl, alkoxy, cyano, nitro or NR10R11 radical,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical,
R13 and R14 represent, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R9 represents a hydrogen atom, an alkyl radical or a —COR15 group.
R15 representing a hydrogen atom or an alkyl, alkoxy or NR16R17 radical,
R16 and R17 representing, independently, a hydrogen atom or an alkyl radical, or R16 and R17 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
and W doesn't exist, or represents a bond, or —O—, —S— or —NR18—, in which R18 represents a hydrogen atom or an alkyl radical;
or a
radical in which Q represents H, —OR22, —SR22, —NR23R24, a phenyl radical optionally substituted by one or more of the substituents chosen independently from a halogen atom, an OH, cyano, nitro, alkyl, alkoxy or —NR10R11 radical and a group of two substituents together representing a methylenedioxy or ethylenedioxy radical, or also Q represents a —COPh, —SO2Ph or —CH2Ph radical, said —COPh, —SO2Ph or —CH2Ph radical being optionally substituted on its aromatic part by one or more of the substituents chosen independently from an alkyl or alkoxy radical and a halogen atom,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R12 representing a hydrogen atom, an alkyl or alkoxy or NR13R14 radical,
R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle with 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R22 representing a hydrogen atom, an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals,
R23 and R24 representing, independently, a hydrogen atom, an alkyl radical or a —CO—R25 radical,
R25 representing an alkyl radical,
and R19, R20 and R21 represent, independently, a hydrogen, a halogen, the OH or SR26 group, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical,
R26 representing a hydrogen atom or an alkyl radical,
R27 and R28 representing, independently, a hydrogen atom, an alkyl radical or a —COR29 group, or R27 and R28 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
q representing an integer from 0 to 2,
R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
R29 representing a hydrogen atom, an alkyl, alkoxy or —NR30R31 radical,
R30 and R31 representing, independently, a hydrogen atom or an alkyl radical, or R30 and R31 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
or a
radical in which R32 represents a hydrogen atom or an alkyl radical, and T represents a —(CH2)m— radical with m=1 or 2,
or finally a
radical in which R33 represents a hydrogen atom or an alkyl, -Σ-NR34R35 or -Σ-CHR36R37 radical,
Σ representing a linear or branched alkylene radical containing 1 to 6 carbon atoms,
R34 and R35 representing, independently, a hydrogen atom or an alkyl radical,
R36 and R37 representing, independently, a hydrogen atom or a carbocyclic or heterocyclic aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro, alkoxy or NR10R11 radicals,
R10 and R11 representing, independently, a hydrogen atom, an alkyl radical or a —COR12 group, or R10 and R11 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
R12 representing a hydrogen atom or an alkyl, alkoxy or NR13R14 radical,
R13 and R14 representing, independently, a hydrogen atom or an alkyl radical, or R13 and R14 forming together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group constituted by the O, N and S atoms,
and T represents a —(CH2)m— radical with m=1 or 2,
or also A represents an alkyl, cycloalkyl or cycloalkylalkyl radical;
X represents S or NR38,
R38 representing a hydrogen atom or an alkyl, cyanoalkyl, aralkyl, alkylcarbonyl or aralkylcarbonyl radical,
Y represents O or S;
R1 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH2)g-Z1R39, —(CH2)g—COR40, —(CH2)g—NHCOR70, aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radical, the aryl group of the aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl radicals being itself optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z2R39 or —(CH2)k—COR40 radicals,
Z1 and Z2 representing a bond, —O—, —NR41— or —S—,
R39 and R41 representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl or cyanoalkyl radical,
R40 representing, independently each time that it occurs, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR42R43 radical,
R42 and R43 representing, independently each time that they occur, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R2 represents a hydrogen atom, an alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl or —(CH2)g—NHCOR71 radical, or also one of the aralkyl or heteroarylalkyl radicals optionally substituted on the aryl or heteroaryl group by one or more of the groups chosen independently from the group composed of a halogen atom and an alkyl, alkoxy, hydroxy, cyano, nitro, amino, alkylamino or dialkylamino radical,
R70 and R71 representing independently an alkyl or alkoxy radical;
or R1 and R2, taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members;
B represents a hydrogen atom, an alkyl radical, a —(CH2)g-Z3R44 radical or a carbocyclic aryl radical optionally substituted 1 to 3 times by the radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical,
Z3 representing a bond, —O—, —NR45— or —S—,
R44 and R45 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical;
Ω represents one of the NR46R47 or OR48 radicals, in which:
R46 and R47 represent, independently, a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH2)g-Z4R50, —(CH2)k—COR51, —(CH2)k—COOR51, —(CH2)k—CONHR51 or —SO2R51 radical, or also a radical chosen from the aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl and in particular pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals, the aryl or heteroaryl group of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more of the substituents chosen independently from halogen, alkyl, alkoxy, hydroxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z5R50, —(CH2)k—COR51 and —(CH2)k—COOR51,
Z4 and Z5 representing a bond, —O—, —NR52— or —S—,
or R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R53)—, —NR54—, —O—, —S— and —CO—,
R50 and R52, representing, independently each time that they occur, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R51 representing, independently each time that they occur, a hydrogen atom, one of the cycloalkyl or cycloalkylalkyl radicals in which the cycloalkyl radical contains 3 to 7 carbon atoms, a linear or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, alkoxyalkyl or NR58R59 radical, or also an aryl or aralkyl radical, said aryl or aralkyl radical being able to be substituted by one or more the substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,
R58 and R59 representing, independently, a hydrogen atom or an alkyl, alkenyl, alkynyl, allenyl, allenylalkyl or cyanoalkyl radical,
R53 and R54 representing, independently, a hydrogen atom or a —(CH2)k-Z7R60 or —(CH2)k—COR61 radical,
Z7 representing a bond, —O—, —NR62— or —S—,
R60 and R62 representing, independently, a hydrogen atom or an alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radical, the aryl or pyridinyl group of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl radicals being optionally substituted by one or more substituents chosen from the group constituted by the alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH2)k-Z8R63 and —(CH2)k—COR64 radicals,
R61 representing a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR65R66 radical,
R65 and R66 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
Z8 representing a bond, —O—, —NR67— or —S—,
R63 and R67 representing, independently, a hydrogen atom, an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
R64 representing a hydrogen atom, an alkyl, allenylalkyl, alkenyl, alkenyl, alkynyl, cyanoalkyl, alkoxy or NR68R69 radical,
R68 and R69 representing, independently, a hydrogen atom or an alkyl, allenyl, allenylalkyl, alkenyl, alkynyl or cyanoalkyl radical,
and R48 represents a hydrogen atom or an alkyl, alkynyl or cyanoalkyl radical;
g and p, each time that they occur, being independently integers from 1 to 6, and k and n, each time that they occur, being independently integers from 0 to 6;
it being understood that when Het is such that the compound of general formula (III) corresponds to general sub-formula (III)4, then:
A represents the 4-hydroxy-2,3-di-tertiobutyl-phenyl radical;
B, R1 and R2 all represent H; and finally
Ω represents OH;
it being also understood that at least one of the following characteristics must be present: -
- when A represents a
- radical in which Q represents OH,
- Ω does not represent an NR46R47 radical in which R46 or R47 are chosen from a hydrogen atom and an alkyl radical or an NR46R47 radical in which R46 or R47 represents an aminophenyl, nitrophenyl, aminophenylcarbonyl, nitrophenylcarbonyl, aminophenylalkyl or nitrophenylalkyl radical;
- A represents a
- radical B represents a carbocyclic aryl radical optionally substituted 1 to 3 times by radicals chosen from the group composed of a halogen atom, a linear or branched alkyl or alkoxy radical containing 1 to 6 carbon atoms, a hydroxy, cyano or nitro radical, an amino, alkylamino or dialkylamino radical and a carbocyclic aryl radical, and one of R1 and R2 represents one of the optionally substituted arylalkyl or heteroarylalkyl radicals;
- A represents a cycloalkyl or cycloalkylalkyl radical;
- Ω represents NR46R47 and one of R46 and R47 represents an alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl or hydroxyalkyl radical;
- one of R1 and R2 represents a cycloalkyl or cycloalkylalkyl radical;
- none of R1 and R2 represent H;
- n=1 and A represents a biphenyl, phenoxyphenyl, phenylthiophenyl, phenylcarbonylphenyl or phenylsulphonylphenyl radical;
- when Het is a thiazole ring and Ω represents the OR48 radical in which R48 is a cyanoalkyl radical, then the cyano group is not attached to the carbon atom immediately adjacent to the oxygen atom;
or the salts of the compounds of general formula (III).
- when A represents a
- According to one of the preferred variants of the invention, the compounds of general formula (III) will be both ROS and MAO inhibitors and have at least one of the following characteristics:
-
- A representing the:
- radical in which Q represents OH, two of the R19, R20 and R21 radicals represent radicals chosen independently from the alkyl, alkoxy, alkylthio, amino, alkylamino or dialkylamino radicals and the third represents a radical chosen from a hydrogen atom and the alkyl, alkoxy, alkylthio, amino, alkylamino or dialkylamino radicals;
- n representing 0 or 1;
- R1 and R2 both representing H;
- Ω representing OH or the NR46R47 radical in which one of R46 and R47 represents a cyanoalkyl radical and the other represents H or alkyl or also in which R46 and R47 taken together form with the nitrogen atom a non aromatic heterocycle with 4 to 8 members, the elements of the chain being chosen from a group composed of —CH(R53)—, —NR54—, —O—, —S—, —CO—, R53 and R54 being as defined in general formula (III).
- A representing the:
- According to another preferred variant of the invention, the compounds of general formula (III) will be modulators of the sodium channels and preferably have one of the following two characteristics:
-
- n=0,
- A represents a
- radical in which Q represents a hydrogen atom or an —OR22 or —SR22 radical in which R22 represents an alkyl radical or an aryl radical optionally substituted by one or more substituents chosen from the alkyl, OH, halogen, nitro and alkoxy radicals, R19, R20 and R21 represent, independently, a hydrogen, a halogen, an SR26 radical, or an alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 or NR27R28 radical, R26 representing an alkyl radical,
- R27 and R28 representing, independently, a hydrogen atom or an alkyl radical or R27 and R28 forming together with the nitrogen atom which carries them a heterocycle with 5 to 6 members chosen from —CH2—, —NH— and —O—,
- R49 and R55 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkylcarbonyl radical,
- q representing an integer from 0 to 2,
- R56 and R57 representing, independently each time that they occur, a hydrogen atom or an alkyl or alkoxy radical,
- and one of R1 and R2 represents a cycloalkyl or cycloalkylalkyl radical or none of R1 and R2 represents a hydrogen atom; or finally
- n=1,
- A represents a biphenyl or cyclohexylphenyl radical,
- B represents a hydrogen atom,
- R1 and R2 each represent a hydrogen atom,
- and Ω represents an NR46R47 radical in which R46 represents a-COOR51 radical, R51 representing an alkyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl radical and R47 representing a hydrogen atom.
- More preferentially, the compounds of general formula (III) which are modulators of the sodium channels are such that Het represents an imidazole ring (i.e. that they correspond to one of general formulae (III)1 or (III)2 in which X represents an NR38 radical in which R38 is as defined previously).
- Generally, the compounds of general formula (III) will be preferably chosen from the compounds described (sometimes in the form of salts) in Examples 1 to 7, 9, 10, 24, 26 to 35, 52, 57, 61, 80, 82, 83, 85 to 87, 90, 94, 113, 115, 123, 127, 130, 132, 134, 138, 139, 147, 152, 154, 161, 164, 169, 171 to 173, 176 to 180, 203, 237 to 239, 243 to 247, 249, 251, 255, 258 to 262, 264 to 271, 273 to 275, 277 to 333 and 335 to 349, or the salts of these compounds.
- More preferentially, the compounds of general formula (III) will be chosen from the compounds described (sometimes in the form of salts) in Examples 1, 3, 6, 7, 24, 26 to 35, 57, 61, 82, 83, 85 to 87, 94, 113, 123, 130, 132, 134, 138, 139, 152, 154, 164, 169, 171 to 173, 176 to 178, 203, 237 to 239, 243 to 247, 249, 255, 258, 259, 261, 262, 264 to 271, 273 to 275, 277 to 281, 283 to 288, 293 to 313, 321, 323, 324, 332 and 338 to 340, or the salts of these compounds.
- The same preferences as those indicated for the compounds of general formula (I) and (II) are moreover applicable by analogy to the compounds of general formula (III).
- In certain cases, the compounds according to the present invention (i.e. the compounds of general formula (I), (II) or (III)) can contain asymmetrical carbon atoms. As a result, the compounds according to the present invention have two possible enantiomeric forms, i.e. the “R” and “S” configurations. The present invention includes the two enantiomeric forms and all combinations of these forms, including the racemic “RS” mixtures. For the sake of simplicity, when no specific configuration is indicated in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.
- The invention also relates to of the pharmaceutical compositions containing, as active ingredient, a compound of general formula (II) or a pharmaceutically acceptable salt of a compound general formula (II), as well as the use of the compounds of general formula (II) for preparing a medicament intended to inhibit the monoamine oxydases, in particular monoamine oxydase B, to inhibit lipidic peroxidation, to have a modulatory activity on the sodium channels or to have two of the three or all three aforementioned activities.
- The invention relates moreover, as medicaments, to the compounds of general formula (III) or their pharmaceutically acceptable salts. Similarly it relates to the pharmaceutical compositions containing, as active ingredient, a compound of general formula (III) or a pharmaceutically acceptable salt of a compound of general formula (III), as well as to the use of the compounds of general formula (III) for preparing a medicament intended to inhibit monoamine oxydases, in particular monoamine oxydase B, to inhibit lipidic peroxidation, to have a modulatory activity on the sodium channels or to have two of the three or all three of the aforementioned activities.
- In particular, the compounds of general formula (I), (II) or (III) can be used for preparing a medicament intended to treat one of the following disorders or one of the following diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depressions, psychoses, migraine or pains and in particular neuropathic pains.
- By pharmaceutically acceptable salt, is meant in particular the addition salts with inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or with organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate and stearate. Also included in the field of the present invention, when they can be used, are the salts formed from bases such as sodium or potassium hydroxide. For other examples of pharmaceutically acceptable salts, reference can be made to “Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201-217.
- The pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories. Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
- The pharmaceutical compositions containing a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, similarly their mixtures, in varying proportions, in water.
- The administration of a medicament according to the invention can be done by topical, oral, parenteral route, by intramuscular injection, etc.
- The administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg to 10 g according to the type of active compound used.
- In accordance with the invention, the compounds of general formula (I) can be prepared by the processes described below.
- Generalities
- The preparations of the compounds of the invention which correspond to general formulae (I), (II) or (III) in which Ω represents OH are carried out in a similar fashion to those described in the PCT Patent Application WO 99/09829 and the European Patent Application EP 432 740.
- As regards the compounds of the invention which correspond to general formulae (I), (II) and (III) and in which Het is an imidazole ring, a person skilled in the art can also usefully consult the PCT Patent Application WO 99/64401.
- The preparations of the other compounds of the invention which correspond to general formulae (I), (II) and (III) are carried out in a similar fashion to those described in the PCT Patent Application WO 98/58934 (cf. in particular on pages 39 to 45 of this document the syntheses of intermediates of general formulae (XXV) and (XXVIII)) or according to the procedures described hereafter.
- Preparation of the Compounds of General Formula (I)
- The compounds of general formula (I) can be prepared by the 8 synthesis routes illustrated below (Diagram 1) starting from the intermediates of general formula (IV), (V), (VI), (VII), (VIII), (IX), (X) and (I)α in which A, B, Q, R1, R2, Het and n are as defined above, L is a parting group such as for example a halogen, Alk is an alkyl radical, Gp is a protective group for an amine function, for example a 2-(trimethylsilyl)ethoxymethyl (SEM) group, and Gp′ a protective group for an alcohol function, for example a group of benzyl, acetate or also silyl type such as tert-butyldimethylsilyl, and finally A represents a bond or a —(CH2)x—, —CO—(CH2)x—, —(CH2)y—O— or —C(═NH)— radical. Of course, a person skilled in the art can choose to use protective groups other than Gp and Gp from those which are known, and in particular those mentioned in: Protective groups in organic synthesis, 2nd ed., (John Wiley & Sons Inc., 1991).
Route 1: Het is Imidazole and K is NR46R47 but Not a Radical of Carbamate Type - The amines and carboxamides of general formula (I), Diagram 2, in which A, B, R1, R2, R46, R47, Het and n are as defined above, are prepared by deprotection for example, in the case where Gp represents SEM, with tert-butylammonium fluoride (TBAF) in THF, of the amine of general formula (IV) in order to release the amine of the heterocycle of the compound of general formula (I). The protected amines of general formula (IV) are accessible by a general synthesis route described in Biorg. and Med. Chem. Lett., 1993, 3, 915 and Tetrahedron Lett., 1993. 34, 1901 and more particularly in the PCT Patent Application WO 98/58934.
Route 2: Het is Imidazole, Oxazole or Thiazole and Ω is NR46R47 - The amines and carboxamides of general formula (I), Diagram 3, in which A, B, R1, R2, R46, Het, g, k and n are as defined above, Δ represents an alkyl, cycloalkylalkyl, arylalkyl, aryl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl or hydroxyalkyl radical and Δ′ represents an alkyl, cycloalkylalkyl, arylalkyl or aryl radical when g or k do not represent 0, or Δ′ represents an alkyl, cycloalkylalkyl, arylalkyl radical or an aryl radical preferably deactivated (i.e. an aryl radical substituted by an electron attractor group such as for example a nitro or cyano group) when g or k represents 0, are prepared by condensation of the amines of general formula (V) with carboxylic acids (or the corresponding acid chlorides) of general formula (XIII) under standard conditions of peptide synthesis, with the aldehydes of general formula (XII) in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium borohydride, in a lower aliphatic alcohol such as methanol and optionally in the presence of molecular sieves, or with halogenated derivatives (Hal=halogen atom) of general formula (XI). In particular, when A represents an allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl or hydroxyalkyl radical, the compounds of general formula (V) are converted to the corresponding compounds of general formula (I) by reaction with the halogenated derivatives of general formula (XI) in a solvent such as acetonitrile, dichloromethane or acetone and in the presence of a base such as for example triethylamine or potassium carbonate at a temperature comprised between ambient temperature and the reflux temperature of the solvent.
- The derivatives of general formula (V) are in particular accessible by a general synthesis route described in Biorg. and Med. Chem. Lett., 1993, 3, 915 and Tetrahedron Lett., 1993. 34, 1901, and more particularly in the Patent Application WO 98/58934. When R46═H, the compounds of general formula (V) can be prepared, for example, according to a protocol described in the Patent Application WO 98/58934 (using the appropriate amino acid in place of N—Boc-sarcosinamide).
- In the particular case where R47 represents a cycloalkyl radical, the amines of general formula (I), Diagram 3a, in which A, B, R1, R2, R46, Het and n are as defined above and i represents an integer from 0 to 4 are prepared by condensation of the amines of general formula (V) with the cycloalkylketones of general formula (XIV) in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium borohydride in a lower aliphatic alcohol such as methanol and optionally in the presence of molecular sieves at ambient temperature.
- The sulphonamides of general formula (I), Diagram 3b, in which A, B, R1, R2, R46, Het and n are as defined above, R47 represents an —SO2-Δ radical and Δ represents an alkyl, cycloalkyl, cycloalkylalkyl or arylalkyl radical, are prepared by condensation of the amines of general formula (V) with the sulphochlorides of general formula (XV) under standard conditions, for example in a solvent such as dimethylformamide at ambient temperature.
- The ureas of general formula (I), Diagram 3c, in which A, B, R1, R2, R46, Het and n are as defined above, R47 represents a —CO—NH-Δ radical and Δ represents an alkyl, cycloalkyl, cycloalkylalkyl or arylalkyl radical, are prepared by reaction of the amines of general formula (V) with the isocyanates of general formula (XVI) in an inert solvent such as dichloromethane or 1,2-dichloroethane.
Route 3: Het is Oxazole or Thiazole, R1 and R2 are both H and Ω is OH. - The alcoholic derivatives of general formula (I), Diagram 4, in which A, B, Het and n are as defined above and R1 and R2 are hydrogen atoms are obtained by reduction of the acids or esters of general formula (VI) (accessible by a general synthesis route described in J. Med. Chem., 1996, 39, 237-245 and the PCT Patent Application WO 99/09829). This reduction can, for example, be carried out by the action of boron hydride or lithium aluminium hydride or also diisobutylaluminium hydride in an aprotic polar solvent such as tetrahydrofuran.
Route 4: Het is Oxazole or Thiazole and Ω is NR46R47. - The amines of general formula (I), Diagram 5, in which A, B, R1, R2, R46, R47, Het, and n are as defined above, are prepared by condensation of the primary or secondary amines of general formula R46—NHR47 with the compounds of general formula (VII) (in which L preferably represents a halogen atom Hal, but can also represent a mesylate or tosylate group) according to a general synthesis route described in J. Med. Chem., 1996, 39, 237-245 and the PCT Patent Application WO 99/09829 or the U.S. Pat. No. 4,123,529. This synthesis route can in particular be used when R46 and R47 taken together form with the nitrogen atom which carries them a non-aromatic heterocycle with 4 to 8 members. The reaction typically takes place in an anhydrous solvent (for example dimethylformamide, dichloromethane, tetrahydrofuran or acetone) in the presence of a base (for example Na2CO3 or K2CO3 in the presence of triethylamine), and preferably while heating.
Route 5: Het is Imidazole and Ω is a Radical of Carbamate Type - When Ω is a radical of carbamate type, the acids of general formula (VIII) can be cyclized in the form of derivatives of imidazoles of general formula (I), Diagram 6, by the addition of caesium carbonate followed by a condensation with an α-halogenoketone of formula A-CO—CH(B)—[Br, Cl] followed by the addition of a large excess of ammonium acetate (for example 15 or 20 equivalents per equivalent of acid of general formula (VIII)). This reaction is preferably carried out in a mixture of xylenes and while heating (one can also, if appropriate, simultaneously eliminate the water formed during the reaction).
Route 6: Het is Imidazole, Oxazole or Thiazole and Ω is NR46R47 - When Ω is an NR46R47 radical in which R47 is a radical comprising a termination of aminophenylene, alkylaminophenylene or dialkylaminophenylene type, the compounds of general formula (I), in which A, B, Het, n, R1, R2 and R46 are as defined above and Λ represents a bond or a —(CH2)x—, —CO—(CH2)x—, —(CH2)y—O— or —C(═NH)— radical, x and y being integers from 0 to 6, can be obtained, Diagram 7, by reduction of the compound of general formula (IX), for example by the action of hydrogen in the presence of a catalyst of palladium on carbon type in a solvent such as for example methanol, ethanol, dichloromethane or tetrahydrofuran. Reduction of the nitro function can also be carried out, for example, by heating the product in an appropriate solvent such as ethyl acetate with a little ethanol in the presence of SnCl2 (J. Heterocyclic Chem. (1987), 24, 927-930; Tetrahedron Letters (1984), 25 (8), 839-842) or in the presence of SnCl2/Zn (Synthesis. (1996), 9, 1076-1078), using NaBH4—BiCl3 (Synth. Com. (1995) 25 (23), 3799-3803) in a solvent such as ethanol, or then by using Raney Ni with hydrazine hydrate added to it (Monatshefte für Chemie, (1995), 126, 725-732), or also using indium in a mixture of ethanol and ammonium chloride under reflux (Synlett (1998) 9, 1028).
- When R47 is a radical of aminophenylene, alkylaminophenylene or dialkylaminophenylene type (Alk and Alk′ are identical or different alkyl radicals), the compound of general formula (IX) is reduced in order to produce the aniline derivative of general formula (I) and optionally mono- or di-alkylated according to standard reactions known to a person skilled in the art. The mono-alkylation is carried out by reducing amination with an aldehyde or by a nucleophilic substitution by reaction with an equivalent of halogenoalkyl Alk-Hal. A second alkylation can then be carried out if appropriate using a halogenoalkyl Alk′-Hal.
- In the particular case where Alk=Alk′=—CH3 and where A does not represents —CH2—, the nitro derivative of general formula (IX) will be treated with suitable quantities of paraformaldehyde under a flow of hydrogen in a solvent such as ethanol and in the presence of a catalyst of palladium on carbon type (Diagram 7a).
Route 7: Het is Imidazole, Oxazole or Thiazole and Ω is OH - This route can be used when Ω is OH. Contrary to route 3, R1 and R2 cannot be hydrogen atoms. In this case, the compounds of general formula (I) can be obtained, Diagram 8, by deprotection of the protected alcohol of general formula (X).
- In the case where Gp′ is a protective group of silyl type, the deprotection can be carried out, for example, by adding tetra-tert-butylammonium fluoride in a solvent such as tetrahydrofuran. In the case where Gp′ is a protective group of benzyl type, the deprotection will be carried out by hydrogenation in a solvent such as for example methanol, ethanol, dichloromethane or tetrahydrofuran. In the case where Gp′ is a protective group of acetate type, the deprotection can be carried out, for example, using sodium or potassium carbonate in an alcoholic solvent such as methanol. For other cases, a person skilled in the art will usefully consult the following document: Protective groups in organic synthesis, 2nd ed., (John Wiley & Sons Inc., 1991).
Route 8: Het is Imidazole, Oxazole or Thiazole and Ω is OR48 with R48H - The compounds of general formula (I) in which Ω is an OR48 radical with R48 H are obtained, for example, Diagram 9, from alcohols of general formula (I)a (which are compounds of general formula (I) as defined previously in which Q represents OH) by reacting the latter with a halide of general formula R48-Hal (Hal=Br, Cl or I) in a solvent such as dichloromethane, acetonitrile, anhydrous tetrahydrofuran or anhydrous ether and in the presence of a base such as potassium or sodium carbonate, sodium hydride or triethylamine.
- In the case where the A, B, R1 and R2 radicals contain alcohol, phenol, amine or aniline functions, it may be necessary to add protection/deprotection stage for these functions according to standard methods known to a person skilled in the art (stages not represented in Diagram 9).
Preparation of the Synthesis Intermediates
Preparation of the Imidazoles and Thiazoles of General Formula (V)
General Outline - The non-commercial ketonic derivative of general formula (V.i) or (V.i), in which A and B are as defined in general formula (I) is converted, Diagram 3.1, to the corresponding α-bromo-ketone of general formula (V.ii) or (V.ii), by reaction with a bromination agent such as CuBr2 (J. Org. Chem. (1964), 29, 3459), bromine (J. Het. Chem. (1988), 25, 337), N-bromosuccinimide (J. Amer. Chem. Soc. (1980), 102, 2838) in the presence of acetic acid in a solvent such as ethyl acetate or dichloromethane, HBr or Br2 in ether, ethanol or acetic acid (Biorg. Med. Chem. Lett. (1996), 6(3), 253-258; J. Med. Chem. (1988), 31(10), 1910-1918) J. Am. Chem. Soc. (1999), 121, 24) or also using a bromination resin (J. Macromol. Sci. Chem. (1977), A11, (3) 507-514). In the particular case where A is a p-dimethylaminophenyl radical, it is possible to use the operating method appearing in the publication Tetrahedron Lett., 1998, 39 (28), 4987. The amine of general formula (V) is then obtained according to the procedures shown in Diagrams 3.2 (imidazoles) and 3.3 (thiazoles) hereafter.
- Alternatively to the synthesis shown in Diagram 3.1, a person skilled in the art can, if appropriate, use an α-chloro-ketone in place of an α-bromo-ketone.
- Obtaining the Imidazoles of General Formula (V)
- The acid of general formula (V.iii), in which Gp represents a protective group for an amine function, for example a protective group of carbamate type, is treated, Diagram 3.2, with Cs2CO3 in a solvent such as methanol or ethanol. The α-halogeno-ketone of general formula (V.ii) in an inert solvent such as dimethylformamide is added to the caesium salt recovered. The intermediate ketoester is cyclized by heating to reflux in xylene (mixture of isomers) in the presence of a large excess of ammonium acetate (15 or 20 equivalents for example) in order to produce the imidazole derivative of general formula (V.iv) (the water formed being optionally eliminated during the reaction).
- In the case where R38 is not H, the amine function of the imidazole ring of the compound of general formula (V.iv) is substituted by reaction with the halogenated derivative R38-Hal (Hal=halogen atom); the protected amine function is then deprotected under standard conditions (for example: trifluoroacetic acid or HCl in an organic solvent when it is a protective group of carbamate type, or also hydrogenation in the presence of palladium on carbon when the protective group is a benzyl carbamate).
Obtaining the Thiazoles of General Formula (V) Intended for the Preparation of Compounds of General Formulae (I)1 or (I)2: - The thiocarboxamide of general formula (V.v), in which Gp represents a protective group for an amine function, for example a protective group of carbamate type, obtained for example by reaction of the corresponding carboxamide with Lawesson reagent or with (P2S5)2, is reacted, Diagram 3.3, with the α-bromo-ketone of general formula (V.ii) or (V.ii)2 according to an experimental protocol described in the literature (J. Org. Chem., (1995), 60, 5638-5642). The protected amine function is then deprotected under standard conditions in a strong acid medium (for example: trifluoroacetic acid or HCl in an organic solvent when it is a protective group of carbamate type), releasing the amine of general formula (V).
Obtaining the Thiazoles (V) Intended for the Preparation of Compounds of General Formula (I)3: - These compounds are obtained according to a method summarized in Diagram 3.4 below. The carboxamide of general formula (VII.ii) is firstly treated, for example, with Lawesson reagent or with (P2S5)2 then the thiocarboxamide of general formula (VII.iii) obtained is reacted with the halogenated derivative of general formula (V.vii) (cf. Biorg. Med. Chem. Lett. (1996), 6(3), 253-258; J. Med. Chem. (1988), 31(10), 1910-1918; Tetrahedron Lett., (1993), 34 (28), 4481-4484; or J. Med. Chem. (1974), 17, 369-371; or also Bull. Acd. Sci. USSR Div. Chem. Sci. (Engl Transl) (1980) 29, 1830-1833). The protected amine of general formula (V.viii) thus obtained is then deprotected under standard conditions for a person skilled in the art (for example: trifluoroacetic acid or HCl in an organic solvent when Gp is a protective group of carbamate type).
Obtaining the Oxazoles of General Formula (V) Intended for the Preparation of Compounds of General Formula (I)3: - These compounds are obtained according to a method summarized in Diagram 3.5 below. The carboxamide of general formula (VII.ii) is reacted with the halogenated derivative of general formula (V.vii). The protected amine of general formula (V.ix) thus obtained is then deprotected under standard conditions for a person skilled in the art in order to produce the compound of general formula (V) (for example: trifluoroacetic acid or HCl in an organic solvent when Gp is a protective group of carbamate type).
Preparation of the Ketonic Derivatives of General Formula (V.i) and of Certain α-Bromoketonic Derivatives of General Formula (V.ii), (V.ii)2 or (V.vii) - The non-commercial ketonic derivatives of general formula (V.i) or their α-bromoketonic homologues are accessible from methods in the literature or similar methods adapted by a person skilled in the art. In particular:
-
- when A represents an indolinyl or tetrahydroquinolyl radical, the compounds of general formula (V.i) are accessible from methods in the literature such as for example J. Med. Chem. (1986), 29, (6), 1009-1015 or J. Chem. Soc., Perkin Trans. 1 (1992), 24, 3401-3406;
- Alternatively, the compounds of general formula (V.ii) in which A represents an indolinyl or tetrahydroquinolyl radical in which R33 represents H can be synthesized according to a protocol which is slightly modified compared to that described in J. Chem. Soc., Perkin Trans 1 (1992), 24, 3401-3406. This protocol is summarized in Diagram 3.6 below.
- The indoline or tetrahydroquinoline (T represents —CH2— or —(CH2)2—) is protected using chloroacetyl chloride in order to produce the compound of general formula (XVII) which is subjected to a Friedel-Crafts reaction (substituted chloroacetyl chloride of general formula (XVIII), in which B has the meaning, indicated previously, in a solvent such as carbon disulphide and in the presence of aluminium chloride) in order to produce the compound of general formula (XIX). Then the compound of general formula (XIX) is hydrolyzed in the presence of acid, for example an acetic acid/HCl mixture, in order to produce the compounds of general formula (V.ii) in the form of a mixture of meta and para isomers. These isomers can be separated by fractioned crystallization from a solvent such as glacial acetic acid.
- A person skilled in the art will know how to adapt the syntheses described previously to the case where A represents an indolinyl or tetrahydroquinolyl radical in which R33 does not represent H. For example, when R33 represents an alkyl or aralkyl radical, the protection and deprotection stages will be unnecessary.
- when A represents a radical of 4-(4-hydroxyphenyl)-phenyl type, the compounds of general formula (V.i) are accessible from methods in the literature such as for example J. Org. Chem., (1994), 59(16), 4482-4489.
-
- The compounds of general formula (V.i) or (V.ii), in which S1, S2, S3 and S4 are chosen independently from a hydrogen atom and OH, cyano, nitro, alkyl, alkoxy or —NR10R11 as defined in general formula (I), are prepared, Diagram 3.7, from the esters of general formula (XX) (cf. in particular Chem. Lett. (1998), 9, 931-932 and Synthesis (1993), 8, 788-790). Of course, the phenol or aniline functions resulting from the nature of the R19, R20, R21, S1, S2, S3 and S4 substituents can lead a person skilled in the art to add to the stages represented in Diagram 3.7 protection stages (and, subsequently in the synthesis of the compounds of general formula (I), deprotection stages) of these functions so that they do not interfere with the remainder of the chemical synthesis. The esters of general formula (XX) are hydrolyzed in order to produce the acids of general formula (XXI). The latter are then subjected to coupling with N,O-dimethylhydroxylamine (Syn. Commun. (1995), 25(8), 1255; Tetrahedron Lett. (1999), 40(3), 411-414) in a solvent such as dimethylformamide or dichloromethane, in the presence of a base such as triethylamine with dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole, in order to produce the intermediates of general formula (XXII). The compounds of general formula (V.i) are prepared from the compounds of general formula (XXII) by a substitution reaction with MeLi (J. Med. Chem. (1992), 35(13), 2392). The bromoacetophenones of general formula (V.ii) are now accessible from the acetophenone of general formula (V.i) under the conditions described previously.
- when A represents a carbazolyl radical, the compounds of general formula (V.i) are accessible from methods in the literature such as for example J. Org. Chem., (1951), 16, 1198 or Tetrahedron (1980), 36, 3017.
- Alternatively, the compounds of general formula (V.ii) in which A represents a carbazolyl radical in which R9 represents H can be synthesized according to a protocol which is slightly modified with respect to that described for A=carbazolyl in Tetrahedron (1980), 36, 3017. This method is summarized in Diagram 3.8 hereafter:
- The carbazole of general formula (XXIII) is protected using acetic anhydride in order to produce the compound of general formula (XXIV), which is subjected to a Friedel-Crafts reaction (substituted chloroacetyl chloride of general formula (XVIII) as defined previously in a solvent such as carbon disulphide and in the presence of aluminium chloride) in order to produce the compound of general formula (XXV).
- Then the acyl group protecting the amine function is hydrolyzed in the presence of acid, for example an AcOH/HCl mixture, in order to produce the compound of general formula (V.ii). When A represents a carbazolyl radical in which R9 represents alkyl or a —COR15 group (case not shown in Diagram 3.8), the initial acylation stage is unnecessary and the last two stages of Diagram 3.8 allow the compounds of general formula (V.ii) to be obtained. Of course, the phenol or aniline functions resulting from the nature of the R4, R5, R6, R7 and R8 substituents can lead a person skilled in the art to add to the stages represented in Diagram 3.8 protection stages (and, subsequently in the synthesis of the compounds of general formula (I), deprotection stages) of these functions so that they do not interfere with the remainder of the chemical synthesis.
- when A represents a phenothiazinyl radical, the intermediates of general formula (V.i) and (V.ii) are accessible from methods in the literature: J. Heterocyclic. Chem. (1978), 15, 175-176 and Arzneimittel Forschung (1962), 12, 48.
- Alternatively, the intermediates of general formula (V.ii) in which A represents a phenothiazinyl radical can be prepared according to a protocol which is slightly modified with respect to that described for the phenothiazinyl radical in Arzneimittel Forschung (1962), 12, 48, which is summarized in Diagram 3.9 hereafter (see also the examples). The phenothiazine of general formula (XXVI) is protected using chloroacetyl chloride in order to produce the compound of general formula (XXVII), which is then subjected to a Friedel-Crafts reaction (compound of general formula (XVIII) in a solvent such as carbon disulphide in the presence of aluminium chloride) in order to produce the compound of general formula (XXVIII). During the last stage of the process, hydrolysis with HCl/acetic acid is accompanied by a halogen exchange and allows the chloroketone of general formula (V.ii) to be obtained. Of course, the phenol or aniline functions resulting from the nature of the R4, R5, R6, R7 and R8 substituents can lead a person skilled in the art to add to the stages shown in Diagram 3.9 protection stages (and, subsequently in the synthesis of the compounds of general formula (I), deprotection stages) of these functions so that they do not interfere with the remainder of the chemical synthesis.
when A represents a phenylaminophenyl radical, the compounds of general formula (V.i) are accessible from methods in the literature such as for example Chem. Commun., (1998), 15, (6) 1509-1510 or Chem Ber., (1986), 119, 3165-3197, or similar methods which a person skilled in the art will have adapted. - For example, the intermediates of general formula (V.i)a and (V.ii)a in which A represents a phenylaminophenyl radical (which correspond to the corresponding compounds of general formula (V.i) and (V.ii) the aniline function of which has been acetylated), can be prepared according to a protocol which is slightly modified with respect to that described for the phenylaminophenyl radical in Chem Ber. (1986), 119, 3165-3197. This protocol is summarized in Diagram 3.10 hereafter.
- In the case (shown in Diagram 3.10) where the R9 radical of the compound of general formula (I) to be synthesized is a hydrogen atom or an acetyl group, the diphenylamine of general formula (XXIX) formed after the coupling reaction in the presence of CuI is protected by acetylation using, for example, acetic anhydride in order to produce the compound of general formula (V.i)a. In the case (not shown in Diagram 3.10) where the R9 radical of the compound of general formula (I) to be synthesized is not a hydrogen atom or an acetyl radical, the acetylation stave is replaced by a substitution stage of the aniline according to standard methods known to a person skilled in the art in order to produce the corresponding compound of general formula (V.i). The compound of general formula (V.i)a (or (V.i), in the case not shown in Diagram 3.10) is then subjected to a bromination reaction using a bromination resin, PVPHP resin (Poly(VinylPyridinium Hydrobromide Perbromide), described in J. Macromol. Sci. Chem. (1977), A11, (3), 507-514, in order to produce the compound of general formula (V.ii)a (or (V.ii), in the case not shown in Diagram 3.10). Of course, the phenol or aniline functions resulting from the nature of the R4, R5, R6, R7 and R8 substituents can lead a person skilled in the art to add to the stages shown in Diagram 3.10 protection stages (and, subsequently in the synthesis of the compounds of general formula (I), deprotection stages) of these functions so that they do not interfere with the remainder of the chemical synthesis. The deprotection of the acetylated aniline function will be carried out in principle during the last stage of the synthesis of the compounds of general formula (I).
when A represents a benzopyran or benzofuran radical as defined in general formula (I) with R32 representing a hydrogen atom, the intermediates of general formula (V.i) and (V.ii) are accessible by the methods illustrated in Diagram 3.11 below. - The compounds of general formulae (V.i) and (V.ii), according to Diagram 3.11, in which T is as defined above and Gp=protective group, are prepared from the acids of general formula (XXX). The acids of general formula (XXX) are subjected to coupling with N,O-dimethylhydroxylamine (Syn. Commun. (1995), 25, (8), 1255; Tetrahedron Lett. (1999), 40, (3), 411-414) in a solvent such as dimethylformamide or dichloromethane, in the presence of a base such as triethylamine with dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazol, in order to produce the intermediates of general formula (XXXI). The protection of the phenol function in the form of a benzylated or tert-butyldimethylsilylated derivative or by other protective groups (Gp) known to a person skilled in the art is then carried out in order to produce the compounds of general formula (XXXII). The compounds of general formula (V.i) are prepared from the compounds of general formula (XXXII) by a substitution reaction with a Grignard reagent, MeMgCl (J. Het. Chem. (1990), 27, 1709-1712) or with MeLi (J. Med. Chem. (1992), 35, 13). The bromoacetophenones of general formula (V.ii) are now accessible from the acetophenone of general formula (V.i) under previously described conditions.
- Alternatively, the compound of general formula (V.ii) in which R32 represents a hydrogen atom or an alkyl radical can be prepared according to a process in only 3 stages (cf. Diagram 3.12—see also the examples). In this process, the bromination in the last stage of the compound of general formula (V.i) in order to produce the compound of general formula (V.ii) will preferably be carried out according to J. Am. Chem. Soc. (1999), 121, 24.
- When A represents a substituted phenol radical, it can be necessary to use intermediates of general formula (V.ii) as defined previously the phenol function of which has been acetylated (hereafter designated as compounds of general formula (V.ii)b). In particular:
-
- when A represents a 4-hydroxy-3,5-diisopropylphenyl radical, the homologous α-bromoketonic derivatives of the compound of formula (V.ii) the phenol function of which is protected by an acetyl radical can be prepared as summarized in Diagram 3.13 hereafter.
- when A represents a 4-hydroxy-3,5-diisopropylphenyl radical, the homologous α-bromoketonic derivatives of the compound of formula (V.ii) the phenol function of which is protected by an acetyl radical can be prepared as summarized in Diagram 3.13 hereafter.
- 2,6-diisopropylphenol is acetylated according to methods known to a person skilled in the art, for example by reacting it with acetic acid in the presence of trifluoroacetic acid anhydride or with acetyl chloride in the presence of a base such as for example K2CO3. The acetylated homologue of 2,6-diisopropylphenol is then subjected to a Fries rearrangement in the presence of aluminium chloride in a solvent such as nitrobenzene in order to produce the compound of formula (V.i). Then the compound of formula (V.i) is acetylated in order to produce the compound of formula (V.i)b. Bromination is then carried out with CuBr2 as previously described in order to produce the compound of formula (V.ii)b. The deprotection stage to release the phenol function will occur subsequently in the synthesis of the compounds of general formula (I) (at the time considered most appropriate by a person skilled in the art).
-
- when A represents a radical of dimethoxyphenol type, the compounds of general formula (V.ii)b can be prepared in a similar fashion to the synthesis described for the compound of formula (V.ii)b derived from 2,6-diisopropylphenol, optionally with a few minor modifications within the scope of a person skilled in the art. For example, when A represents the 3,5-dimethoxy-4-hydroxyphenyl radical, the corresponding α-bromoketonic derivative of formula (V.ii)b can be prepared, for example, as indicated in Diagram 3.13 from the commercial compound of formula (XXXV):
- when A represents a radical of dimethoxyphenol type, the compounds of general formula (V.ii)b can be prepared in a similar fashion to the synthesis described for the compound of formula (V.ii)b derived from 2,6-diisopropylphenol, optionally with a few minor modifications within the scope of a person skilled in the art. For example, when A represents the 3,5-dimethoxy-4-hydroxyphenyl radical, the corresponding α-bromoketonic derivative of formula (V.ii)b can be prepared, for example, as indicated in Diagram 3.13 from the commercial compound of formula (XXXV):
-
- The acids of general formula (XXXVI) are subjected to coupling with N,O-dimethylhydroxylamine (Syn. Commun. (1995), 25, (8), 1255; Tetrahedron Lett. (1999), 40, (3), 411-414) in a solvent such as dimethylformamide or dichloromethane, in the presence of a base such as triethylamine with dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazol, in order to produce the intermediates of general formula (XXXVII). The compounds of general formula (V.i)2 are prepared from the compounds of general formula (XXXVII) by a substitution reaction with lithium compound or magnesium compound derivatives of general formula B-M in which M represents Li or MgHal (Hal=I, Br or Cl) in solvents such as ether or anhydrous tetrahydrofuran. The α-bromo- or α-chloroketones of general formula (V.ii)2 can now be accessed from the ketones of general formula (V.i)2 under the conditions previously described.
-
- The protected amino acids of general formula (XXXVIII) are obtained by protection of the corresponding amino acids by a group of carbamate type according to methods known to a person skilled in the art. The acids of general formula (XXXVIII) are then subjected to coupling with N,O-dimethylhydroxylamine (Syn. Commun. (1995), 25, (8), 1255; Tetrahedron Lett. (1999), 40, (3), 411-414) in a solvent such as dimethylformamide or dichloromethane, in the presence of a base such as triethylamine with dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole, in order to produce the intermediates of general formula (XXXIX). The compounds of general formula (XLI) are prepared from the compounds of general formula (XXXIX) by a substitution reaction with lithium compound or magnesium compound derivatives of general formula (XL) (in which Hal=I, Br or Cl) in solvents such as ether or anhydrous tetrahydrofuran. The bromo or chloroacetophenones of general formula (V.vii) are now accessible from the acetophenone of general formula (XLI) under the conditions previously described.
- Alternatively, a person skilled in the art can also use or adapt the syntheses described in Angew. Chem. Int. (1998), 37 (10), 411-414, Liebigs Ann. Chem. (1995), 1217 or Chem. Pharm. Bull. (1981), 29(11), 3249-3255.
- Preparation of the Acid Derivatives of General Formula (V.iii)
- The acid derivatives of general formula (V.iii) can be obtained, Diagram 3.17, directly by reaction of the commercial amino acid of general formula (V.vi) with the compounds of (ar)alkylchloroformate or di(ar)alkylcarbonate type (Δ represents an alkyl or benzyl radical) under standard conditions known to a person skilled in the art.
Preparations of the Compounds of General Formula (V.v) - The thiocarboxamides of general formula (V.v) can be obtained in three stages starting from the compounds of general formula (V.vi) as indicated in the Diagram 3.18 below. The amine function of the amino acid of general formula (V.vi) is firstly protected under standard conditions with tBu-O—CO—Cl or (tBu-O—CO)2O (or other protective groups known to a person skilled in the art), then the intermediate obtained is converted to its corresponding amide by methods described in the literature (cf. for example, J. Chem. Soc., Perkin Trans. 1, (1998), 20, 3479-3484 or the PCT Patent Application WO 99/09829). Finally, the carboxamide is converted to the thiocarboxamide of general formula (V.v), for example by reaction with Lawesson reagent in a solvent such as dioxane or tetrahydrofuran at a temperature preferably comprised between ambient temperature and the reflux temperature of the mixture, or also using (P2S5)2 under standard conditions for a person skilled in the art.
- Alternatively, the thiocarboxamides of general formula (V.v) can also be obtained, Diagram 3.19, by the addition of H2S on the corresponding cyano derivatives of general formula (V.x) under standard conditions known to a person skilled in the art.
Preparation of the Acids of General Formula (VI)
Preparation of the Acid Derivatives of Thiazoles of General Formula (VI) -
- The carboxamides of general formula (VII.ii) are treated under standard conditions in order to produce the thiocarboxamide of general formula (VII.iii), for example by Lawesson reagent or also using (P2S5)2 under standard conditions for a person skilled in the art. Alternatively the acid of general formula (VII.i) is activated by the action of 1,1′-carbonyldiimidazole then treated with methylamine in an aprotic polar solvent such as for example tetrahydrofuran. The carboxamide intermediate obtained is converted to the thiocarboxamide of general formula (VI.i) under standard conditions, for example using Lawesson reagent or also using (P2S5)2 under standard conditions for a person skilled in the art. The thiocarboxamide of general formula (VII.iii) or (VI.i) is then reacted with the compound of general formula (VI.ii), for example while heating at reflux in a solvent such as benzene, dioxane or dimethylformamide. The ester of general formula (VI.iii) obtained can then be saponified by the action of a base such as for example potash in alcoholic medium or LiOH in tetrahydrofuran in order to produce the acid of general formula (VI).
- Preparation of the Acid Derivatives of oxazoles of General Formula (VI)
-
- The carboxamides of general formula (VII.ii) are reacted with the compound of general formula (VI.ii) while heating, for example at reflux, in the absence or in the presence of a solvent such as dimethylformamide. The ester of general formula (VI.iv) obtained can then be saponified by the action of a base such as for example potash in alcoholic medium or LiOH in tetrahydrofuran in order to produce the acid of general formula (VI).
- Preparation of the Acid Derivatives of Isoxazolines of General Formula (VI)
-
- The acids of general formula (VI) derived from isoxazolines can be prepared as follows: the commercial aldehydes of general formula (VI.v) are reacted with hydroxylamine hydrochloride. The oxime of general formula (VI.vi) thus obtained is activated in the form of oxime chloride, of general formula (VI.vii), by reaction with N-chlorosuccinimide in DMF before reacting with the esters of general formula (VI.viii) (in which Alk represents an alkyl radical) in order to produce the isoxazoline derivatives according to an experimental protocol described in the literature (Tetrahedron Lett., 1996, 37 (26), 4455; J. Med. Chem., 1997, 40, 50-60 and 2064-2084). Saponification of the isoxazolines of general formula (VI.ix) is then carried out in a standard fashion (for example by the action of KOH in an alcoholic solvent or LiOH in a solvent such as tetrahydrofuran) in order to produce the acid derivative of general formula (VI).
- The non-commercial unsaturated esters of general formula (VI.x) can be prepared according to the methods described in the literature (J. Med. Chem., 1987, 30, 193; J. Org. Chem., 1980, 45, 5017).
- Preparation of the Thiazoles and Oxazoles of General Formula (VII)
- General Outline
- The acids of general formula (VII.i), Diagram 5.1, are converted to the corresponding carboxamides of general formula (VII.ii) by methods described in the literature (cf. for example, J. Chem. Soc., Perkin Trans. 1, (1998), 20, 3479-3484 or the PCT Patent Application WO 99/09829). The compounds of general formula (VII) can then be obtained in a standard fashion according to the procedures represented in Diagrams 5.2 and 5.3 (thiazoles) and Diagram 5.4 (oxazoles) hereafter.
-
- When R1 and R2 both represent H, the thiazoles of general formula (VII) intended for the preparation of compounds of general formula (I)3 can be prepared according to the method summarized in Diagram 5.2. The carboxamide of general formula (VII.ii) is converted to the corresponding thiocarboxamide of general formula (VII.iii) in the presence of Lawesson reagent in a solvent such as dioxane or benzene at a temperature preferably comprised between ambient temperature and that of reflux of the mixture. The thiocarboxamide of general formula (VII.iii) is then treated with the α-halogenoketoester of general formula (VII.iv) in which Alk represents an alkyl radical (for example methyl, ethyl or tert-butyl), in order to produce the ester of general formula (VII.v), which is reduced to the corresponding alcohol of general formula (VII.vi), for example by the action of lithium aluminium hydride or diisobutylaluminium hydride in a solvent such as tetrahydrofuran. This latter can then be converted to a halogenated derivative of general formula (VII) according to the methods known to a person skilled in the art, for example, in the case of a brominated derivative (L=Br), by reaction with CBr4 in the presence of triphenylphosphine in dichloromethane at ambient temperature.
- The thiazoles of general formula (VII) intended for the preparation of compounds of general formula (I), can be prepared according to the method summarized in Diagram 5.3. The cyano derivative of general formula (VII.vii) in which Gp′ is a protective group for an alcohol function (for example a benzyl or —CO-ρ group in which ρ represents alkyl, for example methyl or tert-butyl) is converted to the corresponding thiocarboxamide of general formula (VII.viii) by the action of H2S in a solvent such as ethanol in the presence of triethanolamine at a temperature preferably comprised between ambient temperature and that of reflux of the mixture. The thiocarboxamide of general formula (VII.viii) is then treated with the α-halogenoketone of general formula (VII.ix) in order to produce the compound of general formula (VII.x), which is deprotected in order to produce the corresponding alcohol of general formula (VII.xi) according to methods known to a person skilled in the art (for example when Gp′ is a protective group of acetate type, this is removed in situ by the action of an aqueous solution of sodium carbonate). This latter can then be converted to a halogenated derivative of general formula (VII) according to the methods known to a person skilled in the art, for example, in the case of a brominated derivative (L=Br), by reaction with CBr4 in the presence of triphenylphosphine in dichloromethane at ambient temperature.
Obtaining the Oxazoles of General Formula (VII) - When R1 and R2 both represent H, the oxazoles of general formula (VII) intended for the preparation of compounds of general formula (I)3 can be prepared according to the method summarized in Diagram 5.4. The carboxamide of general formula (VII.ii) is treated with the α-halogenoketoester of general formula (VII.iv) in which Alk represents an alkyl radical (for example methyl, ethyl or tert-butyl), in order to produce the ester/acid of general formula (VII.xii). This latter is reduced to the corresponding alcohol of general formula (VII.xiii), for example by the action of lithium and aluminium hydride or diisobutylaluminium hydride in a solvent such as tetrahydrofuran when one starts from the ester or by the action of diborane in tetrahydrofuran when one starts from the acid. This latter can then be converted to a halogenated derivative of general formula (VII) according to methods known to a person skilled in the art, for example, in the case of a brominated derivative (L=Br), by reaction with CBr4 in the presence of triphenylphosphine in dichloromethane at ambient temperature.
Preparation of the Acids of General Formula (VII.i) - The non-commercial acids of general formula (VII.i) are accessible from methods in the literature. In particular:
- when A represents a phenothiazinyl radical, the acids of general formula (VII.i) are accessible from methods in the literature such as for example J. Med. Chem. (1992), 35, 716-724, J. Med. Chem. (1998), 41, 148-156; Synthesis (1988) 215-217; or J. Chem. Soc. Perkin. Trans. 1 (1998), 351-354;
- when A represents an indolinyl radical, the acids of general formula (VII.i) are accessible from methods in the literature such as for example J. Het. Chem. (1993), 30, 1133-1136 or Tetrahedron (1967), 23, 3823;
- when A represents a phenylaminophenyl radical, the acids of general formula (VII.i) are accessible from methods in the literature such as for example J. Amer. Chem Soc. (1940), 62, 3208; Zh. Obshch. Khim. (1953), 23, 121-122 or J. Org. Chem. (1974), 1239-1243;
- when A represents a carbazolyl radical, the acids of general formula (VII.i) are accessible from methods in the literature such as for example J. Amer. Chem Soc., (1941), 63, 1553-1555; J. Chem. Soc. (1934), 1142-1144; J. Chem. Soc. (1945), 945-956; or Can. J. Chem. Soc. (1982), 945-956; and
- when A represents a radical of 4-(4-hydroxyphenyl)-phenyl type, reference will be made for example to the following publication: Synthesis (1993) 788-790.
- Preparation of the Compounds of General Formula (VIII)
- When R1 and R2 both represent H, the protected amino acids of general formula (VIII) are either commercial, or obtained by protection of commercial amino acids by a group of carbamate type according to the methods known to a person skilled in the art.
- When at least one of R1 and R2 is not H, and n=0, the protected amino acids of general formula (VIII) are obtained in one stage, Diagram 6.1, by alkylation, in a solvent such as tetrahydrofuran and at low temperature, of commercial compound of general formula (VIII.i) using 3 equivalents of butyllithium and approximately one equivalent of the halogenated derivative of general formula (VIII.ii) in which R1 represents a radical of alkyl, cycloalkyl, cycloalkylalkyl or arylalkyl type and Hal a halogen atom. Depending on the case, a second alkylation (not represented in Diagram 6.1) can be carried out in a similar fashion, thus allowing the compounds of general formula (VIII) to be obtained in which neither R1 nor R2 represents H.
Preparation of the Imidazoles, Thiazoles and Oxazoles of General Formula (IX) - The preparation of the intermediates of general formula (IX) is described in the Patent Application WO 98/58934 (cf. in particular pages 10 to 50 and the examples of this document) or carried out by analogy from commercial starting products
- Preparation of the Protected Alcohols of General Formula (X)
- The acid of general formula (X.i) is successively treated, Diagram 8.1, with Cs2CO3, the compound of general formula (V.ii) and with NH4OAc, in order to produce the compound of general formula (X). The reaction conditions are similar to those described above for this type of synthesis.
Preparation of the Compounds of General Formula (X) Derived from Thiazoles - The cyano derivative of general formula (X.ii) is treated, Diagram 8.2, with H2S in order to produce the thiocarboxamide of general formula (X.iii), which, condensed with the compound of general formula (V.ii), allows the compound of general formula (X) to be obtained. The reaction conditions are similar to those described above (Diagram 5.3) for this type of synthesis.
Preparation of the Acids of General Formula (XXXVI) - The non commercial acids of general formula (XXXVI) are accessible from methods in the literature or similar methods adapted by a person skilled in the art. In particular:
-
- when A represents a phenothiazinyl radical, the acids of general formula (XXXVI) are accessible from methods in the literature: J. Org. Chem., (1956), 21, 1006; Chem. Abstr., 89, 180029 and Arzneimittel Forschung (1969), 19, 1193.
- when A represents a diphenylamine radical, the acids of general formula (XXXVI) can be accessed from methods in the literature: Chem Ber., (1986), 119, 3165-3197; J. Heterocyclic. Chem. (1982), 15, 1557-1559; Chem. Abstr., (1968), 68, 68730x; or by adaptation of these methods by a person skilled in the art;
- when A represents a radical of 4-(4-hydroxyphenyl)-phenyl type, the acids of general formula (XXXVI) can be accessed from methods in the literature such as for example Tetrahedron Lett. (1968), 4739 or J. Chem. Soc. (1961), 2898.
- when A represents a carbazolyl radical, the acids of general formula (XXXVI) can be accessed from methods in the literature such as for example J. Amer. Chem., (1946), 68, 2104 or J. Het. Chem (1975), 12, 547-549.
- when A represents a radical of benzopyrane or benzofurane type, the acids of general formula (XXXVI) can be accessed by the methods in the literature such as for example Syn. Commun. (1982), 12(8), 57-66; J. Med. Chem. (1995), 38(15), 2880-2886; or Helv. Chim. Acta. (1978), 61, 837-843.
- when A represents an indolinyl or tetrahydroquinolyl radical, the acids of general formula (XXXVI) can be accessed from methods in the literature such as for example J. Med. Chem. (1997), 40, (7), 1049-1062; Bioorg. Med. Chem. Lett. (1997), 1519-1524; Chem. Abstr. (1968), 69, 43814k; or Chem. Abstr. (1966), 66, 17538c.
- Of course, the phenol, amine or aniline functions resulting from the nature of the substituents on the A radical of the compounds of general formula (XXXVI) can lead a person skilled in the art to add protection/deprotection stages of these functions to the stages described so that they do not interfere with the rest of the chemical synthesis.
- Unless defined otherwise, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Likewise, all publications, patent applications, all patents and all other references mentioned here are incorporated by way of reference.
- The following examples are presented to illustrate the above procedures and must in no case be considered as limiting the scope of the invention.
- This product is obtained according to the procedure described in the PCT Patent Application WO 98/58934. Alternatively, it can also be prepared according to the method described below.
- 15.0 g (0.120 mol) of sarcosinamide hydrochloride (N-Me-Gly-NH2.HCl) is dissolved in dichloromethane containing 46.2 ml (0.265 mol) of diisopropylethylamine. The mixture is cooled down to 0° C. then Boc—O—Boc (28.8 g; 0.132 mol) is added in fractions and the mixture is stirred overnight at ambient temperature. The reaction medium is then poured into ice-cooled water followed by extraction with dichloromethane. The organic phase is washed successively with a 10% aqueous solution of sodium bicarbonate and with water, then finally with a saturated solution of sodium chloride. The organic phase is then dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is purified by crystallization from diisopropyl ether in order to produce a white solid with a yield of 72%. Melting point: 103° C.
- 16.0 g (0.085 mol) of intermediate 1.1 is dissolved in dimethoxyethane (500 ml) and the solution obtained is cooled down to 5° C. Sodium bicarbonate (28.5 g; 0.34 mol) then, in small portions, (P2S5)2 (38.76 g; 0.17 mol) are added. The reaction medium is allowed to return to ambient temperature under stirring over 24 hours. After evaporation of the solvents under vacuum, a 10% aqueous solution of sodium bicarbonate is added to the residue and the solution is extracted using ethyl acetate. The organic phase is washed successively with a 10% aqueous solution of sodium bicarbonate and with water, then finally with a saturated solution of sodium chloride. The organic phase is then dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is purified by crystallization from ether in order to produce a white solid with a yield of 65%. Melting point: 150-151° C.
- Intermediate 1.2 (4.3 g; 2.11 mmol) and bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone (6.9 g; 2,11 mmol) are dissolved in benzene (75 ml) under an argon atmosphere, then the mixture is stirred at ambient temperature for 12 hours. The reaction medium is heated under reflux for 4 hours. After evaporation of the solvents, the residue is diluted with dichloromethane and washed with a saturated solution of NaCl. The organic phase is separated, dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 20% ethyl acetate in heptane) in the form of an oil which crystallizes very slowly in a refrigerator with a yield of 28%. Melting point: 126.5-127.3° C.
- 2.3 ml (29 mmol) of trifluoroacetic acid is added dropwise, at 0° C. to a solution of 2.5 g (5.8 mmol) of intermediate 1.3 and 2 ml (1.6 mmol) of triethylsilane in 50 ml of dichloromethane. After stirring for one hour, the reaction mixture is concentrated under vacuum and the residue is diluted in 100 ml of ethyl acetate and 50 ml of a saturated solution of NaHCO3. After stirring and decantation, the organic phase is dried over magnesium sulphate, filtered and concentrated under vacuum. The residue is taken up in heptane in order to produce, after drying, a white solid with a yield of 73%. Melting point: 136° C.
- 2.0 g (0.602 mmol) of intermediate 1.4 is dissolved in anhydrous ether. The solution is cooled down to 0° C. then 18 ml (1.81 mmol) of a 1N solution of HCl in ether is added dropwise. The mixture is allowed to return to ambient temperature under stirring. After filtering and drying under vacuum, a white solid is obtained with a yield of 92%. Melting point: 185.3-186.0° C.
- 0.52 ml (3.7 mmol) of triethylamine and an excess of 0.56 g (7.5 mmol) of chloropropargyl are added dropwise at 0° C. to a solution of 0.5 g (1.5 mmol) of the compound of Example 1 in 15 ml of acetonitrile. After stirring overnight, the reaction mixture is concentrated under vacuum and the residue is diluted with dichloromethane and 50 ml of a saturated solution of NaCl. After stirring and decantation, the organic phase is separated and dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 20% ethyl acetate in heptane). After evaporation, the pure fractions produce a white solid with a yield of 20%. Melting point: 210-215° C.
- MH+=371.20.
- The experimental protocol used is identical to that described for Example 2, chloroacetonitrile being used as starting product in place of the chloropropargyl. A beige solid is obtained with a yield of 54%. Melting point: 150-156° C.
- MH+=372.30
- The experimental protocol used is identical to that described for Example 2, bromovaleronitrile being used as starting product in place of the chloropropargyl. A yellow oil is obtained with a yield of 24%.
- MH+=414.30
- The experimental protocol used is identical to that described for Example 2, bromohexanenitrile being used as starting product in place of the chloropropargyl. A red oil is obtained with a yield of 35%.
- MH+=428.40.
- The experimental protocol used is identical to that described for Example 2, 2-bromoethanol is used as starting product in place of the chloropropargyl. A yellow oil is obtained with a yield of 57%.
- MH+=377.30
- The experimental protocol used is identical to that described for Example 2, benzyl chloride being used as starting product in place of the chloropropargyl. A white solid is obtained with a yield of 52%. Melting point: 165-170° C.
- MH+=423.30
- This product is obtained according to the procedure described in the PCT Patent Application WO 98/58934.
- 0.8 ml of paraformaldehyde and 0.10 g of 20% palladium on carbon is added to a solution of 0.5 g (1.1 mmol) of Example 8 in 20 ml of ethanol. The medium is placed under hydrogen for 4 hours. The catalyst is filtered out and the solvent evaporated to dryness. The expected product is obtained after chromatography on a silica column (eluent: 3% ethanol in dichloromethane). The expected compound is obtained in the form of a brown oil with a yield of 54%.
- MH+=452.30
- The compound is produced according to an experimental protocol described in the Patent Application WO 98/58934 (see preparation of intermediates 26.1 and 26.2), using Z-Gly-NH2 in place of the N—Boc sarcosinamide. The expected compound is obtained in the form of a pale yellow oil with a yield of 99%.
- MH+=453.20
- 0.1 ml of a 40% solution of potassium hydroxide is added dropwise to a solution of 0.106 g (1.1 mmol) of the compound of Example 10 in 10 ml of methanol. After overnight stirring under reflux, the reaction mixture is concentrated under vacuum and the residue is diluted with dichloromethane and washed with a 1N solution of HCl then with 50 ml of a saturated solution of NaCl. The organic phase is separated and dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 5% ethanol in dichloromethane) in the form of a brown foam with a yield of 76%.
- MH+=319.29.
- The experimental protocol used is identical to that described for Example 2, 4-nitro-benzyl bromide being used as starting product in place of the chloropropargyl. A yellow solid is obtained with a yield of 63%. Melting point: 114.4-111.7° C.
- MH+=468.3
- 0.059 g (0.26 mmol) of SnCl2, 2H2O and 0.017 g (0.26 mmol) of Zn are added successively to a solution of 0.05 g (0.107 mmol) of the compound of Example 12 in a mixture of 0.55 ml of glacial acetic acid and 0.07 ml of a 12N solution of HCl. The mixture is stirred for 18 hours at 20° C. The reaction mixture is then made basic by adding a 30% aqueous solution of NaOH. The product is then extracted using two times 50 ml of CH2Cl2. The organic solution is washed with 50 ml of salt water, dried over MgSO4, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: 5% ethanol in dichloromethane). A yellow gum is obtained with a yield of 52%.
- MH+=438.29.
- 0.5 g (1.57 mmol) of the compound of Example 9, 0.237 g (1.57 mmol) of 4-nitrobenzaldehyde and 1 g of previously activated pulverulent 4 Å molecular sieve are added successively to a flask containing 30 ml of anhydrous MeOH, under an inert atmosphere. The reaction mixture is vigorously stirred for 18 hours before the addition, by portions, of 0.06 g (1.57 mmol) of NaBH4. Stirring is maintained for another 4 hours before the addition of 5 ml of water. After a quarter of hour, the sieve is filtered out and the reaction mixture is extracted with two times 100 ml of CH2Cl2. The organic phase is washed successively with 50 ml of water then with 50 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: 50% ethyl acetate in heptane). A yellow oil is obtained with a yield of 55%.
- MH+=454.20.
- The experimental protocol used is identical to that described for Example 13, the compound of Example 14 being used as starting product in place of the compound of Example 12. A yellow gum is obtained with a yield of 83%.
- MH+=424.20.
- The Compounds of the examples 16 to 22 can be obtained according to the procedures described in the PCT Patent Applications WO 98/58934.
- [is intermediate 26.5 of the PCT Application WO 98/58934]
- Intermediate 26.2 of the PCT Application WO 98/58934 is subjected to a hydrogenation as described in Stage 1.2 of the same document using ethanol as reaction solvent in place of methanol. The expected product is isolated in the form of a red foam.
- MH+=316.33.
- [is intermediate 27.2 of the PCT Application WO 98/58934]
- [is intermediate 27.3 of the PCT Application WO 98/58934]
- [is intermediate 22.6 of the PCT Application WO 98/58934]
- [is intermediate 22.7 of the PCT Application WO 98/58934]
- [is intermediate 28.1 of the PCT Application WO 98/58934]
- The compound of Example 23 can be obtained according to the procedures described in the PCT Patent Application WO 99/09829.
- [is intermediate 1.C of the PCT Application WO 99/09829; alternatively, this compound can also be obtained according to the procedure described in J. Med. Chem. (1996), 39, 237-245.]
- The experimental protocol used is identical to that described for Example 2, bromobutyronitrile being used as starting product in place of the chloropropargyl. A yellow oil is obtained with a yield of 18%.
- MH+=400.30.
- The experimental protocol used is identical to that described for Example 14, 3-nitrobenzaldehyde being used as starting product in place of the 4-nitrobenzaldehyde. A yellow oil is obtained with a yield of 28%.
- MH+=454.20.
- The compound of Example 23 is converted to brominated derivative, intermediate 3, according to the procedure indicated in Diagram 1(c) of the PCT Application WO 99/09829. Then the brominated derivative (0.5 g; 1.31 mmol) is added to a solution of N-methylpropargylamine 0.34 ml (3.94 mmol) and potassium carbonate (1.11 g) in dimethylformamide (20 ml). After overnight stirring at 80° C., the reaction mixture is concentrated under vacuum and the residue is diluted with dichloromethane and 50 ml of a saturated solution of NaCl. After stirring and decantation, the organic phase is separated and dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 50% ethyl acetate in heptane). After evaporation, the pure fractions produce a yellow oil with a yield of 24%.
- MH+=369.30.
- The experimental protocol used is identical to that described for the compound of Example 26, methylaminoacetonitrile being used as starting product in place of the N-methylpropargylamine. A white solid is obtained with a yield of 36%. Melting point: 165-167.8° C.
- The experimental protocol used is identical to that described for Example 26, N-methyl-β-alaninenitrile being used as starting product in place of the N-methylpropargylamine. A white solid is obtained with a yield of 56%. Melting point: 104-104.8° C.
- The experimental protocol used is identical to that described for Example 26, tert-butyl piperazinecarboxylate being used as starting product in place of the N-methylpropargylamine. A brown oil is obtained with a yield of 72%.
- MH+=486.20.
- A stream of HCl gas is passed bubblewise into a solution at 0° C. of intermediate 29.1 (0.450 g; 9.27 mmol) in ethyl acetate (30 ml). The mixture is left to return to ambient temperature overnight. A stream of argon is passed through the reaction mass, then the powder obtained is filtered and washed with ethyl acetate then with ether in order to produce a white solid with a yield of 70%. Melting point: >200° C.
- The experimental protocol used is identical to that described for Example 1,2-bromo-1-(10H-phenothiazin-2-yl)ethanone (J. Heterocyclic. Chem., (1978), 15, 175-176 and Arzneimittel Forschung, (1962), 12, 48), being used as starting product in place of the 2-bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone. The product obtained is purified by recrystallization from glacial acetic acid in order to produce a greenish solid. Melting point: >275° C.
- Alternatively, this compound can be obtained according to a similar method, but using 2-chloro-1-(10H-phenothiazin-2-yl)ethanone instead of 2-bromo-1-(10H-phenothiazin-2-yl)ethanone:
- 2-bromo-1-[10-(chloroacetyl)-10H-phenothiazin-2-yl)ethanone (2.2 g; 5.55 mmol; prepared according to a protocol described in J. Heterocyclic. Chem. (1978), 15, 175, followed by a Friedel-Crafts reaction) is dissolved hot in a mixture of acetic acid (20 ml) and 20% HCl (5.5 ml) and the mixture obtained is heated under reflux for 30 minutes. The reaction mixture is allowed to cool down, the precipitate is filtered, the mixture rinsed with acetic acid (5 ml) and dried under vacuum, the solid obtained is purified by crystallization from toluene in order to produce a brown product with a yield of 82%. Melting point: 190-191° C. (value in the literature: 197-198° C.).
- Intermediate 30.1 (0.280 g; 1.0 mmol) and tert-butyl 2-amino-2-thioxoethyl(methyl)carbamate (0.204 g; 1.0 mmol; described for example in PCT Patent Application WO 98/58934) are dissolved in toluene and the mixture is heated under reflux for 18 hours. After the toluene is evaporated off and the reaction mixture cooled down to 0° C., the latter is taken up in a 4N solution of HCl in dioxane (10 ml) and the mixture stirred for one hour at 0° C. before allowing the temperature to return to ambient temperature. The solid formed is filtered and rinsed with ether. The expected product is obtained after purification by crystallization from hot acetic acid in order to obtain a greenish solid. Melting point: >275° C.
- A solution containing β-alanine (8.9 g; 0.1 mol) and 100 ml of a 1N solution of sodium hydroxide is cooled down to 10° C. n-butyl chloroformate (13.66 g; 0.1 mol) and 50 ml of a 2N solution of sodium hydroxide are added simultaneously. After stirring for 16 hours at 23° C., approximately 10 ml of a solution of concentrated hydrochloric acid (approximately 11 N) is added in order to adjust the pH to 4-5. The oil obtained is extracted with ethyl acetate (2×50 ml), washed with water then dried over magnesium sulphate. The product crystallizes from isopentane in the form of a white powder (yield of 68%). Melting point: 50.5° C.
- A mixture of N-(butoxycarbonyl)-β-alanine (prepared in Stage 31.1; 5.67 g; 0.03 mol) and caesium carbonate (4.89 g; 0.015 mol) in 100 ml of ethanol is stirred at 23° C. for 1 hour. The ethanol is eliminated by evaporation under reduced pressure in a rotary evaporator. The mixture obtained is dissolved in 100 ml of dimethylformamide then 4-phenyl-bromoacetophenone (8.26 g; 0.03 mol) is added. After stirring for 16 hours, the solvent is evaporated off under reduced pressure. The mixture obtained is taken up in ethyl acetate then the caesium bromide is filtered. The ethyl acetate of the filtrate is evaporated and the reaction oil is taken up in a mixture of xylene (100 ml) and ammonium acetate (46.2 g; 0.6 mol). The reaction medium is heated at reflux for approximately one hour and 30 minutes then, after cooling down, a mixture of ice-cooled water and ethyl acetate is poured into the reaction medium. After decantation, the organic phase is washed with a saturated solution of sodium bicarbonate, dried over magnesium sulphate then evaporated under vacuum. The solid obtained is filtered then washed with ether in order to produce a light beige-coloured powder (yield of 50%). Melting point: 136.7° C.
- MH+=364.3.
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31, N-(tert-butoxycarbonyl)-β-alanine acid replacing the β-alanine. A yellow-coloured powder is obtained with a yield of 37%.
- MH+=364).
- tert-butyl 2-(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate (4.8 g; 0.013 mol) is stirred in 120 ml of a solution of ethyl acetate saturated in hydrochloric acid for 2 hours 30 minutes at a temperature of 55° C. The solid obtained is filtered and washed with ether. A light beige-coloured powder is obtained with a yield of 89%.
- MH+=264.2.
- A mixture containing valeric acid (0.24 ml; 0.002 mol), dicyclohexylcarbodiimide (2.2 ml; 1M solution in methylene chloride) and 1-hydroxybenzotriazole hydrate (336 mg; 0.0022 mol) in 15 ml of dimethylformamide (DMF) is stirred at 23° C. for thirty minutes. The 2-(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylamine prepared previously is added then the mixture is stirred for 48 hours at 23° C. The dicyclohexylurea formed is filtered then the DMF is evaporated off under reduced pressure. The residue obtained is taken up in ethyl acetate then the residual dicyclohexylurea is filtered again. The filtrate is washed with water and extracted using ethyl acetate. The solvent is evaporated off then purification is carried out on a silica column (eluent: CH2Cl2-MeOH/95-05). A white-coloured powder is obtained with a yield of 13%. Melting point: 166-167° C.
- MH+=348.2.
- A mixture containing 2-(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylamine (obtained in Stage 32.2 of Example 32; 660 mg; 0.0025 mol) and n-butane sulphochloride (390 mg; 0.0025 mol) in 20 ml of DMF is stirred for two hours at 23° C. Potassium carbonate (345 mg; 0.0025 mol.) is then added, then stirring is continued for two hours. The solvent is evaporated off and the reaction mixture is taken up in water and dichloromethane. The organic phase is washed with a saturated solution of sodium chloride then dried. The solvent is evaporated off and the residue obtained is purified on a silica column (eluent: CH2Cl2-MeOH/93-07). A light beige-coloured powder is obtained with a yield of 19%. Melting point: 168.5° C.
- MH+=384.2.
- A mixture containing 2-(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylamine (obtained in Stage 32.2 of Example 32; 660 mg; 0.0025 mol) and n-butyl isocyanate (341 mg; 0.0025 mol) in 20 ml of 1,2-dichloroethane is stirred for fifteen minutes at 60° C. The suspension is stirred for sixteen hours at 23° C. and filtered. The solid obtained is washed with 1,2-dichloroethane and with ether. A white-coloured powder is obtained with a yield of 66%. Melting point: 178° C.
- MH+=363.3.
- This compound is obtained according to an operating method similar to the preparation of the compound of Stage 31.2 of Example 31 using Boc-aminocyclohexylglycine (9.4 g; 0.036 mol) in place of the N-(butoxycarbonyl)-β-alanine and parafluorobromoacetophenone (7.9 g; 0.036 mol) in place of the 4-phenyl-bromoacetophenone. A white-coloured powder is obtained with a yield of 53%.
- MH+=374.2.
- This compound is prepared according to an operating method similar to that of Stage 32.2 of Example 32 using tert-butyl(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methylcarbamate (7.5 g; 0.02 mol) as starting compound. A white-coloured powder is obtained with a yield of 92%.
- MH+=274.2.
- A mixture containing (S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine (prepared in Stage 5.2; 519 mg; 0.0015 mol), triethylamine (0.4 ml; 0.003 mol) and butanone (140 mg; 0.002 mol) in 10 ml of methanol is stirred for thirty minutes at 23° C. Sodium triacetoxyborohydride (630 mg; 0.003 mol) is then added. The reaction mixture is stirred for sixteen hours then poured into water. After extraction with ethyl acetate, the organic phase is washed with a saturated solution of sodium chloride then dried over magnesium sulphate. The solvent is evaporated off and the residue is purified on a silica column (eluent: CH2Cl2-MeOH mixture/95-05). A white-coloured powder is obtained with a yield of 12%. Melting point: 170-172° C.
- MH+=328.2.
- Cyclohexylacetone (5.4 ml, 0.039 mol) and bromine (2 ml, 0.039 mol) are stirred at 23° C. in 100 ml of methanol. After decolourization, 100 ml of water are gently added. The mixture obtained is neutralized with 5 g of sodium bicarbonate. Extraction is carried out with ether followed by washing the organic phase with 100 ml of water. After drying over magnesium sulphate, the mixture is concentrated with a rotary evaporator. An oil is obtained with a yield of 97% c.
- NMR 1H (δ ppm, DMSO): 1.21-1.27 (m, 5H); 1.59-1.83 (m, 5H); 2.59-2.64 (m, 1H); 4.42 (s, 2H).
- A mixture of 2-amino-octanoic acid (25.25 g; 0.156 mol) and di-tert-butyl dicarbonate (37.8 g; 0.173 mol) in 425 ml of dioxane is stirred at reflux for three hours. After returning to 23° C., the mixture is again stirred for twenty four hours then the insoluble part is filtered out. The filtrate is evaporated. An oil is obtained with a yield of 99%. NMR H1 (δ ppm, DMSO): 0.85 (t, 3H); 1.11-1.27 (m, 8H); 1.37 (s, 9H); 1.51-1.65 (m, 2H); 3.81-3.87 (m, 1H); 6.96-6.97 (m, 1H); 12.3 (s, 1H).
- IR (cm−1): 3500; 2860; 1721 (νC═O (acid)); 1680 (νC═O (carbamate)); 1513 (νC—NH (carbamate)).
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31, using 2-[(tert-butoxycarbonyl)amino]octanoic acid (8.1 g; 0.0314 mol) in place of the N-(butoxycarbonyl)-β-alanine and 2-bromo-1-cyclohexylethanone (6.4 g; 0.0314 mol) in place of the 4-phenyl-bromoacetophenone. An oil is obtained which is sufficiently pure to be used in the following reaction (yield of 88%).
- This compound is obtained according to an operating method similar to that of Stage 32.2 of Example 32 using as starting compound tert-butyl 1-(4-cyclohexyl-1H-imidazol-2-yl)heptylcarbamate (prepared in Stage 6.3; 10 g; 0.0275 mol). A yellow solid is obtained in the form of a paste (yield of 37%).
- MH+=264.2
- This compound is obtained according to an operating method similar to that of Stage 35.3 of Example 35 using as starting amine 1-(4-cyclohexyl-1H-imidazol-2-yl)-1-heptanamine (obtained in Stage 6.4; 2.5 g; 0.074 mol) and as ketone, cyclohexanone (1 ml; 0.0097 mol). After purification on a silica column (eluent: ethyl acetate—heptane/7-3 with CH2Cl2-MeOH/95-05), a white-coloured powder is obtained with a yield of 12%. Melting point: 172-174° C.
- MH+=346.3.
- A solution of diisopropylamine (13.2 ml; 0.094 mol) in 130 ml of tetrahydrofuran (THF) is cooled down to −40° C. n-butyllithium (37 ml of a 2.5 M solution in hexane; 0.094 mol) is added dropwise. The temperature is allowed to rise to 0° C. At this temperature, Boc-glycine (5 g; 0.028 mol) in solution in 30 ml of THF is introduced into the mixture. The reaction medium is left for ten minutes at this temperature then 1-bromo-4-methylpentane (7.9 ml; 0.056 mol) in solution in 20 ml of THF is added rapidly. The temperature is allowed to return to 23° C. and the mixture is stirred at this temperature for one hour. After hydrolysis with 100 ml of water then acidification with 150 ml of a saturated solution of potassium hydrogen sulphate, the mixture obtained is extracted twice with 50 ml of ethyl acetate. The organic phase is washed with 100 ml of water then with 100 ml of a saturated solution of sodium chloride. After drying over magnesium sulphate and evaporating the solvent, the residue obtained is purified on a silica column (eluent: ethyl acetate—heptane/6-4) in order to produce a white-coloured powder with a yield of 50%.
- MH+=260.3.
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31 using 2-[(tert-butoxycarbonyl)amino]-6-methylheptanoic acid (3.5 g; 0.0135 mol) in place of the N-(butoxycarbonyl)-β-alanine and 3-bromophenacyl bromide (3.75 g; 0.0135 mol) in place of the 4-phenyl-bromoacetophenone. A white powder is obtained with a yield of 63%. Melting point: 134-136° C.
- MH+=436.2.
- This compound is obtained according to an operating method similar to that of Stage 32.2 of Example 32 using as starting compound tert-butyl 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexylcarbamate (obtained in Stage 37.2; 3.5 g; 0.008 mol). A white-coloured powder is obtained with a yield of 97%. Melting point: 200-202° C.
- MH+=336.2.
- This compound is obtained according to an operating method similar to that of Stage 35.3 of Example 35 using as starting amine, 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine (obtained in Stage 7.3; 0.8 g; 0.0019 mol) and as ketone, cyclohexanone (0.32 ml; 0.0023 mol). A white-coloured powder is obtained with a yield of 38%. Melting point: 236-238° C.
- MH+=418.2.
- This compound is obtained according to an operating method similar to that of Stage 31.2 of Example 31 using 2-[(tert-butoxycarbonyl)amino]octanoic acid (6.2 g; 0.024 mol) in place of the N-(butoxycarbonyl)-β-alanine and 2-bromo-4-fluoroacetophenone (5.2 g; 0.024 mol) in place of the 4-phenyl-bromoacetophenone. A white powder is obtained (yield: 58%) which is sufficiently pure to be used as it is for the following stage.
- This compound is obtained according to an operating method similar to that of Stage 32.2 of Example 32 using as starting compound tert-butyl 1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptylcarbamate (5.2 g; 0.014 mol). After purification on a silica column (eluent: CH2Cl2-MeOH—NH4OH/89-10-1), a grey-coloured powder is obtained (yield of 72%). Melting point: 148-150° C.
- MH+=276.2.
- This compound is obtained according to an operating method similar to that of Stage 35.3 of Example 35 using as starting amine, 1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-heptanamine (0.5 g; 0.0014 mol) and as ketone, cyclohexanone (0.17 ml; 0.0014 mol). A white-coloured powder is obtained with a yield of 15%.
- Melting point: 190-192° C.
- MH+=358.2.
- Triethylamine (0.83 ml; 0.006 mol) is added at 23° C. to a solution containing (1R)-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine (0.7 g; 0.002 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) in 15 ml of acetonitrile. The mixture is stirred for one hour at 23° C. then benzyl chloride (0.23 ml; 0.002 mol) is added. Stirring is maintained for 16 hours. The reaction mixture is concentrated using a rotary evaporator and the oil obtained is taken up in ethyl acetate and water. The aqueous phase is extracted with ethyl acetate and washed with water then with a saturated solution of sodium chloride. The solvents are evaporated off under vacuum. After purification on a silica column (eluent: AE-heptane/7-3), a deep beige-coloured solid is obtained in the form of a paste (yield of 5% c). Free base. Melting point: 60-62° C.
- MH+=463.3.
- (R,S)-1-(4-phenyl-1H-imidazol-2-yl)heptylamine (1 g; 0.003 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 20 ml of dimethylformamide. Potassium carbonate (2.2 g; 0.016 mol) is added at 23° C. then benzyl bromide (1.2 ml; 0.010 mol) is added fairly slowly. The mixture is stirred for 72 hours at 23° C. before being poured into ice-cooled water. The mixture is extracted with ethyl acetate. The organic phase is washed with water then with a saturated solution of sodium chloride. After drying over magnesium sulphate, the solvents are concentrated using a rotary evaporator. After purification on a silica column (eluent: ethyl acetate-heptane/10-90), a white-coloured powder is obtained (yield of 31%). Free base. Melting point: 94-96° C.
- MH+=438.3.
- N-benzyl(4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)methanamine (1 g; 0.0024 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 15 ml of dimethylformamide. Potassium carbonate (1 g; 0.0073 mol) is added at 23° C. then hexane bromide (0.34 ml; 0.0024 mol) is added fairly slowly. The reaction mixture is brought to about 70° C. for 3 hours before being poured into ice-cooled water. The mixture is extracted with ethyl acetate and the organic phase is washed with water. After drying over magnesium sulphate, the solvents are concentrated using a rotary evaporator. After purification on a silica column (eluent: ethyl acetate-heptane/7-3), a light yellow-coloured solid is obtained in the form of a paste (yield of 13%). Free base. Melting point: 120-122° C.
- MH+=424.3.
- (4-[1,1′-biphenyl]-4-yl-1H-imidazol-2-yl)-N-methylmethanamine (1 g; 0.003 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 20 ml of dimethylformamide. Potassium carbonate (1.23 g; 0.009 mol) is added at 23° C. then benzyl bromide (0.34 ml; 0.003 mol) is added fairly slowly. The reaction mixture is stirred at this temperature for 48 hours then poured in ice-cooled water. The mixture is extracted with ethyl acetate and the organic phase washed with water. After drying over magnesium sulphate, the solvents are concentrated using a rotary evaporator. After purification on a silica column (eluent: ethyl acetate-heptane/8-2), a white-coloured solid is obtained in the form of a paste (yield of 16%). Free base. Melting point: 106-108° C.
- MH+=354.2.
- (R,S)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine (1 g; 0.003 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 10 ml of methanol. Triethylamine (0.9 ml; 0.006 mol) is added dropwise then the mixture is stirred for 30 minutes at 23° C. Hexanal (0.45 ml; 0.0036 mol) is then added then the mixture is stirred for one hour at 23° C. Sodium triacetoxyborohydride (1.3 g; 0.006 mol) is finally added. After stirring for two hours at 23° C., water is added and the reaction mixture is extracted with ethyl acetate. The organic phase is washed with water and dried over magnesium sulphate before evaporation of the solvents. After purification on a silica column (eluent: ethyl acetate-heptane/6-4), a brown-coloured solid is obtained in the form of a paste (yield of 3%). Free base. The melting point could not be measured (paste).
- MH+=426.4.
- (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine (2 g; 0.0066 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 10 ml of n-butanol. 2-bromopyrimidine (1 g; 0.0066 mol) then diisoethylamine (1.15 ml, 0.0066 mol) are added dropwise. The mixture is then heated to about 80° C. for 16 hours. The n-butanol is evaporated off then the residue is taken up in water and ethyl acetate. The organic phase is washed with water then with a saturated solution of sodium chloride before being dried over magnesium sulphate and concentrated using a rotary evaporator. After purification on a silica column (eluent: ethyl acetate-heptane/7-3 then CH2Cl2-MeOH—NH4OH/95-4.5-0.5 then ethyl acetate), a white-coloured powder is obtained (the yield is 20%). Free base. Melting point: 138-140° C.
- MH+=381.2.
- (1-benzyl-4-phenyl-1H-imidazol-2-yl)methanamine (0.6 g; 0.0018 mol; prepared under experimental conditions similar to those previously and using suitable starting reagents and reaction products) is diluted in 15 ml of tetrahydrofuran. Triethylamine (1.12 ml; 0.008 mol) then methyl 4-toluenesulphonate (0.75 g; 0.004 mol) are added dropwise. The mixture is stirred for 48 hours at 23° C. then poured into ice-cooled water. After extraction with ether then decantation, the organic phase is washed with water then with a saturated solution of sodium chloride. The organic phase is then dried over magnesium sulphate and concentrated using a rotary evaporator. After purification on a silica column (eluent: ethyl acetate-heptane/7-3 then CH2Cl2-MeOH/95-5), a white-coloured powder is obtained (yield of 44%). Free base. Melting point: 78-80° C.
- MH+=292.2.
- (1R)—N-benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine (0.5 g; 0.00127 mol; prepared under experimental conditions similar to that of Example 38 and using suitable starting reagents and reaction products) is diluted in 25 ml of tetrahydrofuran. Methyl tosylate (0.24 g; 0.00127 mol) is added to the previous solution at 23° C. then potassium tert-butylate (0.15 g; 0.00127 mol) is added fairly slowly. Stirring is maintained for two hours at 23° C. then the mixture is heated to about 60° C. for eight hours. The solvent is evaporated off and the residue obtained taken up in ethyl acetate and a 10% solution of sodium bicarbonate. After decantation, the organic phase is washed with water and dried over magnesium sulphate. The solvent is then evaporated off. After purification on a silica column (eluent: ethyl acetate-heptane/7-3), a light beige-coloured solid is obtained in the form of a paste (yield of 4%). Free base. Melting point: 110-112° C.
- MH+=407.3.
- The compounds of Examples 47 to 318 are obtained, according to procedures similar to those described for Examples 31 to 46 or above iii the part entitled “Preparation of the compounds of general formula (I)”.
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 228-230° C.
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 104-106° C.
- Hydrochloride. Melting point: 228-230° C.
- Hydrochloride. Melting point: 200-204° C.
- Hydrochloride. Melting point: 132-134° C.
- Free base. Melting point: 102-104° C.
- Hydrochloride. Melting point: 279-280° C.
- Hydrochloride. Melting point: 150-152° C.
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 172-176° C.
- Free base. Melting point: 201-203° C.
- Free base. Melting point: 186-188° C.
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 140-142° C.
- Hydrochloride. Melting point: 146-148° C.
- Hydrochloride. Melting point: from 115° C.
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Hydrochloride. Melting point: 110-112° C.
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 118-120° C.
- Free base. Melting point: 68-70° C.
- Free base. Melting point: 192-194° C.
- Free base. Melting point: 130-132° C.
- Free base. The melting point could not be measured (paste).
- Hydrochloride. Melting point: 208-210° C.
- Hydrochloride. Melting point: 155-157° C.
- Hydrochloride. Melting point: 180-182° C.
- Hydrochloride. Melting point: 210-212° C.
- Hydrochloride. Melting point: 144-146° C.
- Free base. Melting point: from 95° C.
- Free base. Foam.
- Free base. Melting point: 172-176° C.
- Free base. Melting point: 100-102° C.
- Hydrochloride. Melting point: 208-210° C.
- Hydrochloride. Melting point: >260° C.
- Hydrochloride. Melting point: 180-182° C.
- Hydrochloride. Melting point: 110-114° C.
- Free base. Melting point: 118-120° C.
- Free base. Melting point: 146-148° C.
- Free base. Melting point: 120-122° C.
- Free base. Melting point: 208-210° C.
- Hydrochloride. The melting point could not be measured (paste).
- Free base. Melting point: 218-220° C.
- Free base. Melting point: 105-108° C.
- Free base. Melting point: 134-136° C.
- Free base. Melting point: 108-110° C.
- Free base. Melting point: 220-222° C.
- Free base. Melting point: 170-172° C.
- Free base. Melting point: 140-142° C.
- Free base. Melting point: 98-100° C.
- Hydrochloride. Melting point: becomes pasty at about 220° C.
- Hydrochloride. Melting point: 248-250° C.
- Free base. Melting point: 94-96° C.
- Hydrochloride. Melting point: 230-232° C.
- Free base. Melting point: 60-62° C.
- Free base. Melting point: 152-154° C.
- Free base. Melting point: 124-126° C.
- Free base. Melting point: 170-172° C.
- Free base. Melting point: 208-210° C.
- Hydrochloride. Melting point: 202-204° C.
- Free base. Compound described in the PCT Application WO 99/64401.
- Free base. Compound described in the PCT Application WO 99/64401.
- Free base. Compound described in the PCT Application WO 99/64401.
- Free base. Compound described in the PCT Application WO 99/64401.
- Free base. Compound described in the PCT Application WO 99/64401.
- Free base. Compound described in the PCT Application WO 99/64401.
- Hydrochloride. Melting point: 210-212° C.
- Free base. Melting point: 114-116° C.
- Free base. Melting point: 88-90° C.
- Free base. Melting point: 134-135° C.
- Free base. Melting point: 134-136° C.
- Free base. Melting point: 130-132° C.
- Hydrochloride. The melting point could not be measured (paste).
- Free base. Melting point: 72-74° C.
- Free base. Melting point: 184-185° C.
- Hydrochloride. Melting point: 174-176° C.
- Hydrochloride. Melting point: 196-198° C.
- Free base. Melting point: 144-146° C.
- Free base. Melting point: 52-54° C.
- Free base. Melting point: 142-144° C.
- Free base. Melting point: 220° C.
- Free base. Melting point: 100-102° C.
- Free base. Melting point: 152-154° C.
- Free base. Melting point: 136-138° C.
- Free base. Melting point: 167-169° C.
- Hydrochloride. Melting point: 240-242° C.
- Hydrochloride. Melting point: 131-134° C.
- Hydrochloride. Melting point: 170-174° C.
- Free base. Melting point: 70-74° C.
- Free base. Melting point: 160-162° C.
- Free base. Melting point: 208-210° C.
- Free base. Melting point: 142-143° C.
- Free base. Melting point: 96-100° C.
- Free base. Melting point: 72-74° C.
- Free base. Melting point: 112-114° C.
- Hydrochloride. Melting point: 206-210° C.
- Free base. Melting point: 140-142° C.
- Free base. Melting point: 70-72° C.
- Hydrochloride. Melting point: 178-180° C.
- Hydrochloride. Melting point: 218-220° C.
- Free base. Melting point: 170-172° C.
- Free base. Melting point: 144-146-C.
- Hydrochloride. Melting point: 218-220° C.
- Hydrochloride. Melting point: 130-132° C.
- Hydrochloride. Melting point: 210-212° C.
- Hydrochloride. Melting point: 228-230° C.
- Hydrochloride. Melting point: 198-200° C.
- Free base. Melting point: 160-162° C.
- Free base. Melting point: 174-176° C.
- Free base. Melting point: 130-132° C.
- Hydrochloride. Melting point: 215-218° C.
- Free base. Melting point: 154-156° C.
- Hydrochloride. Melting point: >250° C.
- Free base. Melting point: 233-238° C.
- Free base. Melting point: 210-213° C.
- Free base. Melting point: 145-146° C.
- Free base. Melting point: 98-99° C.
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 126° C.
- Hydrochloride. Melting point: 197-200° C.
- Free base. Melting point: 152-154° C.
- Free base. Melting point: 195-196° C.
- Free base. Melting point: 254-256° C.
- Hydrochloride. Melting point: >260° C.
- Hydrochloride. Melting point: 244-246° C.
- Hydrochloride. Melting point: 178-180° C.
- Free base. Melting point: 77-80° C.
- Free base. Melting point: 64-65° C.
- Hydrochloride. Melting point: 157-160° C.
- Hydrochloride. Melting point: 238-240° C.
- Free base. Melting point: 200-202° C.
- Free base. Melting point: 125-127° C.
- Hydrochloride. Melting point: 182-184° C.
- Free base. Melting point: 141-143° C.
- Hydrochloride. Melting point: 231-232° C.
- Hydrochloride. Melting point: 230-231° C.
- Free base. Melting point: 142-144° C.
- Acetate. Melting point: 115-116° C.
- Free base. Melting point: 138-140° C.
- Free base. Melting point: 100-102° C.
- Hydrochloride. Melting point: >250° C.
- Free base. Melting point: 136-138° C.
- Free base. Melting point: 220-222° C.
- Hydrochloride. Melting point: 224-226° C.
- Hydrochloride. Melting point: 185-188° C.
- Free base. Melting point: 155-157° C.
- Free base. Melting point: 192-194° C.
- Free base. Melting point: 162-164° C.
- Free base. Melting point: 182-184° C.
- Hydrochloride. Melting point: 218-220° C.
- Free base. Melting point: from 126° C.
- Free base. Melting point: 156-158° C.
- Free base. Melting point: 145.6° C.
- Hydrochloride. Melting point: 155.4° C.
- Hydrochloride. Melting point: 204-206° C.
- Hydrochloride. Melting point: 182-184° C.
- Free base. Melting point: becomes pasty from 130° C.
- Free base. Melting point: 78.6° C.
- Free base. Melting point: 218-220° C.
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 141-142° C.
- Hydrochloride. Melting point: 192° C.
- Hydrochloride. Melting point: 178-181° C.
- Hydrochloride. Melting point: 148-150° C.
- Hydrochloride. Melting point: 138-140° C.
- Free base. The melting point could not be measured (paste).
- Free base. The melting point could not be measured (paste).
- Free base. Melting point: 94-98° C.
- Hydrochloride. Melting point: from 120° C.
- Hydrochloride. Melting point: from 185° C.
- Free base. Melting point: 126-128° C.
- Hydrochloride. Melting point: from 110° C.
- Hydrochloride. Melting point: from 90° C.
- Hydrochloride. Melting point: 170° C.
- Hydrochloride. Melting point: 148-150° C.
- Free base. Melting point: 134-136° C.
- Hydrochloride. Melting point: 200-202° C.
- Acetate. Melting point: 70-72° C.
- Free base. Melting point: 92-94° C.
- Free base. Oil.
- Free base. Melting point: 134-136° C.
- Free base. Melting point: 170-172° C.
- Free base. Melting point: 134-135° C.
- Free base. Melting point: 148-150° C.
- Free base. Melting point: 118-122° C.
- Free base. Melting point: 114-116° C.
- Free base. Melting point: 240-242° C.
- Free base. Melting point: 177.2° C.
- Free base. Melting point: 141.2° C.
- Free base. Melting point: 132.5° C.
- Free base. Melting point: 148-152° C.
- Free base. Melting point: 114-116° C.
- Free base. Melting point: 207-210° C.
- Hydrochloride. Melting point: 194° C.
- Free base. Melting point: 87° C.
- Hydrochloride. Melting point: 168-170° C.
- Hydrochloride. Melting point: 220-222° C.
- Free base. Melting point: 202-204° C.
- Free base. Melting point: 116.5-116.8° C.
- Hydrochloride. Melting point: 180-190° C.
- Hydrochloride. Melting point: 230-232° C.
- Hydrochloride. Melting point: 222-223° C.
- Hydrochloride. Melting point: 225-227° C.
- Hydrochloride. Melting point: 230-232° C.
- Free base. Melting point: 210-212° C.
- Free base. Melting point: 200-202° C.
- Hydrochloride. Melting point: 142-144° C.
- Hydrochloride. Melting point: >250° C.
- Hydrochloride. Melting point: 180-182° C.
- Hydrochloride. The melting point could not be measured (paste).
- Hydrochloride. Melting point: 151-152° C.
- Free base. Melting point: 138.4° C.
- Free base. Melting point: 150° C.
- Free base. Melting point: 136-140° C.
- Free base. Melting point: 140.5° C.
- Hydrochloride. Melting point: 216.7° C.
- Hydrochloride. Melting point: 221.4° C.
- Free base. Melting point: 146-148° C.
- Hydrochloride. Melting point: 190-192° C.
- Free base. Melting point: 224-226° C.
- Acetate. Melting point: from 130° C.
- Free base. Gum.
- Hydrochloride. Melting point: 190-194° C.
- Free base. Melting point: 132-134° C.
- Free base. Melting point: 166° C.
- Free base. Melting point: 96-98° C.
- Free base. Melting point: 260-262° C.
- Free base. Melting point: 180-182° C.
- Free base. Melting point: 144-145° C.
- Free base. Melting point: 149-150° C.
- Free base. Melting point: 182.3° C.
- Free base. Melting point: 123.3° C.
- Free base. Melting point: 134.3° C.
- Hydrochloride. Melting point: 204-206° C.
- Hydrochloride. Melting point: 254.6° C.
- Hydrochloride. Melting point: 204-210° C.
- Free base. Melting point: 184.8° C.
- Free base. Melting point: 106-108° C.
- Hydrochloride. Melting point: 190-192° C.
- Hydrochloride. Melting point: 214.1° C.
- Hydrochloride. Melting point: 230.4° C.
- Free base.
- Free base. Melting point: 99-100° C.
- Free base. Melting point: 104-105° C.
- Free base. Melting point: 140-142° C.
- Free base. Melting point: 104-106° C.
- Free base. Melting point: 130-132° C.
- Free base. Melting point: 186-188° C.
- Free base. Melting point: 143.9° C.
- Hydrochloride. Melting point: 206.3° C.
- Hydrochloride. Melting point: 198-200° C.
- Hydrochloride. Melting point: 148-149° C.
- Free base. Melting point: 217-218° C.
- Hydrochloride. Melting point: 216-217° C.
- Hydrochloride. Melting point: 238-241° C.
- Hydrochloride. Melting point: 180-186° C.
- Free base. Melting point: 125° C.
- Hydrochloride. Melting point: 213.9° C.
- Hydrochloride. Melting point: decomposes from 250° C.
- Hydrochloride. Melting point: 222-228° C.
- Hydrochloride. Melting point: 165-166° C.
- Hydrochloride. Melting point: 188.2° C.
- The compound of Example 319 can be obtained according to a protocol analogous to that described for the compound of Example 38, Stage E of PCT Patent Application WO 99/09829, except that ethyl bromopyruvate replaces the 3-chloroacetoacetate in Stage 38.C and that disobutylaluminium hydride replaces the lithium aluminium hydride in Stage 38.E.
- Alternatively, this compound can also be obtained according to the procedure described in J. Med. Chem. (1996), 39, 237-245. White solid. Melting point: 123-124° C.
- 1-(chloroacetyl)-2,3-dihydro-1H-indole (3.9 g; 20 mmol) is dissolved in carbon disulphide (40 ml). AlCl3 (6.15 g; 46 mmol) is added slowly then chloroacetyl chloride (1.835 ml; 22 mmol) is added dropwise to the mixture which is then heated under reflux for 18 hours. After the reaction medium is cooled down, the CS2 is decanted and ice-cooled water containing concentrated HCl is added. After extraction with dichloromethane, the organic phase is separated and dried over magnesium sulphate before being filtered and concentrated under vacuum. The expected product (a 50/50 mixture of the meta and para isomers) is obtained by purification by crystallization from glacial acetic acid. White-coloured solid (1.6 g; yield of 30%).
- MH+=271.
- Intermediate 320.1 (mixture of isomers; 1.6 g; 6.0 mmol) is dissolved hot in a mixture of acetic acid (10 ml) and 20% HCl (2 ml). The reaction medium is heated under reflux for 24 hours. After evaporation then purification by crystallization of the hydrochloride from glacial acetic acid in order to separate the mixture of isomers, the meta isomer crystallizes in the form of a brown solid (the para isomer remains in the mother liquors) with a yield of 47%. Melting point: decomposition from 158° C.
- MH+=196.
- The meta structure of the compound was established by NMR/NOESY.
- The experimental protocol used is identical to that described for compound 30.2 of Example 30, intermediate 320.2 being used as the starting product instead of intermediate 30.1, tetrahydrofuran replacing the toluene in the presence of one equivalent of triethylamine in order to release the base of the salt. A brown-coloured solid is obtained with a yield of 9%. Melting point: decomposition from 235° C.
- MH+=246.
- 2.2 g (22.0 mmol) of O,N-dimethylhydroxylamine hydrochloride, triethylamine (6.2 ml), 3.0 g (22.0 mmol) of hydroxybenzotriazole and 4.2 g (22.0 mmol) of 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride are added successively to a solution of 5.0 g (20.0 mmol) of (R,S) 6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid (Trolox®) in 175 ml of DMF. After the reaction mixture is stirred overnight at 25° C., the mixture is diluted with ice-cooled water and stirring is maintained for 30 more minutes. The product is extracted using 3 times 100 ml of ethyl acetate. The organic solution is washed successively with a 10% aqueous solution of sodium bicarbonate, with water, with a 10% aqueous solution of citric acid and finally with a saturated solution of sodium chloride. The organic phase is then dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is purified by crystallization from ether in order to produce a white-coloured solid with a yield of 63%. Melting point: 139-140° C.
- MH+=294.
- A solution of methyllithium (1.6 M; 31.25 ml; 50.0 mmol) is added dropwise at a temperature of −30° C. to a solution of 2.93 g (10.0 mmol) of intermediate 321.1 in 100 ml of THF and the mixture is left under stirring for 1 hour at −10° C. The reaction medium is hydrolyzed with NH4Cl in a saturated aqueous solution. The product is extracted using 3 times 150 ml of ethyl acetate. The organic phase is finally washed with sodium chloride in a saturated aqueous solution before being dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is purified by crystallization from diisopropyl ether in order to produce a white solid with a yield of 80.7%. Melting point: 97-98° C.
- MH+=248.
- Intermediate 321.2 (0.777 g; 3.13 mmol) is dissolved in ethanol (25 ml) under a stream of argon. The solution is cooled down to 0° C. and bromine (0.18 ml; 4.20 mmol) is added in one go (see J. Am. Chem. Soc. (1999), 121, 24), then the mixture is stirred for 30 minutes allowing the temperature to rise to ambient temperature. The excess bromine is eliminated by bubbling through argon then the mixture is left under stirring for 2.5 hours. The ethanol is evaporated off and the product obtained is purified by crystallization from toluene. After filtering and washing with isopentane, a brown solid is obtained with a yield of 36%. Melting point: decomposition from 125° C.
- MH+=326.
- The experimental protocol used is analogous to that described for compound 30.2 of Example 30, intermediate 321.3 being used as the starting product instead of intermediate 30.1, and benzene replacing the toluene as solvent. The product obtained is purified by crystallization from a minimum amount of dichloromethane in order to produce a white solid with a yield of 48%. Melting point: 153-155° C.
- This compound is obtained according to Tetrahedron (1980), 36, 3017-3019. The carbazole (10 g; 60 mmol) is suspended in 150 ml of acetic anhydride. 70% perchloric acid (0.5 ml) is added. After stirring for 30 minutes at ambient temperature, the mixture is poured into ice and the precipitate formed is filtered. After drying under vacuum, redissolving in dichloromethane and treatment with bone charcoal, the suspension is filtered on celite, the solvents are evaporated off and the product recrystallized from heptane. 12 g of brown crystals (yield of 90%) is obtained in this way. Melting point: 70-71° C. (literature: 72-74° C.).
- This compound is obtained according to a protocol analogous to that of Stage 320.1 of Example 320, using 5 g (24 mmol) of intermediate 322.1. 5.4 g of the expected compound is obtained (yield of 79%). White solid. Melting point: 175-176° C.
- Intermediate 322.2 (2.85 g; 1 mmol) is suspended in a mixture of acetic acid (50 ml) and concentrated HCl (5 ml). The reaction medium is heated under reflux for 2 hours before being left to return to ambient temperature. The new precipitate formed is filtered. After drying under vacuum, 1.9 g of a greenish solid is obtained (yield of 78%). Melting point: 203-204° C.
- This compound is obtained according to a protocol analogous to that of Stage 30.2 from 487 mg (2 mmol) of intermediate 322.3 and 408 mg (2 mmol) of tert-butyl 2-amino-2-thioxoethyl(methyl)carbamate. 300 mg of the expected product is obtained (yield of 43%). White solid. Melting point: >250° C.
- 5.0 g (1.41 mmol) of ethyl 3′,5′-ditert-butyl-4′-hydroxy-1,1′-biphenyl-4-carboxylate (Chem. Lett. (1998), 9, 931-932) is dissolved in ethanol (25 ml). The solution is cooled down to 0° C. then a 1N solution of soda is added dropwise. After stirring overnight at ambient temperature, the reaction medium is heated under reflux in order to complete the reaction. After evaporation of the solvents and dilution of the residue with water, the mixture obtained is acidified with a 1N solution of HCl and extraction is carried out with dichloromethane. The organic phase is washed with sodium chloride in a saturated aqueous solution before being dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is purified by crystallization from diisopropyl ether in order to produce a yellow-white solid with a yield of 47%. Melting point: >240° C.
- The experimental protocol used is identical to that described for intermediate 321.1, with acid 323.1 replacing the Trolox® as starting product. A yellowish solid is obtained with a yield of 93%. Melting point: 175.6-177° C.
- The experimental protocol used is identical to that described for intermediate 321.2, intermediate 323.2 replacing intermediate 321.1. A white solid is obtained with a yield of 74%. Melting point: 144-144.7° C.
- The experimental protocol used is identical to that described for intermediate 321.3, intermediate 323.3 replacing intermediate 321.2. A yellow-orange oil is obtained which is sufficiently pure to be used in the following stage (yield of 100%).
- This compound is prepared according to the experimental protocol described in Example 1, Stage 1.3, using intermediate 323.4 instead of bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone. The expected compound is obtained in the form of a colourless oil with a yield of 46%.
- MH+=509.43.
- 0.230 g (0.452 mmol) of intermediate 323.5 is dissolved in ethyl acetate (20 ml). HCl gas is bubbled through the solution previously obtained cooled down to 0° C. The stirred mixture is then allowed to return to ambient temperature. The solid formed is filtered and washed with ethyl acetate then with ether before being dried under vacuum. A white solid is obtained with a yield of 85%. Melting point: 220-221° C.
- The compounds of Examples 324 to 330 are obtained according to procedures analogous to those described for Examples 31 to 46 or above in the part entitled “Preparation of compounds of general formula (I)”.
- Hydrochloride. Melting point: 173-180° C.
- Hydrochloride. Melting point: decomposes from 168° C.
- Free base. Melting point: 128.5° C.
- Hydrochloride. Melting point: 210-213° C.
- Hydrochloride. Melting point: from 140° C.
- Hydrochloride. Melting point: 111.5° C.
- Free base. Melting point: 180.9° C.
- 3.0 g (15.3 mmol) of 3,5-dimethoxy-4-hydroxyacetophenone is dissolved in dichloromethane (30 ml) and 2.53 g (18.3 mmol) of K2CO3 is added. Triethylamine (2.6 ml) is then added dropwise. The reaction medium is cooled down to 0° C. and acetyl chloride (1.31 ml; 18.3 mmol) is added. The mixture is stirred for 24 hours at ambient temperature then poured into ice-cooled water. After extraction with dichloromethane, the organic phase is washed with sodium chloride in a saturated aqueous solution before being dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is purified by crystallization from ether in order to produce a white solid with a yield of 99%. Melting point: 145° C.
- Intermediate 331.1 (0.850 g; 3.57 mmol) is solubilized in ethyl acetate then 1.35 g (6.07 mmol) of previously dried CuBr2 is added. The mixture is heated under reflux for 2.5 hours before being left to return to ambient temperature. Ground charcoal is added and the mixture is stirred for 10 minutes. After filtering and evaporating to dryness, the solid obtained is taken up in diisopropyl ether. After filtering, a grey solid is obtained with a yield of 75%. Melting point: 124.2-126.3° C.
- Intermediate 331.3 is prepared according to an experimental protocol described in Example 1, Stage 1.3, using intermediate 331.2 instead of bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone. The expected compound is obtained in the form of a white solid with a yield of 55%. Melting point: 135.2-137.4° C.
- 0.530 g (1.25 mmol) of intermediate 331.3 is dissolved in methanol (20 ml). The solution is cooled down using an ice bath then a 1N solution of NaOH is added dropwise. The mixture is left to return to ambient temperature under stirring. After evaporation to dryness and dilution of the residue with water, the solution is neutralised using citric acid followed by extraction with dichloromethane. The organic phase is washed with sodium chloride in a saturated aqueous solution before being dried over magnesium sulphate, filtered and concentrated under vacuum. The product is obtained in the form of a yellow oil with a yield of 96%.
- MH+=381.20.
- The experimental protocol used is identical to that described for intermediate 323.6, intermediate 331.4 replacing intermediate 323.5. A light beige solid is obtained with a yield of 97%. Melting point: 229.8-232.0° C.
- 3.45 g (16.4 mmol) of trifluoroacetic anhydride is added to 0.83 ml (14.6 mmol) of acetic acid at 0° C. while leaving the mixture to return to ambient temperature over 2 hours. The mixture is then cooled down to 0° C. and 1.95 g (11.0 mmol) of 2,6-diisopropylphenol is added dropwise. The reaction medium is maintained under stirring for 12 hours before being poured into ice-cooled water. After extraction with dichloromethane, the organic phase is washed with sodium chloride in a saturated aqueous solution before being dried over magnesium sulphate, filtered and concentrated under vacuum. A colourless oil is obtained with a yield of 86%. This product is sufficiently pure to be used directly in the following stage.
- 1.94 g (14.53 mmol) of AlCl3 is dissolved in nitrobenzene (5 ml). At the same time, 2.0 g (9.08 mmol) of intermediate 332.1 is dissolved in nitrobenzene (1 ml). The solution of intermediate 332.1 is added dropwise to the solution of AlCl3 at ambient temperature. The mixture is taken to 50° C. for 48 hours before being left to return to ambient temperature. The reaction medium is then poured into ice-cooled water. A 1N solution of HCl (5 ml) and then a concentrated solution of HCl (2 ml) are added. The mixture is stirred at ambient temperature followed by extraction with dichloromethane. The organic phase is washed with sodium chloride in a saturated aqueous solution before being dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 13% of ethyl acetate in heptane). After evaporation, the pure fractions produce a grey-white solid with a yield of 25%. Melting point: 88-93° C.
- The experimental protocol used is identical to that described for intermediate 331.1, intermediate 332.2 replacing the 3,5-dimethoxy-4-hydroxyacetophenone. A sand-coloured solid is obtained with a yield of 95%. Melting point: 102-103° C.
- The experimental protocol used is identical to that described for intermediate 331.2, intermediate 332.3 replacing intermediate 331.1. A yellow oil is obtained which crystallizes slowly with a yield of 88%. This product is sufficiently pure to be used directly in the following stage.
- Intermediate 332.5 is prepared according to a protocol identical to that described for Example 1, Stage 1.3, using intermediate 332.4 instead of the bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone. The expected compound is obtained in the form of a pale yellow solid with a yield of 76%.
- MH+=447.20.
- The experimental protocol used is identical to that described for intermediate 331.4, intermediate 332.5 replacing intermediate 331.3. An ochre oil is obtained with a yield of 91%. This product is sufficiently pure to be used directly in the following stage.
- MH+=405.20.
- The experimental protocol used is identical to that described for intermediate 323.6, intermediate 332.6 replacing intermediate 323.5. A beige-pink solid is obtained with a yield of 69%. Melting point: loses its colour at 162° C. and melts at 173-177° C.
- The experimental protocol used is identical to that described for intermediate 331.2, 4-hydroxy-acetophenone replacing intermediate 331.1. A brown-pink solid is obtained with a yield of 60%. Melting point: 118° C.
- Intermediate 333.2 is prepared according to a protocol identical to that described for Example 1, Stage 1.3, using intermediate 333.1 instead of the bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone and toluene replacing the benzene. The expected compound is obtained in the form of a clear-yellow oil which very slowly crystallizes cold with a yield of 35%.
- MH+=321.30.
- The experimental protocol used is identical to that described for intermediate 323.6, intermediate 333.2 replacing intermediate 323.5. A pale yellow solid is obtained with a yield of 100%. Melting point: 258-260° C.
- [this is intermediate 6.d1) of Patent Application EP 432 740]
- Intermediate 334.1 is prepared according to a protocol identical to that described for Example 1, Stage 1.3, using 2-(tert-butylcarbonyloxy)thioacetamide instead of the 2-{[(1,1-dimethylethoxy)carbonyl]methyl}amino-ethanethioamide and toluene replacing the benzene. The expected compound is obtained in the form of a white solid with a yield of 100%. Melting point: 114.6-116.0° C.
- The experimental protocol used is identical to that described for intermediate 331.4, intermediate 334.1 replacing intermediate 331.3. A white solid is obtained with a yield of 88%. Melting point: 126.4-127.4° C.
- 4-amino-acetophenone (4.87 g; 36.0 mmol) is dissolved in dimethylformamide (75 ml). 15 g (0.108 mol) of potassium carbonate (previously dried at 170° C. under an argon atmosphere), 7.236 g (36.0 mmol) of iodobenzene, 0.4 g of copper powder and a catalytic quantity of copper iodide are added. The reaction mixture is taken to reflux for 12 hours. After leaving the reaction medium to return to ambient temperature, the latter is filtered on celite and poured into ice-cooled water. After extraction with ethyl acetate, the organic phase is washed with water before being dried over magnesium sulphate, filtered and concentrated under vacuum. The product obtained is-purified by crystallization from heptane in order to produce a yellow solid with a yield of 53.4%. Melting point: 105° C.
- The experimental protocol used is identical to that described for intermediate 322.1, with intermediate 335.1 replacing the 9-acetyl-9H-carbazole and the reaction medium being however heated for 15 minutes at 70° C. After crystallization from heptane, a yellow solid is obtained with a yield of 54.2%. Melting point: 118-120° C. (value in the literature: 122-123° C.).
- Intermediate 335.2 (0.633 g; 2.5 mmol) is dissolved in methanol (20 ml) and 1 g (2.0 mmol) of bromination resin PVPHP (J. Macromol. Sci. Chem. (1977), A11, (3), 507-514) is added. After stirring under an argon atmosphere for 4 hours, filtration is carried out and the resins are rinsed with methanol. After evaporation of the filtrate solvents and crystallization from methanol, a white solid is obtained with a yield of 59%. Melting point: 152-153° C.
- Intermediate 335.4 is prepared according to a protocol identical to that described for Example 1, Stage 1.3, using intermediate 335.3 instead of the bromo-1-(3,5-ditert-butyl-4-hydroxyphenyl)ethanone and toluene replacing the benzene. The expected compound is obtained in the form of an oil with a yield of 73%.
- MH+=438.30.
- The experimental protocol used is identical to that described for intermediate 322.3, intermediate 335.4 replacing intermediate 322.2. A white-cream solid is obtained with a yield of 53%. Melting point: >250° C.
- The experimental protocol used is identical to that described for intermediate 322.3, intermediate 335.5 replacing intermediate 322.2 and the reaction medium being heated under reflux for 12 hours instead of 2 hours. A grey solid is obtained with a yield of 68%. Melting point: >250° C.
- 1.5 g (4.70 mmol) of intermediate 334.2, (2,6-ditert-butyl-4-[2-(hydroxymethyl)-1,3-thiazol-4-yl]phenol is dissolved in dichloromethane (30 ml). After adding CBr4 (2.02 g; 6.10 mmol), the reaction medium is cooled down to 0° C. PPh3 (1.48 g; 5.63 mmol) is added by fractions then the mixture is left to return to ambient temperature. The reaction medium is then poured into ice-cooled water before being extracted with dichloromethane. The organic phase is washed with salt water before being dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 30% of ethyl acetate in heptane), in order to produce a brown oil with a yield of 92%. This product is sufficiently pure to be used directly in the following stage.
- MH+=382.20.
- 0.8 ml (1.57 mmol) of dimethylamine and 0.4 ml (2.62 mmol) of triethylamine are dissolved in dimethylformamide (15 ml). 0.400 g (1.05 mmol) of intermediate 336.1 dissolved in dimethylformamide (5 ml) is added then the mixture is stirred at ambient temperature for 18 hours. The reaction medium is then poured into ice-cooled water followed by extraction with ethyl acetate. The organic phase is washed with salt water before being dried over magnesium sulphate, filtered and concentrated under vacuum. The expected product is obtained after chromatography on a silica column (eluent: 50% of ethyl acetate in heptane), in order to produce an orange oil with a yield of 92%. The hydrochloride is then obtained by solubilizing the base in ether and adding 1.2 ml of a 1N solution of HCl in ether. After filtering and washing of the solid formed with ether then with isopentane, a beige-pink solid is obtained with a yield of 15.2%. Melting point: 166.8-169.0° C.
- The compounds of Examples 337 to 345 are obtained according to procedures analogous to those described for Examples 31 to 46 or above in the part entitled “Preparation of compounds of general formula (I)”.
- Hydrochloride. Melting point: 214-215° C.
- Free base. Melting point: 158.7° C.
- Free base. Melting point: 110.6° C.
- Free base. Melting point: 103° C.
- Free base. Melting point: 180° C.
- Free base. Melting point: 127-130° C.
- Hydrochloride. Melting point: 245-246° C.
- Free base. Melting point: 176.5° C.
- Free base. Melting point: 157.3° C.
- The experimental protocol used is identical to that described for intermediate 336.1, the compound of Example 319 replacing intermediate 334.2, 1,2-dichloroethane replacing the dimethylformamide and the reaction medium being heated under reflux for 12 hours. A reddish oil is obtained with a yield of 77%. This product is used as it is directly in the following stage.
- The experimental protocol used is identical to that described for intermediate 336.2, intermediate 346.1 replacing intermediate 336.1, a 2N solution of methylamine in tetrahydrofuran replacing the dimethylamine and acetonitrile replacing the dimethylformamide. The hydrochloride is obtained by solubilizing the base in ether and adding a 1N solution of HCl in ether. The solid formed is filtered and purified by recrystallization from acetone in order to produce a white solid with a yield of 18%. Melting point: 184.0-185.0° C.
- The experimental protocol used is identical to that described for intermediate 336.2, piperidine replacing the dimethylamine. A white solid is obtained with a yield of 56%. Melting point: >195° C.
- The experimental protocol used is identical to that described for intermediate 336.2, N-methylpiperazine replacing the dimethylamine. A light brown solid is obtained with a yield of 62%. Melting point: 234.6-235.2° C.
- The experimental protocol used is identical to that described for intermediate 336.2, N—Boc-piperazine replacing the dimethylamine. A pale orange solid is obtained with a yield of 64%. Melting point: 108-109° C.
- The experimental protocol used is identical to that described for intermediate 323.6, intermediate 349.1 replacing intermediate 323.5. A white solid is obtained with a yield of 86%. Melting point: 255.4-257.7° C.
- Pharmacological Study of the Products of the Invention
- Study of the Effects on the Bond of a Specific Ligand of MAO-B, [3H]Ro 19-6327
- The inhibitory activity of the products of the invention is determined by measurement of their effects on the bond of a specific ligand of MAO-B, [3H]Ro 19-6327.
- a) Mitochondrial Preparation of the Cortex of Rats
- The mitochondrial preparation of the cortex of rats is carried out according to the method described in Cesura A M, Galva M D, Imhof R and Da Prada M, J. Neurochem. 48 (1987), 170-176. The rats are decapitated and their cortex is removed, homogenized in 9 volumes of a 0.32 M sucrose buffer, buffered to pH 7.4 with 5 mM of HEPES, then centrifuged at 800 g for 20 minutes. The supernatants are recovered and the pellets are washed twice with the 0.32 M sucrose buffer as previously. The collected supernatants are centrifuged at 10000 g for 20 minutes. The pellets obtained are suspended in a Tris buffer (50 mM Tris, 130 mM NaCl, 5 mM KCl, 0.5 mM EGTA, 1 mM MgCl2, pH 7.4) and centrifuged at 10000 g for 20 minutes. This stage is repeated twice, and the final pellet, corresponding to the mitochondrial fraction, is stored at −80° C. in the Tris buffer. The proteinic content of the preparation is determined by the Lowry method.
- b) Bond of [3H]Ro 19-6327
- 100 μl of the mitochondrial preparation (2 mg protein/ml) are incubated for 1 hour at 37° C. in an Eppendorf tube, in the presence of 100 μl of [3H] Ro 19-6327 (33 nM, final concentration) and 100 μl of Tris buffer containing or not containing the inhibitors. The reaction is stopped by the addition of 1 ml of unlabelled Tris buffer into each tube, then the samples are centrifuged for 2 minutes at 12000 g. The supernatants are removed by suction and the pellets washed with 1 ml of Tris buffer. The pellets are then solubilized in 200 μl of sodium dodecyl sulphate (20% weight/volume) for 2 hours at 70° C. The radioactivity is determined by counting the samples using liquid scintillation.
- c) Results
- The compounds of Examples 1, 3, 6, 22, 24, 26 to 29, 323 and 332 described above show an IC50 lower than 10 μM.
- Study of the Effects on Lipidic Peroxidation of the Cerebral Cortex of the Rat
- The inhibitory activity of the products of the invention is determined by measuring their effects on the degree of lipidic peroxidation, determined by the concentration of malondialdehyde (MDA). The MDA produced by peroxidation of unsaturated fatty acids is a good indication of lipidic peroxidation (H Esterbauer and K H Cheeseman, Meth. Enzymol. (1990) 186: 407-421). Male Sprague Dawley rats weighing 200 to 250 g (Charles River) were sacrificed by decapitation. The cerebral cortex is removed, then homogenized using a Thomas potter in a 20 mM Tris-HCl buffer, pH=7.4. The homogenate is centrifuged twice at 50000 g for 10 minutes at 4° C. The pellet is stored at −80° C. On the day of the experiment, the pellet is resuspended at a concentration of 1 g/15 ml and centrifuged at 515 g for 10 minutes at 4° C. The supernatant is used immediately to determine the lipidic peroxidation. The homogenate of rat's cerebral cortex (500 μl) is incubated at 37° C. for 15 minutes in the presence of the compounds to be tested or of the solvent (10 μl). The lipidic peroxidation reaction is initiated by adding 50 μl of FeCl2 at 1 mM, EDTA at 1 mM and ascorbic acid at 4 mM. After incubation for 30 minutes at 37° C., the reaction is stopped by adding 50 μl of a solution of hydroxylated di-tert-butyl toluene (BHT, 0.2%). The MDA is quantified using a colorimetric test, by reacting a chromogenic reagent (R), N-methyl-2-phenylindol (650 μl) with 200 oil of the homogenate for 1 hour at 45° C. The condensation of an MDA molecule with two molecules of reagent R produces a stable chromophore the maximum absorbence wavelength of which is equal to 586 nm. (Caldwell et al. European J. Pharmacol. (1995) 285, 203-206). The compounds of Examples 1 to 3, 6 to 17, 20 to 30, 320, 321, 323, 331 and 332 described above show an IC50 lower than 10 μM.
- Bond Test on the Cerebral Sodium Channels of the Cortex of the Rat
- The test consists in measuring the interaction of the compounds vis-à-vis the bond of tritiated batrachotoxin on the voltage-dependent sodium channels according to the protocol described by Brown (J. Neurosci. (1986), 6, 2064-2070).
- Preparation of Homogenates of Cerebral Cortices of the Rat
- The cerebral cortices of Sprague-Dawley rats weighing 230-250 g (Charles River, France) are removed, weighed and homogenized using a Potter homogenizer provided with a teflon piston (10 strokes) in 10 volumes of isolation buffer the composition of which is as follows (sucrose 0.32 M; KHPO4 5 mM; pH 7.4). The homogenate is subjected to a first centrifugation at 1000 g for 10 minutes. The supernatant is removed and centrifuged at 20000 g for 15 minutes. The pellet is taken up in the isolation buffer and centrifuged at 20000 g for 15 minutes. The pellet obtained is resuspended in incubation buffer (HEPES 50 mM; KCl 5.4 mM; MgSO4 0.8 mM; glucose 5.5 mM; choline chloride 130 mM pH 7.4) then aliquoted and stored at −80° C. until the day of assay. The final protein concentration is comprised between 4 and 8 mg/ml. The assay of proteins is carried out using a kit marketed by BioRad (France).
- Measurement of the Bond of Tritiated Batrachotoxin
- The bond reaction is carried out by incubating for 1 hour 30 minutes at 25° C. 100 μl of homogenate of rat cortex containing 75 μg of proteins with 100 μl of [3H] batrachotoxin-A 20-alpha benzoate (37.5 Ci/mmol, NEN) at 5 nM (final concentration), 200 μl of tetrodotoxin at 1 μM (final concentration) and scorpion venom at 40 μg/ml (final concentration) and 100 μl of incubation buffer alone or in the presence of the products to tested at different concentrations. The non-specific bond is determined in the presence of 300 μM of veratridine and the value of this non-specific bond is subtracted from all the other values. The samples are then filtered using a Brandel (Gaithersburg, Md., USA) using Unifilter GF/C plates pre-incubated with 0.1% of polyethylene imine (20 μl/well) and rinsed twice with 2 ml of filtration buffer (HEPES 5 mM; CaCl2 1.8 mM; MgSO4 0.8 mM; choline chloride 130 mM; BSA 0.01%; pH 7.4). After having added 20 μl of Microscint 0®, the radioactivity is counted using a liquid scintillation counter (Topcount, Packard). The measurement is carried out in duplicate. The results are expressed as a % of the specific bond of tritiated batrachotoxin relative to the control.
- Results
- The compounds of Examples 1, 6, 7, 11, 13, 15, 17, 20, 24, 31 to 38, 42, 43, 46 to 48, 53, 56, 57, 59 to 61, 64 to 80, 82 to 88, 92 to 95, 97, 105, 106, 108, 110, 113, 117, 118, 121 to 123, 125, 128, 130 to 139, 142 to 145, 149, 151, 152, 154, 162 to 166, 168 to 178, 181, 183 to 186, 188, 190 to 196, 198 to 206, 208 to 210, 212 to 218, 220 to 231, 233 to 250, 252 to 259, 261 to 281, 283 to 288, 293 to 313, 324 and 338 to 340 described above all show an IC50 lower than or equal to 1 μM. Moreover, the compounds of Examples 3, 9, 10, 26, 28 to 30 and 321 described above show an IC50 lower than or equal to 3.5 μM.
Claims (10)
1-21. (canceled)
22. A method of treating Parkinson's disease in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound of the formula
in racemic, enantiomeric form or any combination of these forms,
in which
A is
in which Q is selected from the group consisting of H, —OR22, —NR23R24, phenyl optionally substituted by at least one substituent independently selected from the group consisting of —OH, cyano, nitro, alkyl, alkoxy or —NR10R11 and a group with two
substituents representing together a methylenedioxy or ethylenedioxy, or Q is selected from the group consisting of —COPh, —SO2Ph or —CH2Ph, said COPh, —SO2Ph or —CH2Ph optionally substituted on its aromatic parts by at least one independently alkyl or alkoxy or halogen,
R10 and R11 are independently selected from the group consisting of hydrogen, alkyl and —COR12, or R10 and R11 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being independently selected from the group consisting of O, N and S,
R12 is selected from the group consisting of hydrogen, alkyl, alkoxy and NR13R14,
R13 and R14 are independently; hydrogen or alkyl, or R13 and R14 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being chosen independently from the group consisting of O, N and S,
R22 is selected from the group consisting of hydrogen, alkyl and aryl optionally substituted by at least one substituent selected from the group consisting of alkyl, OH, halogen, nitro and alkoxy,
R23 and R24 are independently selected from the group consisting of hydrogen, alkyl and —CO—R25,
R25 is alkyl,
and R19, R20 and R21 are independently selected from the group consisting of hydrogen, halogen, —OH, —SR26, alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 and NR27R28,
R27 and R28 are independently selected from the group consisting of hydrogen, alkyl and —COR29, or R27 and R28 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being independently selected from the group consisting of O, N and S,
R49 and R55 are independently each time that they occur, hydrogen or alkyl or alkylcarbonyl,
q is an integer from 0 to 2,
R56 and R57 are, each time that they occur, hydrogen or alkyl or alkoxy,
R29 is selected from the group consisting of hydrogen, alkyl, alkoxy and —NR30R31,
R30 and R31 are independently selected from the group consisting of hydrogen and alkyl, or R30 and R31 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being independently selected from the group consisting of O, N and S,
Y is O or S;
R1 is hydrogen, alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethyl, alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, —(CH2)g-Z1R39, —(CH2)g—COR40, —(CH2)g—NHCOR7, aryl, aralkyl, arylcarbonyl, heteroarylalkyl and aralkylcarbonyl, the aryl group of the aryl, aralkyl, arylcarbonyl, heteroarylalkyl or aralkylcarbonyl itself being optionally substituted by at least one substituent selected from the group consisting of alkyl, halogen, alkoxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, —(CH2)k-Z2R39 and —(CH2)k—COR40−, Z1 and Z2 are selected from the group consisting of a bond, —O—, —NR41— and —S—,
R39 and R41 are independently each time that they occur, selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cyanoalkyl,
R40 is, independently each time that it occurs, selected from the group consisting of hydrogen, alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy and NR42R43,
R42 and R43 are independently, each time that they occur, selected from the group consisting of hydrogen, alkyl, allenyl, allenylalkyl, alkenyl, alkynyl and cyanoalkyl and R2 is selected from the group consisting of hydrogen, alkyl, aminoalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethylalkyl,
—(CH2)g—NHCOR71, aralkyl and heteroarylalkyl optionally substituted on the aryl or heteroaryl by at least one member selected from the group consisting of halogen, alkyl, alkoxy, hydroxyl, cyano, nitro, amino, alkylamino and dialkylamino,
R70 and R71 are independently alkyl or alkoxy;
or R1 and R2, taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members;
B is selected from the group consisting of hydrogen, alkyl, —(CH2)g-Z3R44 and carbocyclic aryl optionally substituted 1 to 3 times by a member selected from the group consisting of halogen, alkyl and alkoxy of 1 to 6 carbon atoms, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino and a carbocyclic aryl,
Z3 is selected from the group consisting of a bond, —O—, NR45— and —S—,
R44 and R45 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, allenyl, allenylalkyl and cyanoalkyl;
Ω is NR46R47 or OR48;
R46 and R47 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, —(CH2)g-Z4R50, —(CH2)k—COR51, —(CH2)k—COOR51, —(CH2)k—CONHR51, —SO2R51, aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl, the aryl or heteroaryl of said aryl, aralkyl, aryloxyalkyl, arylcarbonyl, arylimino, aralkylcarbonyl, heteroaryl, pyridinylalkyl or pyridinylcarbonyl being optionally substituted by at least one member independently selected from the group consisting of halogen, alkyl, alkoxy, hydroxy, nitro, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, -Z5R50, —(CH2)k—COR51 and
—(CH2)k—COOR51,
Z4 and Z5 are selected from the group consisting of a bond, —O—, —NR52— and —S—, or R46 and R47 taken together form with the nitrogen atom a non-aromatic heterocycle with 4 to 8 ring members, the elements of the chain being selected from the group consisting of —CH(R53)—, —NR54—, —O—, —S— and —CO—,
R50 and R52 are independently each time that they occur, selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, allenyl, allenylalkyl and cyanoalkyl, R51 is, independently each time that they occur, selected from the group consisting of hydrogen, cycloalkyl and cycloalkylalkyl in which the cycloalkyl has 3 to 7 carbon atoms, alkyl of 1 to 8 carbon atoms, alkenyl, alkynyl, allenyl, allenylalkyl, cyanoalkyl, alkoxyalkyl, NR58R59, aryl or aralkyl, said aryl or aralkyl optionally substituted by at least one member selected from the group consisting of halogen, alkyl and alkoxy,
R58 and R59 are independently a member selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, allenyl, allenylalkyl and cyanoalkyl,
R53 and R54 are independently a member selected from the group consisting of hydrogen or —(CH2)k-Z7R60 and —(CH2)k—COR61,
Z7 is a member selected from the group consisting of a bond, —O—, —NR62— and —S—,
R60 and R62 are independently a member selected from the group consisting of hydrogen, alkyl, alkenyl, allenyl, allenylalkyl, alkynyl, cyanoalkyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl, the aryl or pyridinyl of the aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, pyridinyl, pyridinylalkyl or pyridinylcarbonyl being optionally substituted by at least one substituent selected from the group consisting of alkyl, halogen, nitro, alkoxy, cyano, cyanoalkyl, —(CH2)k-Z8R63 and —(CH2)k—COR64,
R61 is a member selected from the group consisting of hydrogen, alkyl, allenyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy and NR65R66,
R65 and R66 are independently selected from the group consisting of hydrogen, alkyl, allenyl, allenylalkyl, alkenyl, alkynyl and cyanoalkyl,
Z8 is a member selected from the group consisting of a bond, —O—, —NR67— and —S—,
R63 and R67 are independently a member selected from the group consisting of hydrogen, alkyl, allenyl, allenylalkyl, alkenyl, alkynyl and cyanoalkyl,
R64 is a member of the group consisting of hydrogen, alkyl, allenylalkyl, alkenyl, alkynyl, cyanoalkyl, alkoxy and NR68R69,
R68 and R69 are independently a member selected from the group consisting of hydrogen, alkyl, allenyl, allenylalkyl, alkenyl, alkynyl cyanoalkyl,
and R48 is a member selected from the group consisting of hydrogen, alkyl, alkynyl and cyanoalkyl;
g and p, each time that they occur, being independently integers from 1 to 6, and k and n, each time that they occur, being independently integers from 0 to 6;
or a salt thereof sufficient to treat Parkinson's disease.
23. The method of claim 22 wherein
A is
in which Q is selected from the group consisting of —H, —OR22, —SR22, —NR23R24, phenyl optionally substituted by at least one member selected from the group consisting of halogen, —OH, cyano, nitro, alkyl, alkoxy and —NR10R11 and a group of two substituents together being methylenedioxy or ethylenedioxy, or Q is selected from the group consisting of —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph, said —COPh, —OPh, —SPh, —SO2Ph or —CH2Ph being optionally substituted on its aromatic part by at least one member selected from the group consisting of alkyl, alkoxy and halogen,
R10 and R11 are independently selected from the group consisting of hydrogen, alkyl, or R10 and R11 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 ring members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being independently selected from the group consisting of O, N and S,
R22 is selected from the group consisting of hydrogen, alkyl and aryl optionally substituted by at least one member selected from the group consisting of alkyl, —OH, halogen, nitro and alkoxy,
R23 and R24 are, independently, hydrogen, or alkyl or —CO—R25,
R25 is alkyl,
and R19, R20 and R21 are independently selected from the group consisting of hydrogen, halogen, OH, SR26, alkyl, cycloalkyl, alkenyl, alkoxy, cyano, nitro, —SO2NHR49, —CONHR55, —S(O)qR56, —NH(CO)R57, —CF3, —OCF3 and NR27R28,
R26 is hydrogen or alkyl,
R27 and R28 are independently selected from the group consisting of hydrogen, alkyl and —COR29, or R27 and R28 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 ring members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being selected from the group consisting of O, N and S,
R49 and R55 are, independently each time that they occur, hydrogen or alkyl or alkylcarbonyl,
q is an integer from 0 to 2,
R56 and R57 are, independently each time that they occur, hydrogen or alkyl or alkoxy,
R29 is selected from the group consisting of hydrogen, alkyl, alkoxy and —NR30R31,
R30 and R31 are independently selected from the group consisting of hydrogen, alkyl, or R30 and R31 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 ring members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being selected from the group consisting of O, N and S.
24. The method of claim 22 wherein
A is
in which Q is —OR22, —SR22, —NR23R24, phenyl optionally substituted by at least one member selected from the group consisting of halogen, —OH, cyano, nitro, alkyl, alkoxy and —NR10R11,
R10 and R11 are independently selected from the group consisting of hydrogen or alkyl, or R10 and R11 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 ring members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being selected from the group consisting of O, N and S,
R22 is selected from the group consisting of hydrogen, alkyl and aryl optionally substituted by at least one member selected from the group consisting of alkyl, —OH, halogen, nitro and alkoxy,
R23 and R24 are, independently, hydrogen or alkyl,
and R19, R20 and R21 are independently selected from the group consisting of hydrogen, halogen, —OH, —SR26, alkyl, alkenyl, alkoxy and NR27R28,
R26 is hydrogen or alkyl,
R27 and R28 are independently selected from the group consisting of hydrogen, alkyl, or R27 and R28 form together with the nitrogen atom an optionally substituted heterocycle containing 4 to 7 members and 1 to 3 heteroatoms including the nitrogen atom already present, the additional heteroatoms being selected from the group consisting of O, N and S.
25. The method of claim 24 wherein
A is
in which Q is selected from the group consisting of —OR22, —SR22 and phenyl substituted by —OH and optionally by at least one member selected from the group consisting of halogen, —OH, alkyl and alkoxy,
R22 is hydrogen or alkyl,
and R19, R20 and R21 are independently selected from the group consisting of hydrogen, halogen, —OH, SR26, alkyl and alkoxy,
R26 is hydrogen or alkyl.
26. The method of claim 25 wherein
the compound corresponds to formula (I)3 in which Y is O
A is
in which Q is —OH, two of the R19, R20 and R21 are selected from the group consisting of alkyl, alkoxy, alkylthio, amino, alkylamino and dialkylamino and the third is selected from the group consisting of hydrogen, alkyl, alkoxy, alkylthio, amino, alkylamino and dialkylamino, or Q is phenyl substituted by —OH and at least one member selected from the group consisting of halogen, —OH, alkyl, alkoxy and —NR10R11, R10 and R11 are independently hydrogen or alkyl.
28. The method of claim 22 wherein Y is O;
A is
in which Q is —OH, two of the R19, R20 and R21 are alkyl and the third is hydrogen,
or in which Q is phenyl substituted by —OH and at least one alkyl;
B is hydrogen;
n is 0 or 1;
R1 and R2 both are hydrogen.
and Ω is NR46R47, R46 is selected from the group consisting of hydrogen, alkyl, alkynyl, hydroxyalkyl and cyanoalkyl and R47 is hydrogen or alkyl or R46 and R47 form together with the nitrogen atom which carries them a non-aromatic heterocycle with 5 to 7 ring members, the additional members are —CH2— or —NH—.
29. The method of claim 28 , wherein the compound is selected from the group consisting of
4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine;
2-[({4-[3,5-di(tert-butyl)-4-hydroxyphenyl]-1,3-thiazol-2-yl}methyl)(methyl)amino]-acetonitrile;
2,6-di(tert-butyl)-4-(2-{[(2-hydroxyethyl)(methyl)amino]methyl}-1,3-thiazol-4-yl)phenol;
4-[{[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}(methyl)amino]-butanenitrile;
2,6-ditert-butyl-4-(4-(2-[methyl(2-propynyl)amino]ethyl-1,3-oxazol-2-yl)phenol;
3-[(2-[2-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-oxazol-4-yl]ethyl)(methyl)amino]-propanenitrile;
2,6-ditert-butyl-4-{4-[2-(1-piperazinyl)ethyl]-1,3-oxazol-2-yl}phenol;
and the pharmaceutically acceptable salts of the latter.
30. The method of claim 22 wherein the compound is selected from the group consisting of 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-oxazoleethanol, 2,6-ditert-butyl-4-(4-{2-[methyl(2-propynyl)amino]ethyl}-1,3-oxazol-2-yl)phenol, [{2-[2-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-oxazol-4-yl]ethyl}(methyl)amino]acetonitrile, 3-[{2-[2-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-oxazol-4-yl]ethyl}(methyl)amino]-propanenitrile, 2,6-ditert-butyl-4-{4-[2-(1-piperazinyl)ethyl]-1,3-oxazol-2-yl}phenol hydrochloride, 2,6-ditert-butyl-4-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenol and 2,6-ditert-butyl-4-{4-[(methylamino)methyl]-1,3-thiazol-2-yl}phenol hydrochloride.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/256,901 US20070021390A1 (en) | 1999-10-11 | 2005-10-24 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US11/708,531 US20070179153A1 (en) | 1999-10-11 | 2007-02-20 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9912643A FR2799461B1 (en) | 1999-10-11 | 1999-10-11 | 5-CHAIN CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
FR99/12643 | 1999-10-11 | ||
FR0010151A FR2812546B1 (en) | 2000-08-01 | 2000-08-01 | 5-CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
FR00/10151 | 2000-08-01 | ||
FR0011169 | 2000-09-01 | ||
FR00/11169 | 2000-09-01 | ||
PCT/FR2000/002805 WO2001026656A2 (en) | 1999-10-11 | 2000-10-10 | 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
US8999302A | 2002-04-04 | 2002-04-04 | |
US11/256,901 US20070021390A1 (en) | 1999-10-11 | 2005-10-24 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/002805 Division WO2001026656A2 (en) | 1999-10-11 | 2000-10-10 | 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
US8999302A Division | 1999-10-11 | 2002-04-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/708,531 Division US20070179153A1 (en) | 1999-10-11 | 2007-02-20 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070021390A1 true US20070021390A1 (en) | 2007-01-25 |
Family
ID=27248695
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/256,901 Abandoned US20070021390A1 (en) | 1999-10-11 | 2005-10-24 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US11/708,531 Abandoned US20070179153A1 (en) | 1999-10-11 | 2007-02-20 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US12/001,439 Expired - Fee Related US7956075B2 (en) | 1999-10-11 | 2007-12-11 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US13/053,092 Expired - Fee Related US8288560B2 (en) | 1999-10-11 | 2011-03-21 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/708,531 Abandoned US20070179153A1 (en) | 1999-10-11 | 2007-02-20 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US12/001,439 Expired - Fee Related US7956075B2 (en) | 1999-10-11 | 2007-12-11 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US13/053,092 Expired - Fee Related US8288560B2 (en) | 1999-10-11 | 2011-03-21 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
Country Status (27)
Country | Link |
---|---|
US (4) | US20070021390A1 (en) |
EP (3) | EP1223933B1 (en) |
JP (1) | JP4972263B2 (en) |
KR (2) | KR20070068491A (en) |
CN (1) | CN100488506C (en) |
AR (1) | AR029006A1 (en) |
AT (2) | ATE522213T1 (en) |
AU (1) | AU783129B2 (en) |
BR (1) | BR0014649A (en) |
CA (1) | CA2388505C (en) |
CY (1) | CY1106237T1 (en) |
CZ (1) | CZ304331B6 (en) |
DE (1) | DE60030574T2 (en) |
DK (2) | DK1589007T3 (en) |
ES (2) | ES2270873T3 (en) |
HK (1) | HK1049957B (en) |
HU (1) | HU228254B1 (en) |
IL (3) | IL148896A0 (en) |
MX (1) | MXPA02003665A (en) |
MY (1) | MY145388A (en) |
NO (1) | NO331874B1 (en) |
NZ (2) | NZ533429A (en) |
PL (1) | PL215580B1 (en) |
PT (2) | PT1589007E (en) |
RU (1) | RU2271355C2 (en) |
TW (2) | TWI283577B (en) |
WO (1) | WO2001026656A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070185174A1 (en) * | 2001-07-26 | 2007-08-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of thiazole derivatives for preparing a medicament intended to protect the mitochondria |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
FR2823208B1 (en) * | 2001-04-10 | 2004-03-19 | Sod Conseils Rech Applic | 5-CHAIN CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
FR2818978B1 (en) * | 2000-12-28 | 2003-02-28 | Sod Conseils Rech Applic | MODULATORS OF SODIUM CHANNELS DERIVED FROM 2-PIPERIDYLIMIDAZOLES |
TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
FR2825926A1 (en) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Use of new and known imidazole derivatives as sodium channel modulators used for treating e.g. pain, epilepsy, cardiac rhythm disorders, neurodegeneration, depression, irritable bowel syndrome, and diabetic retinopathies |
EP1430017A2 (en) * | 2001-09-26 | 2004-06-23 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
EP1443930A1 (en) | 2001-10-25 | 2004-08-11 | AstraZeneca AB | Isoxazoline derivatives useful as antimicrobials |
WO2003048140A1 (en) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
FR2835254B1 (en) * | 2002-01-25 | 2006-04-07 | Sod Conseils Rech Applic | THIAZOLE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISEASES |
FR2842808B1 (en) | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | NOVEL ARYLIMIDAZOLA DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS |
CN1691944A (en) * | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
AU2003259068B2 (en) | 2002-08-09 | 2009-07-02 | Astrazeneca Ab | "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5 |
WO2004071448A2 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
WO2004089918A1 (en) * | 2003-04-09 | 2004-10-21 | Japan Tobacco Inc. | Heteroaromatic pentacyclic compound and medicinal use thereof |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
TWI256952B (en) | 2003-08-27 | 2006-06-21 | Sk Corp | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
EP1533295A1 (en) * | 2003-11-24 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | Cyclopentyl Derivatives |
US20070185217A1 (en) | 2003-12-23 | 2007-08-09 | Abraxis Bioscience, Inc. | Propofol analogs, process for their preparation, and methods of use |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
EP1765789B1 (en) * | 2004-06-18 | 2013-02-27 | Novartis AG | N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer |
ES2462341T3 (en) * | 2004-12-10 | 2014-05-22 | Msd Italia S.R.L. | Heterocyclic derivatives such as histone deacetylase inhibitors (HDAC) |
ATE506951T1 (en) * | 2005-01-19 | 2011-05-15 | Merck Sharp & Dohme | TERTIARY CARBINAMINES ACTIVE AS INHIBITORS OF BETA-SECRETASE WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
FR2888116A1 (en) * | 2005-07-08 | 2007-01-12 | Sod Conseils Rech Applic | THIAZOLE DERIVATIVES FOR TREATING DYSKINESIES |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
DK2091948T3 (en) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
US7820646B2 (en) | 2007-01-05 | 2010-10-26 | Novartis Vaccines And Diagnostics, Inc. | Cyclized derivatives as Eg-5 inhibitors |
TW200848417A (en) * | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
AU2008223916A1 (en) * | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
ES2371210T3 (en) * | 2008-03-28 | 2011-12-28 | Magforce Nanotechnologies Ag | APPLICATION DEVICE FOR ALTERNATE MAGNETIC FIELD FOR WARMING OF MAGNETIC OR MAGNETIZABLE SUBSTANCES IN BIOLOGICAL FABRIC. |
CN102186350A (en) * | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | Compositions and methods of using (r)-pramipexole |
GB0822486D0 (en) * | 2008-12-10 | 2009-01-14 | Univ Liverpool | Compounds for use in the treatment of pain |
KR101220182B1 (en) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | Azole derivatives, composition comprising thereof and method for treating parkinson's disease using the compounmd |
MX2012002993A (en) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase. |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
JP5688745B2 (en) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | Heterocyclic inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
ES2570167T3 (en) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Benzimidazole derivatives as glutaminyl cyclase inhibitors |
RU2506082C2 (en) * | 2011-05-24 | 2014-02-10 | Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова | Antihypotonic agent |
SG11201401032YA (en) * | 2011-10-26 | 2014-07-30 | Pfizer Ltd | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
ES2858500T3 (en) | 2013-07-12 | 2021-09-30 | Knopp Biosciences Llc | Treatment of elevated levels of eosinophils and / or basophils |
AU2014306683B2 (en) | 2013-08-13 | 2017-10-12 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
HUE055850T2 (en) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
ES2812698T3 (en) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Glutaminyl cyclase inhibitors |
WO2022015782A1 (en) * | 2020-07-15 | 2022-01-20 | Board Of Trustees Of Michigan State University | Compositions and related methods for closed-loop recycling of polyesters |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR4231E (en) | 1905-08-25 | Francisque Voland | New arrangement of the loom, with a view to obtaining a biased fabric | |
US1743083A (en) * | 1928-02-03 | 1930-01-07 | Winthrop Chem Co | Catechol thiazoles and process of making the same |
FR2132632A1 (en) * | 1971-04-07 | 1972-11-24 | Berlin Chemie Veb | Prepn of 2-aminomethyl imidazole derivs - hypotensives mao inhibitors anticonvulsant s, antiphlogistics, choleretics and ant |
US4123529A (en) | 1976-04-23 | 1978-10-31 | Lilly Industries Limited | Phenylpiperazine derivatives |
DE2702714A1 (en) | 1977-01-24 | 1978-07-27 | Lek Tovarna Farmacevtskih | Anti:traumatic, antiinflammatory phenothiazinyl-2-acetic acids - prepd. by reacting an amine and sulphur with 2-acetyl-phenothiazine, conversion to the thioamide, hydrolysis and opt. alkylation |
US4348404A (en) * | 1980-07-21 | 1982-09-07 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines |
US4372964A (en) * | 1980-10-30 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols |
JPS62132871A (en) * | 1985-12-03 | 1987-06-16 | Yamanouchi Pharmaceut Co Ltd | Novel thiazole derivative |
JP3003148B2 (en) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | Thiazole compound, process for producing the same, and pharmaceutical composition containing the same |
CA2012716A1 (en) * | 1989-03-22 | 1990-09-22 | Akito Tanaka | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
DE3941438A1 (en) * | 1989-12-15 | 1991-06-20 | Hoechst Ag | NEW 2-SUBSTITUTED 4- (3-ALKYL-5-TERT.-BUTYL-4-HYDROXY-PHENYL) -THIAZOLE, PROCESS FOR THEIR MANUFACTURE, THE MEDICAMENT CONTAINING THEIR AND ITS USE |
GB9204958D0 (en) * | 1992-03-06 | 1992-04-22 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
JPH10504808A (en) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
AU4368996A (en) * | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
FR2727969B1 (en) * | 1994-12-09 | 1997-01-17 | Roussel Uclaf | NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
IL129748A (en) * | 1996-10-07 | 2003-11-23 | Lilly Co Eli | Phenyl oxazole, thiazole, oxazoline, oxadiazole and benzoxazole compounds and neuro-protective pharmaceutical compositions comprising the same |
JP2001505585A (en) * | 1996-12-16 | 2001-04-24 | 藤沢薬品工業株式会社 | Novel amide compounds and their use as nitric oxide synthase inhibitors |
FR2764889B1 (en) * | 1997-06-20 | 2000-09-01 | Sod Conseils Rech Applic | NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6335445B1 (en) * | 1997-03-24 | 2002-01-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
EP0908180A3 (en) * | 1997-08-28 | 1999-04-21 | Eli Lilly And Company | Use of phenyl oxazole or phenyl thiazole derivatives for treating pain |
AU9575698A (en) * | 1997-10-06 | 1999-04-27 | Eli Lilly And Company | Novel compounds useful as neuro-protective agents |
PT1086086E (en) * | 1998-06-12 | 2005-02-28 | Sod Conseils Rech Applic | IMIDAZOLYL DERIVATIVES AND THEIR USE AS SOMATOSTATIN RECEPTOR LIGANDS |
CZ20004580A3 (en) * | 1998-06-12 | 2001-12-12 | Societe De Conseils De Recherches Et D'application | Beta-carboline compounds |
DE69941307D1 (en) * | 1998-12-31 | 2009-10-01 | Ipsen Pharma | Prenyl transferase inhibitors |
PT1173169E (en) * | 1999-03-26 | 2010-08-19 | Euro Celtique Sa | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
TWI283577B (en) | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
WO2002049652A1 (en) | 2000-12-20 | 2002-06-27 | Astrazeneca Ab | Method of treatment |
TWI248438B (en) | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
-
2000
- 2000-10-09 TW TW089121109A patent/TWI283577B/en not_active IP Right Cessation
- 2000-10-09 TW TW093132951A patent/TWI292316B/en not_active IP Right Cessation
- 2000-10-10 BR BR0014649-8A patent/BR0014649A/en not_active IP Right Cessation
- 2000-10-10 MX MXPA02003665A patent/MXPA02003665A/en active IP Right Grant
- 2000-10-10 DK DK05076749.0T patent/DK1589007T3/en active
- 2000-10-10 DE DE60030574T patent/DE60030574T2/en not_active Expired - Lifetime
- 2000-10-10 IL IL14889600A patent/IL148896A0/en active IP Right Grant
- 2000-10-10 EP EP00967988A patent/EP1223933B1/en not_active Expired - Lifetime
- 2000-10-10 CA CA2388505A patent/CA2388505C/en not_active Expired - Fee Related
- 2000-10-10 CN CNB008158479A patent/CN100488506C/en not_active Expired - Fee Related
- 2000-10-10 HU HU0203841A patent/HU228254B1/en not_active IP Right Cessation
- 2000-10-10 EP EP05076749.0A patent/EP1589007B1/en not_active Expired - Lifetime
- 2000-10-10 CZ CZ2002-1292A patent/CZ304331B6/en not_active IP Right Cessation
- 2000-10-10 ES ES00967988T patent/ES2270873T3/en not_active Expired - Lifetime
- 2000-10-10 NZ NZ533429A patent/NZ533429A/en not_active IP Right Cessation
- 2000-10-10 JP JP2001529718A patent/JP4972263B2/en not_active Expired - Fee Related
- 2000-10-10 NZ NZ518304A patent/NZ518304A/en not_active IP Right Cessation
- 2000-10-10 AT AT02076763T patent/ATE522213T1/en not_active IP Right Cessation
- 2000-10-10 DK DK00967988T patent/DK1223933T3/en active
- 2000-10-10 AU AU77965/00A patent/AU783129B2/en not_active Ceased
- 2000-10-10 WO PCT/FR2000/002805 patent/WO2001026656A2/en active Application Filing
- 2000-10-10 AT AT00967988T patent/ATE338547T1/en active
- 2000-10-10 PL PL355147A patent/PL215580B1/en not_active IP Right Cessation
- 2000-10-10 MY MYPI20004725A patent/MY145388A/en unknown
- 2000-10-10 PT PT50767490T patent/PT1589007E/en unknown
- 2000-10-10 ES ES05076749.0T patent/ES2544856T3/en not_active Expired - Lifetime
- 2000-10-10 EP EP02076763A patent/EP1228760B1/en not_active Expired - Lifetime
- 2000-10-10 KR KR1020077013941A patent/KR20070068491A/en active IP Right Grant
- 2000-10-10 KR KR1020027004578A patent/KR100731698B1/en not_active IP Right Cessation
- 2000-10-10 PT PT00967988T patent/PT1223933E/en unknown
- 2000-10-10 RU RU2002112227/15A patent/RU2271355C2/en not_active IP Right Cessation
- 2000-10-11 AR ARP000105353A patent/AR029006A1/en active IP Right Grant
-
2002
- 2002-03-26 IL IL148896A patent/IL148896A/en not_active IP Right Cessation
- 2002-04-10 NO NO20021689A patent/NO331874B1/en not_active IP Right Cessation
-
2003
- 2003-03-06 HK HK03101645.4A patent/HK1049957B/en not_active IP Right Cessation
-
2005
- 2005-10-24 US US11/256,901 patent/US20070021390A1/en not_active Abandoned
-
2006
- 2006-11-08 CY CY20061101600T patent/CY1106237T1/en unknown
-
2007
- 2007-02-20 US US11/708,531 patent/US20070179153A1/en not_active Abandoned
- 2007-08-08 IL IL185118A patent/IL185118A0/en not_active IP Right Cessation
- 2007-12-11 US US12/001,439 patent/US7956075B2/en not_active Expired - Fee Related
-
2011
- 2011-03-21 US US13/053,092 patent/US8288560B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070185174A1 (en) * | 2001-07-26 | 2007-08-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of thiazole derivatives for preparing a medicament intended to protect the mitochondria |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070021390A1 (en) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | |
US7291641B2 (en) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | |
US20040132788A1 (en) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | |
RU2288224C2 (en) | Derivatives of five-membered heterocycles, their preparing and using as medicinal agents | |
ES2370274T3 (en) | DERIVATIVES OF 5-MEMBER HETEROCICLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICATIONS. | |
KR100822085B1 (en) | 5-Membered Heterocycle Derivatives, Production Thereof and Use Thereof as Medicaments | |
RU2380362C2 (en) | Derivatives of five-member heterocycles, method of production and use thereof as medicinal agents | |
FR2812546A1 (en) | Five-membered heterocycles having monoamine oxidase inhibiting, lipidic peroxidation inhibiting and sodium channel modulating activity for the treatment of e.g. central and peripheral nervous disorders | |
FR2823208A1 (en) | New thiazole, oxazole or imidazole derivatives, are monoamine oxidase or lipid peroxidation inhibitors and/or sodium channel modulators useful e.g. for treating senile dementia, schizophrenia, depression or pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |